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1. INTRODUCTION TO THE SCIENTIFIC PROJECT  
 
The present cumulative thesis has been prepared on the basis of a translational 
neuroscience approach based on schizophrenic patients of the GRAS (Göttingen 
Research Association for Schizophrenia) data collection (Ribbe, Friedrichs et al. 
2010): translating the findings from basic research using animal models back to 
human, and vice versa. The thesis includes three original publications that focus on 
the establishment of novel genetic mouse models of neuropsychiatric phenotypes. 
The first paper identifies BAIAP3/Baiap3 as a genetic factor that modulates anxiety 
and the response to benzodiazepines in mouse and man (Wojcik, Tantra, Stepniak et 
al. 2013). The second paper focuses on an elevated seizure propensity as the 
phenotypical consequences of mildly overexpressing the transcriptional regulator 
Mecp2 at ~1.5fold wild-type level (Bodda, Tantra et al. 2013). The third publication 
expanding the results published in the second paper, now reveals that subtle 
alterations in the expression level of Mecp2/MECP2 influence social, particularly 
aggressive behavior (Tantra, Hammer, Kästner et al. submitted). 
 
The complexity of neuropsychiatric disorders: comorbidity is 
common, but causality is difficult to determine 
 
Neuropsychiatric disorders, such as autism spectrum disorders (ASD), schizophrenia, 
anxiety disorders, major depression and substance use disorders are highly prevalent 
(Kessler Rc 2005) and contribute substantially to disease burden worldwide. 
Neuropsychiatric disorders are complex traits that result from multiple genetic 
determinants interacting in the context of poorly understood environmental factors to 
trigger the emergence of clinically diverse phenotypes (Cristino, Williams et al. 2013). 
Family and twin studies have revealed that genetic factors play a major role in 
psychiatric disorders. For example, twin studies showed that heritability for 
schizophrenia is estimated to be ~80% (Kas, Fernandes et al. 2006), while 
concordance between monozygotic twins is as high as 90% for ASD (Abrahams and 
Geschwind 2008). Many putative genetic factors that confer risk to these disorders 
have been identified in individuals from diverse population, but the fact that affected 
individuals harbor different risk alleles in a heterogeneous genetic background still 
make candidate disorder genes difficult to detect (Cristino, Williams et al. 2013).  
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However, despite large research efforts, the exact neurobiological mechanisms of 
neuropsychiatric disorders remain largely unknown.  
 
Decades of research in psychiatry have revealed that anxiety disorders and 
substance use disorders (SUDs) are commonly found in a comorbid state at greater 
rates than would be expected by chance alone (Smith and Book 2008). Anxiety 
disorders, with lifetime prevalence of 28.8% and SUDs, with lifetime prevalence of 
14.6% are among the most frequent psychiatric problems (Kessler Rc 2005).  Recent 
analyses from an epidemiological survey on more than 40.000 individuals (the 
National Epidemiologic Survey on Alcohol and Related Conditions, USA) revealed 
striking rates of co-occuring anxiety and SUD: anxiety disorders were significantly 
related to alcohol and drug use disorders (Compton Wm 2007; Smith and Book 2008). 
When anxiety disorders co-occur with SUDs, there is a clinical impact since these 
disorders are functionally intertwined in both the development and maintenance of the 
comorbidity (Smith and Book 2008). The pathways to comorbidity of anxiety disorders 
and SUDs can vary (Smith and Book 2008): 
(1) a self-medication pathway wherein an anxiety disorder leads to a substance 
use disorder (i.e. to alleviate the symptoms of anxiety, a person self-
medicates, which in turn leads to SUD) 
(2) a substance-induced anxiety disorder pathway (i.e. the consumption of a 
substance like alcohol, cocaine leads to intoxication which induces anxiety) 
(3) a third variable pathway (e.g. genetic predisposition to develop either 
anxiety disorder and/ or substance abuse) 
 
Alternatively, genetic factors might already play a role in modulating the above 
mentioned pathways (figure 1). The heritability for anxiety disorders is estimated to be 
20-40% (Hettema, Prescott et al. 2005) and 40-70% for SUD, respectively (Ducci and 
Goldman 2012). This implies that individuals are differentially vulnerable to anxiety 
disorders and SUD. If an individual carries a genetic load to develop anxiety disorders, 
this individual will likely possess the behavioral traits that predispose it to develop 
drug-seeking behavior (DeMartini and Carey 2011; Pasche 2012) as a consequence 
of self-medication to alleviate the anxiety symptoms, which increases the risk of 
anxiety disorder and SUD co-occurs. Similarly, the converse might also be true. For 
an individual who carries the genetic predisposition for drug-seeking behavior, the 
odds to develop substance-induced anxiety will increase, contributing to the 
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comorbidity of SUD and anxiety disorders. However, it is also very likely that there are 
common factors – both genetic and environmental – which interact with each other 











Modified from (Smith and Book 2008) 
 
Figure 1. Development and mutual maintenance of comorbid anxiety disorder and 
SUD can happen through several pathways.  
 
Although there have been a wide range of studies on finding candidate genes 
associated with addiction and anxiety disorders (Bierut, Madden et al. 2007; Gratacos, 
Sahun et al. 2007; Hamilton 2009; Al-Eitan, Jaradat et al. 2012; Ducci and Goldman 
2012; Guo, Liu et al. 2012; Harari, Wang et al. 2012), our understanding of the 
etiology of these disorders are still limited, due to the role of environmental risk factors 
which also contribute to the emergence of the disorders. Thus, finding common 
factors underlying both disorders will help elucidating the pathways to the emergence 
of the disorders, which in turn will be valuable for future treatments for comorbid 




Dysregulation of the transcriptional regulator, MECP2 is attributable 
to a wide spectrum of neuropsychiatric phenotypes 
 
The transcriptional regulator MECP2 gene encodes for methyl-CpG-binding protein2 
(MECP2), which binds to methylated CpG DNA sequences and modulates 
transcription of genes in the vicinity of methylated sequences (Lewis, Meehan et al. 
1992; Nan, Ng et al. 1998; Amir, Van den Veyver et al. 1999; Chahrour and Zoghbi 
2007; Chahrour, Jung et al. 2008; Guy, Cheval et al. 2011). Initially, MECP2 was 
thought to act as a transcriptional regulator, through the interaction with corepressor 
Sin3a and HDAC (Jones, Veenstra et al. 1998; Nan, Ng et al. 1998; Chahrour and 
Zoghbi 2007). Upon binding to methylated CpG islands, MECP2 recruits HDAC at the 
methylation loci which leads to the alteration of the chromatin, making it compact and 
thus, inaccessible to the transcription machinery (Jones, Veenstra et al. 1998; Nan, 
Ng et al. 1998; Chahrour and Zoghbi 2007). However, recent studies have elucidated 
another role of MECP2, as a transcriptional activator (Chahrour, Jung et al. 2008). 
MECP2 was shown to be associated with actively transcribed genes (Chahrour, Jung 
et al. 2008; Mellén, Ayata et al. 2012). Association between MECP2 and the 
transcriptional activator CREB1 was found on an active, but not repressed form of the 
same gene (Yasui, Peddada et al. 2007; Chahrour, Jung et al. 2008). Besides its role 
as a transcriptional regulator, MECP2 was also found to be involved in RNA splicing 
(Chahrour, Jung et al. 2008). 
 
The MECP2 gene is X-linked and thereby a subject to X-inactivation during dosage 
compensation in females (Adler, Quaderi et al. 1995). This phenomenon is crucial, as 
it leads to different outcomes in individuals with MECP2 mutations, depending on 
gender, with males being more severely affected than females owing to hemizygosity 
(Guy, Cheval et al. 2011). MECP2 mutations are the cause of Rett syndrome (RTT), a 
neurological disorder affecting mainly girls during early childhood (Amir, Van den 
Veyver et al. 1999; Bienvenu, Carrie et al. 2000; Lee, Wan et al. 2001), with an 
incidence of ~1/10000 female live births (Chahrour and Zoghbi 2007). RTT is 
classically characterized by a period of normal development milestones until ~6-18 
months of age, followed by loss of acquired cognitive, motor and social skills 
(Chahrour and Zoghbi 2007). The occurrence of epilepsy – from easily controlled to 
intractable epilepsy, with the most common types being partial and tonic-clonic 
seizures, is also a distinct feature of the disorder (Jian, Nagarajan et al. 2006; 
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Chahrour and Zoghbi 2007). Also, symptoms of autism belong to the behavioral 
features of Rett syndrome (Mount, Charman et al. 2003; Moretti and Zoghbi 2006). 
Rett syndrome and autism have been recognized to have common clinical 
manifestations: RTT patients were regarded as an autism subgroup before Rett 
syndrome was recognized as a distinct disorder (Mount, Charman et al. 2003). 
 
The discovery that loss-of-functions mutations in MECP2 cause the neurological 
disorder termed Rett syndrome, has led to the identification of other neuropsychiatric 
phenotypes caused by MECP2 mutations. Until now, more than 100 cases of copy 
number gains of the MECP2 gene have been reported (Ramocki, Tavyev et al. 2010; 
Breman, Ramocki et al. 2011; Van Esch 2012), causing a neurological disorder, 
termed as MECP2 duplication syndrome with symptoms overlap with Rett syndrome 
(Moretti and Zoghbi 2006; Van Esch 2012). Autism is common in boys with 
duplications spanning MECP2, and anxiety is a comorbid condition (Ramocki, Peters 
et al. 2009; Ramocki, Tavyev et al. 2010). MECP2 duplication syndrome is 
characterized by symptoms such as infantile hypotonia, severe mental retardation, 
poor speech development, progressive spasticity, ataxia and seizures (Ramocki, 
Tavyev et al. 2010; Van Esch 2012). A more severe phenotype is observed in 
individuals with triplications spanning MECP2 (del Gaudio, Fang et al. 2006). 
 
The clinical picture of MECP2 mutations points to the necessity of a tight regulation of 
gene expression to ensure for proper function. Similar results were also obtained from 
studies on variety of mouse models of Mecp2 dysfunctions (Chen, Akbarian et al. 
2001; Guy, Hendrich et al. 2001; Shahbazian, Young et al. 2002; Collins, Levenson et 
al. 2004; Guy, Gan et al. 2007; Samaco, Fryer et al. 2008; Goffin, Allen et al. 2012). 
Mice carrying Mecp2 mutations which lead to loss-of-functions displayed features 
similar to Rett syndrome, including neurological phenotypes, tremors, motor 
dysfunctions, seizures and breathing abnormalities (Table 1), with the severity of the 
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Adapted from (Chahrour and Zoghbi 2007) 
 
Table 1. Summary of phenotypes induced by alterations of Mecp2 level in mouse 
models of Mecp2 mutations. 
 
Additionally, other mouse models carrying Mecp2 mutations at specifically targeted 
regions have been characterized, for example mutants with deletion of Mecp2 in 
Sim1-expressing neurons (hypothalamus), aminergic neurons and GABAergic 
neurons (Fyffe, Neul et al. 2008; Samaco, Mandel-Brehm et al. 2009; Chao, Chen et 
al. 2010). These mutant mice also displayed features of Rett syndrome. 
 
In contrast to mouse models of Mecp2 loss-of-functions, the study on Mecp2 
overexpression mouse model is just at the beginning. Previously, a transgenic Mecp2  
mouse (Mecp2-Tg1) was generated by overexpressing wild-type human protein using 
a large genomic clone containing the entire human MECP2 locus, resulting in Mecp2 
expression at ~2fold wild-type level (Collins, Levenson et al. 2004). The phenotypes 
of these mice are reminiscent of the human MECP2 duplication syndrome. The 
transgenic mice appeared normal until the age of 10-12 weeks; soon afterwards they 
develop progressive neurological symptoms which include stereotyped movements, 
motor dysfunction, epilepsy, hypoactivity, ataxia, kyphosis, followed by premature 
death (Collins, Levenson et al. 2004). Also, it was reported that increasing the copy 
numbers of Mecp2 in the transgenic mice which results in higher Mecp2 level, caused 
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even more severe phenotypes (Collins, Levenson et al. 2004). Overall, it is evident 
that the level of Mecp2 is critical to ensure proper function, as both loss- and gain-of-
function cause neurological phenotypes (figure 2) (Chao and Zoghbi 2012). 
 
 
       From (Chao and Zoghbi 2012) 
 
Figure 2. Phenotypic severity of mutant Mecp2 increases as Mecp2 function 
decreases. Severity also increases however, as Mecp2 increases beyond normal 
(100%) level. 
 
Mice as a model system to study complex human disorders 
 
Mice as a model system play an important role in elucidating the molecular pathways 
underlying such complex behavioral disorders. The similarity of the mouse and 
human genomes is remarkable, with most genes of one species occurring in the other, 
arranged in haplotypes of DNA that share many of the same genes in the same order 
in both species (Waterston, Lindblad-Toh et al. 2002). In fact, a working draft of the 
mouse genome has led to estimates that a mouse version may be identified for 99% 
of human genes (Tecott 2003). In accordance with their genomic homologies, 
humans and mice share numerous features of brain organization and may therefore 
exhibit similar behavioral responses to many pharmacological agents (Tecott 2003). 
Moreover, transgenic technology has allowed specific human alleles to be inserted 
into the mouse genome to create remarkable models for research (Wahlsten 2011). In 
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the frame of complex human behavioral disorders, since the introduction of gene 
targeting techniques, diverse mutant mice carrying mutations of candidate genes of 
psychiatric disorders have been generated. Some of these mutant mouse strains 
were found to exhibit behavioral abnormalities reminiscent of human psychiatric 
disorders (Shahbazian, Young et al. 2002; Collins, Levenson et al. 2004; Jamain, 
Radyushkin et al. 2008; Radyushkin, Hammerschmidt et al. 2009; El-Kordi, Winkler et 
al. 2012). 
 
In the context of modeling complex human behavioral disorders in mice, the study of 
animal behaviors as the final output of the nervous system is relevant because the 
behavioral traits/ phenotypes observed are: (1) influenced by multiple genes, (2) 
responsive to environmental influences and (3) normally distributed across the range 
of phenotypic expression (Bazzett 2008). Moreover, the use of mice in behavioral 
neuroscience has a long and illustrious history, containing well-validated and carefully 
controlled methods for behavioral testing of sensory abilities, motor functions, learning 
memory, social behavior, drug self-administration and traits relevant to 
neuropsychiatric disorders (Crawley 2007).  
 
In my thesis, I will address a concept which focuses on the genetics of behavioral 
domains relevant to mouse behavior in the frame of human psychiatric disorders: 
abnormal social behavior associated with Mecp2 overexpression and Baiap3 deletion 
associated with anxiety-like phenotypes accompanied by an altered response to 
benzodiazepines. It will be shown in my thesis that interspecies trait genetics, which 
were assed by (1) comprehensive behavioral studies of genetic mouse models to find 
affected  behavioral domains and (2) a phenotype-based genetic association study 
(PGAS) using the GRAS database, will optimize genotype-phenotype relationships for 
psychiatric disorders and facilitate the identification of biological substrates underlying 
these complex behavioral disorders. 
Focus of the present work 
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2. FOCUS OF THE PRESENT WORK 
 
This cumulative thesis has been prepared in the frame of a translational neuroscience 
effort, applying studies from mice to men and vice versa, to delineate the biological 
basis of complex human behavioral disorders within a schizophrenic (GRAS, 
Göttingen Research Association for Schizophrenia) population. As part of a 
translational research group with a multidisciplinary character, my scientific work has 
been committed to the establishment of novel genetic mouse models of 
neuropsychiatric conditions. Working bi-directionally, the results from comprehensive 
behavioral characterizations of mutant mice provide the basis for further 
identifications of specific genotype-phenotype relationships using a phenotype-based 
genetic association study (PGAS), or vice versa. Presented in the thesis are 3 original 
first-authorship publications that investigate (1) the role of a member of the Munc13 
family – synaptic regulators of neurotransmitter exocytosis – in modulating behavioral 
phenotypes relevant for human psychiatric disorders and (2) the consequences of 
subtle alterations in expression level of a transcriptional regulator MECP2. A forth 
publication which I co-author has been accepted for publication in Molecular 
Psychiatry. The manuscript is given in the appendix. 
 
a. Aims of project I 
The focus of the first study was to investigate the role of Baiap3/BAIAP3, which is 
highly expressed in brain regions involved in fear processing, and therefore possibly 
in mediating behavioral phenotypes relevant for human psychiatric disorders (Wojcik 
SM, Tantra M and Stepniak B et al. 2013). 
To identify the role of Baiap3, a basic behavioral characterization of Baiap3 deficient 
mice 1 and their wild-type (WT) littermates was performed. Subsequently, further 
behavioral experiments were designed to target specific phenotypes related to Baiap3 
expression patterns: anxiety-like phenotypes and benzodiazepines dependence, 
tolerance and withdrawal. In parallel, in vitro analyses were performed to investigate 
whether lack of Baiap3 leads to alterations in neuronal activity. Additionally, the 
association between genetic variations of human BAIAP3 and behavioral phenotypes 
(anxiety and benzodiapine use disorder) was studied in the GRAS population. 
                                                 
1Baiap3 deficient mice were generated by Dr. Sonja M. Wojcik (Max Planck Institute of Experimental Medicine, 
Göttingen) 
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b. Aims of project II 
The second paper focused on identifying the earliest evidence of pathologies as 
consequences of gain-of-function properties of Mecp2, elicited by mildly 
overexpressing Mecp2 (Bodda C and Tantra M et al. 2013). 
To evaluate the Mecp2 gene dosage effect, a transgenic mouse model of Mecp2 
overexpression on FVB/N genetic background was generated, resulting in transgenic 
mice with an overexpression of Mecp2 at ~1.5fold wild-type (WT) level 2 . A 
comprehensive behavioral characterization of the male transgenic and WT mice was 
performed, with repetition over several cohorts, during early postnatal (neonatal) 
period and adulthood. The effect of Mecp2 overexpression on neuronal maturation 
and characterization and calcium homeostasis was also evaluated in vivo. 
 
c. Aims of project III 
In the third study, expanding the results of the second project, we aimed to explore 
behavioral consequences of mildly increased Mecp2/MECP2 expression, both in mice 
and humans (Tantra M, Hammer C, Kästner A et al. submitted). 
First, using the Mecp2 transgenic construct expressed in two different mouse strains 
(FVB/N and C57BL/6N), we investigated behavioral domains, such as social behavior, 
which were targeted by Mecp2 overexpression. Furthermore, it was also our aim to 
translate the findings from mice back to humans, by investigating whether naturally 
occurring genetic variants such as single nucleotide polymorphisms (SNPs) of the 
MECP2 gene have an influence on social behavior. Putting the data obtained from the 
mouse and the human study in a context, we strive for mechanistic insights looking at 
SNP-related MECP2 expression differences, possibly due to miRNA regulations.
                                                 
2
 The transgenic Mecp2 mice were generated by PD Dr. Ashraf Mannan (Institute of Human Genetics, University 
Medical Center, Göttingen) 
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3. MOUSE MODEL TARGETING BAIAP3 GENE: 
Genetic markers of a Munc13 protein family member, 
BAIAP3, are gender-specifically associated with anxiety 
and benzodiazepine abuse in mouse and man 
 
a. Overview of project I 
Diagnoses of psychiatric disorders rely heavily on the presence of a cluster of 
behavioral symptoms and their time course and a threshold beyond which the 
symptoms are considered to be clinically relevant, rather than the presence of any 
biological markers. Moreover, the observable symptoms are very much unlikely to be 
unique for a specific disorder. Potential problems with the process of establishing the 
diagnoses increase further when substance use disorders (SUDs) and psychiatric 
syndromes occur together (Schuckit 2006).  
 
Anxiety disorders and SUDs, including benzodiazepine use disorder, are frequently 
comorbid (Smith and Book 2008). The interaction between anxiety disorders and 
SUDs is likely bi-directional and varies by the type of anxiety (Marmorstein 2012) and 
genetically determined anxiousness personality traits may predispose an individual 
more to develop an addiction (DeMartini and Carey 2011; Pasche 2012). Furthermore, 
the comorbidity of anxiety disorders and SUDs might reduce the treatment efficacy for 
either disorder. Benzodiazepines, which rank among the most frequently abused 
prescription medications (National Institute on Drug Abuse [http://www.nida.nih.gov]), 
are prescribed often to people with substance abuse problems (Mueller, Pagano et al. 
2005) and also are still used as leading treatment of anxiety disorders (Clocis and 
Ferreira 2009; Baldwin, Allgulander et al. 2012). Benzodiazepines are advantageous 
treatments for anxiety disorders because they work quickly to alleviate the symptoms 
(Clocis and Ferreira 2009), however, there are concerns regarding their abuse liability, 
withdrawal reactions and development of tolerance (Argyropoulos and Nutt 1999). For 
these reasons, individuals with anxiety disorders with an existing comorbid 
benzodiazepine use disorder or a genetic liability for benzodiazepine use disorder 
may be at risk of adverse treatment outcomes. The identification of genetic predictors 
for anxiety disorders, and especially for benzodiazepine use disorder, could aid the 
selection of the best treatment option and improve clinical outcomes. In addition to 
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human genetic association studies, animal models are used to study the genetic and 
neural circuitries of anxiety disorders and addiction. The selection of candidate genes 
targeted in animal studies is driven by hypotheses of neural circuitries and 
neurotransmitter systems which thought to be involved in mediating fear and anxieties 
(Gratacos, Sahun et al. 2007).  Using a candidate gene approach, we investigated the 
involvement of the brain specific angiogenesis inhibitor I-associated protein 3 
(Baiap3), which is highly expressed in brain regions involved in processing fear, such 
as the amygdala, hypothalamus and periaqueductal gray, and therefore in behavioral 
phenotypes relevant for human anxiety disorders. 
 
Baiap3 is a member of the mammalian uncoordinated 13 (Munc13) family of synaptic 
regulators of neurotransmitter exocytosis (Shiratsuchi, Oda et al. 1998; Koch, 
Hofmann et al. 2000). The cellular function of Baiap3 is currently unknown, however, 
all other Munc13s are regulators of vesicle exocytosis in various cell types (Wojcik 
and Brose 2007). To uncover the function of Baiap3, we combined the behavioral 
analyses of Baiap3 null-mutant (KO) mice with a phenotype-based genetic 
association study (PGAS) of human BAIAP3 in a schizophrenic (GRAS) population. 
 
The behavioral characterization of Baiap3 mice revealed that deletion of Baiap3 led to 
enhanced seizure propensity in mice of both genders and increased anxiety, a 
phenotype which was more pronounced in female mice.  Accordingly, we 
hypothesized that genetic variation in human BAIAP3 may also be associated with 
anxiety. Two human BAIAP3 single nucleotide polymorphisms (SNPs) risk genotypes 
(AA for rs2235632 and TT for rs1132358) were identified. Both risk genotypes 
showed a significant association with anxiety in women and, surprisingly, with 
benzodiazepine abuse in men. Translating the findings of PGAS back to mice, we 
established an experimental paradigm of chronic benzodiazepine administration to 
investigate the development of dependence, tolerance and withdrawal to 
benzodiazepines in Baiap3 KO and WT mice of both genders. We found that male, 
but not female Baiap3 KO mice develop tolerance to diazepam more quickly than 
control mice. Furthermore, to assess whether Baiap3 KO mice would also be more 
likely to orally self-administer benzodiazepine, we performed an experiment of chronic 
self-administration of midazolam (a short-acting benzodiazepine). Here, no genotype-
dependent differences were observed, indicating that Baiap3 deficiency affected the 
development of tolerance and dependence to benzodiazepines at an early stage, 
Mouse model targeting BAIAP3 gene 
13 
prior to the development of addiction. One hypothesis regarding predisposition to the 
development of addiction is an altered response to addictive substance and its 
withdrawal at the cellular level. Subsequently, the response to diazepam treatment 
and withdrawal in hypothalamus neurons in vitro was studied. The results revealed a 
lack of homeostatic adaptation to diazepam treatment and withdrawal in Baiap3 KO 
hypothalamus slices. In summary, the first project of my thesis delivers evidence for 
Baiap3/BAIAP3 as a common genetic factor underlying anxiety and benzodiazepine 
abuse in mice and human. 
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benzodiazepine tolerance, dependence and withdrawal as well as the establishment 
of oral self administration of midazolam in Baiap3 KO and WT mice. I also performed 
the behavioral data analysis and prepared the figures for the manuscript (see Figure 2 
and 3, Supplementary figure S3 and S6). Furthermore, I participated in the 
conception, design, drafting, revision and publication of the manuscript. Under the 
supervision of Prof. Hannelore Ehrenreich, I wrote and cited appropriately the 
materials and methods of the animal experiments sections of the manuscript. I also 
wrote the results section and the figure legends, designed the layouts of the figures of 
the results section and delivered the interpretations of the results for the discussion 
section of the manuscript.  
INTRODUCTION
Anxiety disorders have high lifetime
prevalence rates (1) and exhibit a re-
markable comorbidity with substance
use disorders (2–4). This association
worsens treatment outcomes for both
conditions (5) and represents a signifi-
cant burden on individuals and society.
Both anxiety disorders and substance
use disorders are complex disorders that
arise from a combination of genetic in-
fluence and environmental factors. To
improve upon established treatment op-
tions, which include pharmacological as
well as cognitive-behavioral therapies
(6,7), a more detailed picture of the etiol-
ogy of these disorders is instrumental.
Estimates of heritability from twin and
family studies are in the range of
20–40% across the different anxiety dis-
orders (8,9) and in the range of 40–70%
for the major substance use disorders
(10). Recent studies point to the involve-
ment of a large number of genes with
relatively small effect sizes for both anxi-
ety disorder (11,12) and substance use
disorder (13–15). Although the interac-
tion between anxiety disorders and sub-
stance use disorders is likely bidirec-
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tional and varies by the type of anxiety
(16), genetically determined anxiousness
personality traits may make the devel-
opment of an addiction more likely
(2,17–19). The recommended first-line
pharmacological treatments of anxiety
disorders are selective serotonin or sero-
tonin/norepinephrine reuptake in-
hibitors and the calcium channel modu-
lator pregabaline (6). However, primary
care physicians often still prescribe ben-
zodiazepines, which rank among the
most frequently abused prescription
medications (National Institute on Drug
Abuse [http://www.nida.nih.gov]), to
patients suffering from anxiety disorders
(20). Identifying genetic risk markers
would advance our understanding of
the biology of anxiety and benzodi-
azepine abuse and would be a valuable
step in improving treatment options for
these complex diseases.
In addition to human family, twin and
genome-wide association studies, animal
models are used to study the genetic
basis and neural circuitries of anxiety
and addiction. For both animals and hu-
mans, anxiety is an adaptive defensive
response to threatening stimuli necessary
for the survival of the species, whereas
anxiety disorders are an extreme and
maladaptive manifestation of normal
anxiety (21). Somatic anxiety symptoms
are mediated by the release of specific
neurotransmitters and neuropeptides.
The selection of candidate genes that are
being investigated in animal studies is
still largely driven by hypotheses of the
neural circuitries and neurotransmitter
systems thought to be involved in medi-
ating fear and anxiety (22). By using a
candidate gene approach, we investigate
the involvement of the brain-specific an-
giogenesis inhibitor I–associated protein
3 (Baiap3), which is highly expressed in
brain regions involved in processing fear,
such as the amygdalae, hypothalamus
and periaqueductal gray, in behavioral
phenotypes relevant for human psychiat-
ric disorders.
Baiap3 is a member of the mammalian
uncoordinated 13 (Munc13) family of
synaptic regulators of neurotransmitter
exocytosis (23–25). Baiap3 has a unique
and striking expression pattern (Allen
Brain Atlas [http://mouse.brain-
map.org]) in brain regions such as the
central, medial and basomedial amyg-
daloid nuclei; the hypothalamus; and the
periaqueductal gray. These areas are in-
volved in regulating autonomic functions
and are also critical in processing fearful
stimuli and mediating anxiety-related be-
haviors (26,27). The cellular function of
Baiap3 is currently unknown; however,
all other Munc13 members are regulators
of vesicle exocytosis in various cell types
(28). In the brain, Munc13-1 and
Munc13-2 are essential for membrane fu-
sion of synaptic vesicles containing clas-
sical neurotransmitters, such as gluta-
mate or γ-aminobutyric acid (GABA)
(25). Munc13-4, a non-neuronal Munc13
isoform most closely related to Baiap3 at
the sequence level, is involved in exocy-
tosis in cells of the hematopoietic system
(29,30).
To explore the function of Baiap3, we
combined the behavioral analysis of
Baiap3 knockout (KO) mice with a phe-
notype-based genetic association study
(PGAS) of the human BAIAP3 gene by
using the Göttingen Research Associa-
tion for Schizophrenia (GRAS) database
(31,32). Using this two-pronged ap-
proach, we identify Baiap3/BAIAP3 as the
first genetic risk marker for anxiety and




Animal maintenance. All experiments
were approved by the local Animal Care
and Use Committee of Lower Saxony,
Oldenburg, Germany. The first three cod-
ing exons of the murine Baiap3 gene were
preplaced with a neomycin resistance
cassette through homologous recombina-
tion in embryonic stem cells (129/Ola)
(Supplementary Figure S1A). Baiap3 mu-
tant mice of mixed 129/Ola;C57BL/6N
background were backcrossed for seven
more generations to C57BL/6N; all ex-
periments were done with WT and KO
littermates of the resulting generation 8.
After weaning, mice were group-housed
in standard plastic cages (n = 5 per cage)
and maintained in a temperature-
 controlled environment (21 ± 2°C) on a
12-h light–dark cycle with food and
water ad libitum, unless stated otherwise.
Drugs used in animal experiments.
Two classical benzodiazepines, positive
allosteric modulators of GABA type A re-
ceptors (GABAAR) were used: (i) the
long-acting benzodiazepine diazepam
(ratiopharm GmbH, Ulm, Germany) was
suspended in saline containing polysor-
bate 80 for intraperitoneal (IP) injection,
and (ii) the short-acting benzodiazepine
midazolam (ratiopharm) was added to
2% sucrose solution for oral administra-
tion. Antagonists used were as follows:
(i) flumazenil (Sigma-Aldrich Chemie,
Munich, Germany), routinely applied in
the clinic to counteract benzodiazepine
overdoses, was dissolved in saline con-
taining polysorbate 80 and HCl; and (ii)
pentylenetetrazole (PTZ) (Sigma-Aldrich
Chemie), a noncompetitive GABA antag-
onist with epileptogenic properties, was
dissolved in saline for IP injection.
Phenotypical characterization of
Baiap3 KO mice. Behavioral characteri-
zation of naive Baiap3 KO mice and their
WT littermates of both sexes began at the
age of 8 wks and was performed in the
following order: elevated plus-maze,
open field, light–dark box, hole board,
rotarod and exposure to a fear-condition-
ing chamber to assess novelty-induced
freezing behavior. Mouse numbers of all
individual experiments are given in the
figure legends.
Elevated plus-maze. The mouse was
placed in the central platform, facing an
open arm of the plus-maze. Behavior
was recorded over 5 min by an overhead
video camera. A personal computer
equipped with Viewer software 
(Biobserve, Bonn, Germany) was used to
calculate the time each animal spent in
open versus closed arms. The proportion
of time spent in open arms (natural aver-
sion) was used as a fear equivalent.
Open field. Spontaneous activity in
open field was tested in a gray Perspex
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arena (120 cm in diameter, 25 cm high),
virtually divided into three zones: cen-
tral, intermediate and peripheral. The
mouse was placed in the center, and the
test was started when the mouse reached
the wall. Over 7 min, the mouse was al-
lowed to freely explore the open field.
Behavior was recorded by a personal
computer–linked overhead video camera
and calculated using Viewer software.
Readouts were as follows: velocity, dis-
tance traveled, time spent in each zone
and initial latency to reach the wall.
Hole board. The hole board apparatus
(TSE Systems GmbH, Bad Homburg,
Germany) for measuring exploratory 
activity consisted of a 50 cm × 50 cm ×
35 cm transparent Perspex chamber with
a nontransparent floor raised above the
bottom of the chamber. The floor had 16
equally spaced holes, 2.4 cm in diameter,
fitted with a light barrier sensor (8 mm
below floor). Mice were allowed to ex-
plore the chamber for 5 min, and the
number of explored holes (head dips)
was recorded.
Rotarod. This test for motor function,
balance and coordination consists of a ro-
tating drum (Ugo Basile, Comerio,
Varese, Italy), accelerated from 4 to 40
revolutions per minute over 5 min. Each
mouse was placed individually on a
drum and the latency of falling from the
drum was recorded using a stopwatch.
To assess motor learning, the test was re-
peated 24 h later.
Novelty-induced fear response. To as-
sess novelty-induced fear response (indi-
cated by freezing behavior), a chamber
designed for training and testing of con-
text fear conditioning was used. Mice
were placed inside the chamber and al-
lowed to explore the chamber freely for
2 min, during which time no additional
stimulus was presented (equivalent to
the assessment of baseline freezing of the
fear-conditioning paradigm). Duration of
freezing behavior, defined as the ab-
solute lack of movement (excluding res-
piratory movements), was recorded by a
video camera and a personal computer
equipped with Video Freeze software
(MED Associates, St. Albans, VT, USA).
Pentylenetetrazole-induced seizures.
Seizure activity was induced in wakeful
mice by using a single IP injection of PTZ
(50 mg/kg body weight) (33). After injec-
tion of the compound, the mouse was
placed in a small, clear home cage and
closely observed for 30 min. Latencies to
focal (partial clonic), generalized (gener-
alized clonic) and maximal (tonic-clonic)
behavioral seizures were recorded. Fur-
thermore, four phases in the continuum
of behavioral response to IP PTZ injec-
tion were defined as follows: (i) hypoac-
tivity (progressive decrease in motor ac-
tivity until the animal came to rest in a
crouched or prone position with the ab-
domen in full contact with the cage bot-
tom); (ii) partial clonus (clonus seizure
activity affecting face, head and/or fore-
limb or forelimbs); (iii) generalized
clonus (sudden loss of upright posture,
whole body clonus involving all four
limbs and tail, rearing and autonomic
signs); and (iv) tonic-clonic (maximal)
seizure (generalized seizure character-
ized by tonic hindlimb extension—also
associated with death). Finally, latencies
to partial clonus (PC), generalized clonus
(GC) and tonic-clonic (TC) seizures were
summed to assign a seizure score to each
mouse, used as a quantitative trait mea-
sure for mapping according to the fol-
lowing equation: seizure score = [(0.2) ×
(1/PC latency) + (0.3) × (1/GC latency) +
(0.5) × (1/TC latency)] × 1,000. The
weighting factors (0.2, 0.3 and 0.5) in the
equation were included as a means of in-
corporating a measure of the progressive
nature of the PTZ-induced seizure phe-
notype into the severity rating because
generalized clonus is regarded as a more
significant event than partial clonus and
tonic hind limb extension as the most se-
vere component of the phenotype. There-
fore, the seizure score reflects the degree
of progression of the seizure phenotype
in each mouse (33).
Diazepam dependence, tolerance and
withdrawal. The mice received injections
of diazepam (5 mg/kg body weight IP)
for 10 consecutive days. Rotarod test was
performed 30 min after each diazepam
injection for 7 d, with baseline rotarod
training performed for 2 d before starting
injections. On d 11, diazepam with-
drawal was induced by flumazenil 
(15 mg/kg body weight IP), followed by
injection of PTZ (50 mg/kg body weight
IP) to induce withdrawal-related
seizures. Seizure induction by PTZ 
(50 mg/kg body weight IP) was also per-
formed on drug-naive mice.
Midazolam oral self-administration
and behavior testing in the addicted
state. To induce benzodiazepine depen-
dence as a prerequisite for oral self-
 administration (document of addiction),
group-housed mice received midazolam 
(ratiopharm) in 2% sucrose (to reduce the
bitter taste), instead of drinking water.
Midazolam concentration was increased
weekly, starting from 0.005 mg/mL 
until the maximum concentration of 
0.05 mg/mL was reached after 10 wks. A
respective control group received 2% 
sucrose only. One set of midazolam 
mice was then exposed to a midazolam
preference test. For this purpose, mice
were first switched to single housing
with a continued supply of midazolam
(0.05 mg/mL) for 2 wks. For the prefer-
ence test, every mouse had a choice of
two bottles containing either midazolam
(0.05 mg/mL) in 2% sucrose or 2% su-
crose alone for another 2 wks. The rela-
tive consumption of midazolam solution
was calculated. The other set of mice
(midazolam and control mice) stayed
group-housed and underwent automated
home cage observation using the
 LABORAS™ system (Metris, Hoofddorp,
Netherlands). LABORAS is a fully auto-
mated system for continuous behavior
recognition and tracking in small rodents.
For habituation before testing, mice were
temporarily put in single cages similar to
the LABORAS cage in the testing room
for 2 consecutive nights (1700 to 0900).
On the day of testing, Makrolon type 3
cages (840 cm2), filled with a 2-cm layer
of bedding used during the habituation
phase, were placed on each triangular
sensor platform (95 cm × 75 cm × 75 cm).
Food and sucrose solution with midazo-
lam (addicted group) or 2% sucrose (con-
trol group) were provided ad libitum. 
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Before each session, LABORAS was cali-
brated by using the calibration procedure
and reference weights supplied by
Metris. Movements during nighttime
(1800 to 0900) were recorded and distin-
guished as separate behavioral patterns
by the LABORAS software. Locomotion
duration and scratching frequency dur-
ing the dark phase (2000 to 0800) was 
analyzed.
Statistical analysis. Behavioral data
were analyzed separately for males and
females by the Mann-Whitney U test and
two-way analysis of variance (ANOVA),
including post hoc Bonferroni testing,
where applicable, using Prism4 (Graph-
Pad Software, San Diego, CA, USA). Sig-
nificance level was set to p < 0.05. All
data are presented as mean ± standard
error of the mean (SEM).
Human Sample
Schizophrenic patient sample. The
schizophrenic patient sample (n = 1,086)
was recruited across 23 sites throughout
Germany in the cross-sectional GRAS
study and most comprehensively pheno-
typed (31,32). The study was approved
by the Ethics Committee of the Georg-
August-University (Göttingen, Germany)
and the review boards of participating
centers and complies with the Declara-
tion of Helsinki. Patients fulfilling Diag-
nostic and Statistical Manual of Mental Dis-
orders: DSM-IV-TR, 4th edition, text
revision (34) criteria for schizophrenia or
schizoaffective disorder were included in
the analyses regardless of their disease
stage (acute, chronic, residual or remit-
ted). Almost all patients were of Euro-
pean Caucasian descent (Caucasian
94.7%; other ethnicities 1.9%; unknown
3.4%).
Healthy control sample. Voluntary
blood donors (n = 1,142) recruited fol-
lowing the national guidelines for blood
donation were included for case control
analysis (31,32). Also the majority of con-
trol subjects are of European Caucasian
ethnicity (Caucasian 97.8%; other ethnici-
ties 2%; unknown 0.2%).
Sociodemographic and clinical vari-
ables. Sociodemographic data (age, years
of education, level of unemployment),
information on substance use disorder
(summarizing abuse and dependence
based on the DSM-IV-TR criteria for alco-
hol and cannabis) and clinical variables
describing disease severity were used to
characterize the sample. Clinical vari-
ables included Positive and Negative
Syndrome Scale (PANSS) positive scale
as a measure of positive symptom sever-
ity (35) as well as chlorpromazine equiv-
alents to estimate the relative dose of an-
tipsychotic medication. The Global
Assessment of Functioning (GAF) scale
(DSM-IV-TR) was used as a measure of
impairment of psychological, social and
occupational functioning.
Target variables. The dichotomous
DSM-IV-TR benzodiazepine use disorder
diagnosis (summarizing abuse and de-
pendence) and the quantitative anxiety
composite score were our target vari-
ables. The anxiety composite score is
based on the aggregation of four anxiety-
related variables: (i) Brief Symptom In-
ventory (BSI) subscale anxiousness; (ii)
State-Trait Anxiety Inventory (STAI) sub-
scale trait anxiety; (iii) STAI subscale
state anxiety; and (iv) anxiety item of the
PANSS general psychopathology sub-
scale (Supplementary Figure S2).
DNA extraction and normalization.
Genomic DNA was purified from whole
blood by using JETQUICK Blood and
Cell Culture DNA Spin Kit (Genomed,
Loehne, Germany) according to the man-
ufacturer’s protocol. DNA aliquots were
stored at –80°C. For further analyses,
DNA was normalized to 50 ng/µL with
an automated robotic platform (Microlab
Star, Hamilton, Bonaduz, Switzerland).
Each sample was analyzed with a 0.8%
agarose gel for quality control.
Genotyping. The three selected SNPs
(rs11648169, rs2235632, rs1132358) of
BAIAP3 were analyzed by using Simple
Probes (TIB Molbiol, Berlin, Germany)
and genotyped using the LightCycler®
480 Genotyping Software implemented
in the LightCycler 480 system (Roche,
Mannheim, Germany). The reaction mix-
ture (10 µL) was prepared with 20 ng
DNA in 384-well plates following the
standard protocol (Roche). In each run,
eight positive controls (hgDNA, Bioline,
Luckenwalde, Germany) and negative
water blanks were included for quality
and internal control purposes. Of the
GRAS patients, a total of n = 1,082
(99.63%) were successfully genotyped for
BAIAP3 SNP1 (C/G) rs11648169, n =
1,086 (100%) for BAIAP3 SNP2 (G/A)
rs2235632 and n = 1,069 (98.43%) for
BAIAP3 SNP3 (C/T) rs1132358 and in-
cluded in the analyses. Of the healthy
control subjects, all n = 1,142 were suc-
cessfully genotyped for SNP1, SNP2 and
SNP3 of the BAIAP3 gene.
Statistical analyses. For all analyses,
statistical significance was set to 0.05.
Statistical analyses of human data were
performed by using SPSS for Windows,
version 17.0. Group differences in cate-
gorical and continuous variables were
assessed using χ2 or Mann-Whitney U
tests; in cases of normal distribution of
the continuous variable, t tests were per-
formed. Anxiety score composition was
done using z-standardized mean sub-
scale scores (BSI anxiousness, STAI trait
anxiety, STAI state anxiety) or, in the case
of PANSS anxiety, a z-standardized
single item, organized such that higher
values represent higher symptom sever-
ity. Intercorrelations and internal consis-
tency of the anxiety composite score was
calculated by using Pearson correlation
coefficient and Cronbach α (36). In the
GRAS sample, the following items or
scales were incomplete: BSI anxiousness
7.5% missing, STAI trait anxiety 20.2%,
STAI state anxiety 21.6% and PANSS
anxiety 3.2%. If all four anxiety variables
were available, the mean was calculated
for each respective subject as an individ-
ual anxiety composite score. In the case
of missing data, a linear regression-based
multiple imputation model (10 iterations)
of missing data was applied, if at least
three out of the four variables per subject
were available. For the 190 individuals
with imputed values, the final anxiety
composite score represents the mean of
10 imputed values for the missing item,
increasing the availability of the anxiety
score from n = 771 to n = 961 schizo-
1 3 8 |  W O J C I K E T  A L .  |  M O L  M E D  1 9 : 1 3 5 - 1 4 8 ,  2 0 1 3
B A I A P 3  I S  A S S O C I A T E D  W I T H  A N X I E T Y  A N D  B E N Z O D I A Z E P I N E  A B U S E
phrenic subjects (37). Analysis of covari-
ance (adjusted for age, PANSS positive
subscale score and chlorpromazine
equivalents) was used to analyze the ef-
fect of SNP genotypes on the standard-
ized anxiety composite score. For the
phenotype-genotype association analyses
(including peripheral blood mononuclear
cells [PBMCs]; see below) of the BAIAP3
SNP rs2235632, G carriers (GG and AG)
were aggregated and contrasted with in-
dividuals homozygous for the A allele,
and in the case of SNP rs1132358, C carri-
ers (CC and TC) were aggregated and
contrasted with TT individuals. SNP
rs11648169 was excluded from further




were perfusion-fixed, and organotypic
hypothalamus slices were immersion
fixed in 4% paraformaldehyde in phos-
phate buffer (pH 7.4). Brains were post-
fixed for 1 h, cryoprotected with 30%
 sucrose and frozen. For immunofluores-
cence analysis, free-floating brain sec-
tions of 40 µm thickness or organotypic
sections of 300 µm thickness were incu-
bated in primary antibodies for 72 h fol-
lowed by incubation with IgG- coupled
Alexa Fluor 488, Alexa Fluor 555 and
Alexa Flour 633 dyes (Invitrogen [Life
Technologies, Darmstadt, Germany]) for
24 h. Rabbit and guinea pig antibodies to
Baiap3 were raised to a purified frag-
ment (amino acids 617–973) containing
the munc homology domain (MHD)-1
and MHD-2 of mouse Baiap3. Commer-
cial primary antibodies used were rabbit
and guinea pig anti-vesicular glutamate
transporter 1 (VGLUT1), rabbit and
guinea pig anti-VGLUT2, rabbit and
guinea pig anti-vesicular inhibitory
amino acid transporter (Viaat), mouse
anti-Gephyrin (mAB7a) (all from Synap-
tic Systems, Göttingen, Germany), and
mouse anti-postsynaptic density protein
95 (PSD-95) (clone K28/48,  NeuroMab).
False color images of brain sections and
organotypic slices were obtained with a
fluorescence stereomicroscope (Leica
 FluoCombi III™) and an ApoTome™ flu-
orescence microscope (Axio Imager Z1;
Zeiss), respectively.
Hypothalamus slice culture. Organ-
otypic hypothalamus slices of 300-µm
thickness from postnatal d 5 (P5) and P6
mice were prepared in Hanks balanced
salt solution (24020-091; Invitrogen [Life
Technologies]) with 20% glucose and 
1 mmol/L kynurenic acid (Sigma-
Aldrich, Germany) (pH 7.4), by using a
McIlwain Tissue Chopper. Slices were
cultured in six-well plates on confetti cut
from 0.45-µm filters (FHLC04700; EMD
Millipore [Millipore Ireland B.V., Tulla-
green, Carrigtwohill County Cork, Ire-
land]) that were placed in 0.4-µm Milli-
cell cell culture inserts (PICM03050;
Millipore) for 5 d using a mixture of 41%
Earle basal medium Eagle (BME) (F 0225;
Biochrom, Berlin, Germany), with 25%
Earle balanced salt solution (1.8 mmol/L
CaCl2, 1 mmol/L NaH2PO4, 0.8 mmol/L
MgSO4, 116 mmol/L NaCl, 26.2 mmol/L
NaHCO3, 5.4 mmol/L KCl, 5 mmol/L glu-
cose), 20% heat-inactivated horse serum,
10% H2O, 25 mmol/L 4-(2- hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES)
(Biochrom), 28 mmol/L glucose, 1 mmol/L
GlutaMAX™ (35050; Invitrogen [Life Tech-
nologies]), 1 µg/mL insulin, 88 µg/mL
ascorbic acid, 0.25% MEM Vitamine Solu-
tion (K0373; Biochrom) and 0.5% MEM
Amino Acids (K0363; Biochrom). On d 5
in vitro, the cultures were switched to a
medium with identical components but
containing 5% horse serum, 55% BME
and 2 mmol/L GlutaMAX. At the same
time, diazepam was added to the me-
dium from a 60 mmol/L stock solution in
dimethylsulfoxide (DMSO) for a final
concentration of 10 µmol/L. For control
cultures, DMSO was added as a vehicle
control at the same dilution of 1:6,000.
The CO2 concentration was 5%, and me-
dium changes were done on the day after
culture and every 48 h after that.
Electrophysiological analyses. Organ-
otypic slices containing the ventromedial
hypothalamus were transferred to the
recording chamber between DIV10 and
DIV17. Recordings were started after a 
30-min recovery time, the extracellular
recording solution contained 120 mmol/L
NaCl, 26 mmol/L NaHCO3, 1 mmol/L
KH2PO4, 2 mmol/L KCl, 20 mmol/L glu-
cose, 2 mmol/L MgCl2, 2 mmol/L CaCl2
and 250 nmol/L flumazenil. Cells were
whole-cell voltage clamped at –70 or
–20 mV or recorded in current clamp mode
with an EPC 10 USB Double (HEKA,
 Lambrecht/Pfalz, Germany) under control
of the Patchmaster 2.52 program (HEKA).
All analyses were performed by using the
Mini Analysis Program (Synaptosoft, De-
catur, GA, USA). Recordings of miniature
inhibitory postsynaptic currents (mIPSCs)
were performed in the presence of
1 µmol/L tetrodotoxin (Tocris [R&D Sys-
tems, Wiesbaden- Nordenstadt, Germany])
and 10 µmol/L 2,3-dioxo-6-nitro-1,2,3,4-
 tetrahydrobenzo[ f ]quinoxaline-7-
sulfonamide (NBQX) (Tocris [R&D Sys-
tems]), with an intracellular solution
containing 100 mmol/L KCl, 50 mmol/L
K-gluconate, 10 mmol/L HEPES, 
0.1 mmol/L EGTA, 0.3 mmol/L GTP, 
4 mmol/L ATP and 0.2% biocytin. Action
potentials and spontaneous inhibitory post-
synaptic currents (IPSCs) were recorded
with an intracellular solution containing
20 mmol/L KCl, 130 mmol/L K-gluconate,
10 mmol/L HEPES, 0.1 mmol/L EGTA,
0.3 mmol/L GTP, 4 mmol/L ATP and
0.2% biocytin. Action potentials analyzed
were from the first minute of a 2-min
recording; membrane potentials were
measured after setting the current injec-
tion to 0 pA at the end of the recording.
IPSCs were recorded for 5 min after
switching the cell to a holding potential of
–20 mV and waiting for 1 min. Statistical
analyses were performed using GraphPad
Prism5.
Analysis of BAIAP3 mRNA levels in
PBMCs. PBMCs from 121 patients were
isolated by using the standard Ficoll-
Paque Plus isolation procedure (GE
Healthcare, Munich, Germany). For RNA
isolation, the miRNeasy Mini Kit (Qiagen,
Hilden, Germany) was used. A total of
1 µg RNA, a mixture of oligo dT, hexamer
primers, dNTPS (10 mmol/L each) and
SuperScriptIII (200 U; Invitrogen [Life
Technologies]) were used for transcription
into cDNA (20-µL reaction). The mixture
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was incubated for 10 min at 25°C and 45
min at 50°C, followed by 45 min at 55°C.
For the quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR), a
1:10 dilution of the cDNA was used and
three replicate experiments per sample
were performed: 5 µL Power SYBR mix
(Applied Biosystems) and 1 pmol of 
each primer were added. BAIAP3 qRT-





The following cycling profile was run on
the LightCycler480 system (Roche): pre-
heating at 95°C for 10 min; 45 cycles of
95°C for 15 s, 60°C for 1 min. Cycle thresh-
old values of BAIAP3 were standardized
to cycle threshold values of GAPDH.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Generation of Baiap3 KO Mice
Baiap3 shares the basic domain struc-
ture of other Munc13 isoforms, with two
munc-homology domains flanked by
two C2 domains but lacks the N-termini
contained in Munc13-1, -2 and -3 (23).
The murine Baiap3 gene contains 33 cod-
ing exons that span 8.7 kb. We generated
Baiap3 KO mice by homologous recombi-
nation in embryonic stem cells, replacing
the first three coding exons with a
neomycin selection cassette (Supplemen-
tary Figure S1A). Baiap3 KO mice are vi-
able, fertile and indistinguishable from
their wild-type (WT) littermates in the
home cage. In WT brain, the expression
pattern of Baiap3 protein analyzed by
immunofluorescence staining largely
matches the distribution of Baiap3
mRNA published in the Allen Brain
Atlas. Baiap3 protein is prominently ex-
pressed throughout the hypothalamus
and in the central, medial and basome-
dial amygdaloid nuclei, as well as in the
paraventricular nucleus of the thalamus
(Figure 1). Strong expression is further
detected in the septum, bed nucleus of
the stria terminalis, midbrain including
the periaqueductal gray and inferior col-
liculus, and brain stem including the
parabrachial nucleus and nucleus tractus
solitarius (Figure 1). Baiap3 immunoreac-
tivity appears punctate, but does not
seem to localize to either glutamatergic
or GABAergic pre- or postsynapses to a
significant degree (Supplementary Fig-
ures S1C–G). Adult Baiap3 KO mice lack
any detectable expression of Baiap3 pro-
tein by immunofluorescence and Western
blot analysis (Figure 1B, Supplementary
Figure S1B). Western blot analysis of
brains taken from newborn Baiap3 KO
animals revealed the presence of a weak
band that most likely corresponds to
Baiap3 protein expressed from a start
codon present in coding exon 4; how-
ever, this putative truncated Baiap3
product is barely detectable by the age of
3 wks and not present in adult animals
(Supplementary Figure S1B).
Novelty-Induced Anxiety in Baiap3
KO Mice
The striking expression pattern of
Baiap3 in the amygdala and other brain
regions involved in processing fear
piqued our interest, and we chose to as-
sess whether the genetic deletion of
Baiap3 led to any detectable behavioral
alterations. We subjected Baiap3 KO mice
and WT littermates of both sexes to a
battery of standard behavioral tests (Fig-
ures 2A–L; Supplementary Figures
S3A–J). In the open field, both male and
female Baiap3 KO mice showed an in-
creased latency to reach the wall upon
release in the center zone (Figures 2A, B).
Female but not male KO mice also made
fewer visits to the center (Figures 2C, D)
and spent significantly more time in the
periphery (Figures 2E, F). When placed
in a novel chamber (fear-conditioning
box), both male and female KO mice
showed an increased novelty-induced
freezing response (Figures 2K, L). Taken
together, these findings are indicative of
a heightened novelty-induced anxiety
level in Baiap3 KO animals, with a more
pronounced effect noted in females. In
contrast, classical tests, measuring anxi-
ety in the context of an inherent conflict
between a protected and a more anxio-
genic area, that is, elevated plus-maze
and light–dark box, did not reveal any
genotype differences (Figures 2G–J). Fur-
thermore, the distance traveled (motor
activity) in open field and elevated plus-
maze (Supplementary Figures S3A–D),
exploratory behavior (hole board; Sup-
plementary Figures S3E, F), motor learn-
ing and coordination (rotarod; Supple-
mentary Figures S3G, H) and body
weight (Supplementary Figures S3I, J)
were not affected by genotype.
BAIAP3 Is a Risk Marker for Anxiety in
Women
To explore the possibility of an associa-
tion of genetic variability in the human
BAIAP3 gene with specific biological
readouts, we made use of the GRAS data-
base of schizophrenic patients (31,32). Our
hypotheses regarding Baiap3/BAIAP3
function were based on the anxiety phe-
notype observed in Baiap3 KO mice and
on the prominent expression of Baiap3 in
brain regions involved in processing fear-
ful stimuli as well as in substance use dis-
orders. We selected three single-nucleotide
polymorphisms (SNPs) in the BAIAP3
gene: rs11648169 (C/G, intronic),
rs2235632 (G/A, intronic) and rs1132358
(C/T, coding sequence, synonymous
Asp1040Asp) (Supplementary Figure S4A)
from public databases [http://www.ncbi.
nlm. nih. gov/projects/SNP/; http://
browser. 1000genomes.org; http://
hapmap. ncbi. nlm.nih.gov/]. The selection
of SNPs was based on (i) a high minor al-
lele frequency (MAF ≥ 0.36) distribution
within the European Caucasian popula-
tion (http://www.ncbi.nlm.nih. gov/
SNP/), to increase the power to detect ge-
netic effects, and (ii) the potential for
functional consequences. The last criterion
could only partially be fulfilled; the ex-
onic SNP rs1132358 (C/T, Asp1040Asp,
synonymous) might potentially affect
mRNA structure or stability. All SNPs ful-
filled Hardy-Weinberg equilibrium crite-
ria, both in cases and in controls (p >
0.05). A construction of haplotype blocks
of the three SNPs revealed a similarly
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high degree of linkage disequilibrium be-
tween them in the GRAS sample (Supple-
mentary Figure S4B) and in healthy con-
trols (Supplementary Figure S4C). Case
control analysis of genotype frequencies
of the three SNPs did not reveal any sig-
nificant differences, indicating that the 
selected genetic variation in BAIAP3 is
not associated with schizophrenia risk
(Supplementary Figure S4D). We subse-
quently used the PGAS approach (32) to
analyze the three SNPs for association
with specific phenotypic readouts rele-
vant for anxiety disorders and substance
use disorders. For this step, an anxiety
composite score was constructed using
four anxiety-relevant variables (Supple-
mentary Figure S2), which showed a sig-
nificant association with only two of the
three selected SNPs (as expected because
of the high linkage disequilibrium be-
tween both markers and their similar
MAFs) for women but not for men 
(Table 1). SNP rs11648169 was excluded
from further analyses, since it yielded no
statistically significant effects.
BAIAP3 Is a Risk Gene for
Benzodiazepine Abuse in Men
Because anxiety disorders and sub-
stance use disorders often occur together,
and BAIAP3 is expressed in brain regions
relevant for emotionality and drug de-
pendence, we also screened for a possible
association between genetic variation in
BAIAP3 and substance use disorder. The
same risk genotypes (AA for rs2235632,
TT for rs1132358) that were associated
with anxiety in women showed a statisti-
cally significant association with benzodi-
azepine use disorder in men (Table 1).
Even though there was a similar ten-
dency for women (benzodiazepine use
disorder associated with 7.0%/7.7% in
AA/TT genotypes versus 4.7%/4.6% in
G/C carrier status), it did not reach sta-
tistical significance, perhaps because of
the lower numbers of women than men
in the GRAS sample. The genotype fre-
quencies of rs2235632 and rs1132358 did
not differ between men and women in




women 29.8%/46.9%/23.3%), and neither
of these two SNPs was associated with
disease-related or sociodemographic con-
trol variables (Table 1).
For the purpose of an association anal-
ysis of the relevant BAIAP3 genotypes
(GG/AG/AA in rs2235632 and
CC/TC/TT in rs1132358) with benzodi-
azepine use disorder, the GRAS sample
delivers an ideal, nearly experimental set-
ting. The distribution of these genotypes
among benzodiazepine users versus
nonusers is highly comparable, allowing
the identification of risk genotypes lead-
ing to benzodiazepine use disorder (Sup-
plementary Table S1). Most importantly,
the benzodiazepine dose was equal
across all genotypes (Supplementary
Table S1). Hence, the BAIAP3 risk geno-
types (AA for rs2235632, TT for
rs1132358) appear to confer a specific ge-
netic risk of developing benzodiazepine
use disorder given equal dose and likeli-
hood of exposure. Interestingly, neither
alcohol nor cannabis abuse were found to
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Figure 1. Immunofluorescence analysis of Baiap3 expression in mouse brain. (A) Sagittal
brain section of adult Baiap3 WT mouse stained with rabbit anti-Baiap3 antibody. (B)
Sagittal brain section of adult Baiap3 KO littermate showing the absence of Baiap3 im-
munoreactivity. Please note that the signal observed in the hippocampus of both WT and
KO brain is a nonspecific background staining. (C) Coronal brain section of adult WT
mouse stained for Baiap3 with a corresponding coronal diagram, adapted from the
mouse Paxinos brain atlas (Bregma –1.46). PB, parabrachial nucleus; NTS, nucleus tractus
solitarius; Hi, hippocampus; SC, superior colliculus; IC, inferior colliculus; PAG, periaqueduc-
tal gray; LS, lateral septum; Th, thalamus; Hy, hypothalamus; BST, bed nucleus of the stria
terminalis; PV, paraventricular thalamic nucleus; DM, dorsomedial hypothalamic nucleus;
VMH, ventromedial hypothalamic nucleus; Arc, arcuate nucleus; Ce, central amygdaloid
nucleus; BLA, basolateral amygdaloid nucleus, anterior part; BMA, basomedial amyg-
daloid nucleus, anterior part; ME, medial amygdaloid nucleus; ACo, anterior cortical
amygdaloid nucleus. Scale bars equal 1 mm.
be associated with the two SNPs, point-
ing to a specific benzodiazepine link with
the selected BAIAP3 genotypes (Table 1).
To determine whether the identified
risk genotypes are associated with al-
tered expression of BAIAP3, we analyzed
the mRNA levels of BAIAP3 in PBMCs
obtained from 121 subjects by qRT-PCR.
We found a statistically significant asso-
ciation of the BAIAP3 risk genotypes
(AA for rs2235632, TT for rs1132358)
with lower BAIAP3 mRNA levels in
PBMCs of male individuals, which is at
least partially comparable to a gene dose
reduction or KO situation. This result is
not found in women, possibly because of
the lower numbers available for analysis
(Supplementary Figure S5). However,
these findings could also support the in-
terpretation that the effects of BAIAP3
risk alleles are gender specific.
Male Baiap3 KO Mice Show Faster
Development of Tolerance to
Benzodiazepines
On the basis of the identification of
human BAIAP3 risk genotypes for ben-
zodiazepine abuse in male patients, we
tested Baiap3 KO and WT littermates of
both sexes in experimental paradigms of
chronic benzodiazepine administration
to assess the development of tolerance,
dependence and withdrawal (Figure 3A).
The baseline performance of each mouse
in the rotarod test was established on
two consecutive days of rotarod training.
No significant genotype-dependent dif-
ferences were detected in baseline per-
formance (Supplementary Figures S3G,
H). Benzodiazepine dependence in
Baiap3 KO and WT mice of both sexes
was then induced with daily diazepam
injections (5 mg/kg IP) for 10 consecu-
tive days. To monitor the development of
tolerance to diazepam, motor perform-
ance on rotarod at 30 min after each in-
jection was evaluated over the first 7 d of
diazepam treatment. Rapid development
of tolerance to daily diazepam injections
was apparent in both sexes and genotypes
by an increase of the latency of falling
from rotarod over the course of 7 d (Fig-
ures 3B, C). Here, male Baiap3 KO mice
performed significantly better than their
WT littermates (Figure 3B), whereas no
such difference was detected for females
(Figure 3C). Thus, male Baiap3 KO mice
show faster development of tolerance to
diazepam.
Baiap3 KO Mice Have an Increased
Seizure Propensity
To evaluate whether Baiap3 genotype
would affect the propensity for di-
1 4 2 |  W O J C I K E T  A L .  |  M O L  M E D  1 9 : 1 3 5 - 1 4 8 ,  2 0 1 3
B A I A P 3  I S  A S S O C I A T E D  W I T H  A N X I E T Y  A N D  B E N Z O D I A Z E P I N E  A B U S E
Figure 2. Anxiety phenotype in Baiap3 KO mice. (A–F) Open field parameters. (A, B) The latency to reach the wall of the open field was
significantly increased in Baiap3 KO mice of both sexes, whereas visits to the center (C, D) and stay in the periphery (E, F) revealed anxi-
ety-like behavior only in females. Elevated plus-maze (G, H) and light–dark box (I, J) revealed no genotype-dependent differences in ei-
ther sex. (K, L) As readout of unspecific novelty-related anxiety, a higher freezing response was found in male as well as female Baiap3 KO
mice. Numbers tested: males, WT = 16–25, KO = 16–25; females, WT = 18–23, KO = 10–28. Mann-Whitney U test (A–D, I–L) and two-way




























































Table 1. Phenotype comparison of GRAS patients sorted by BAIAP3 genotypes.
BAIAP3 rs2235632 BAIAP3 rs1132358
G carriers p C carriers p
GRAS sample (GG/AG) AA (F/T/Z/χ2 value)a (CC/TC) TT (F/T/Z/χ2 value)a
Males n = 471–538b n = 155–187b n = 474–538b n = 152–175b
Target variables
Benzo use disorder [n (%)] 11 (2.3) 9 (5.4) 0.047 (χ2 = 3.93) 11 (2.3) 9 (5.7) 0.034 (χ2 = 4.47)
Anxiety composite score (mean ± SD)c,d –0.06 ± 0.74 –0.07 ± 0.70 0.499 (F = 0.46) –0.07 ± 0.73 –0.05 ± 0.72 0.651 (F = 0.21)
Sociodemographic
Age (at examination) (years) (mean ± SD [range]) 37.33 ± 12.01 [18–78] 36.17 ± 11.91 [17–75] 0.225 (Z = –1.21) 37.28 ± 11.96 [18–78] 36.34 ± 12.06 [17–75] 0.309 (Z = –1.02)
Education (years) (mean ± SD [range])e 14.17 ± 3.48 [8–28] 14.42 ± 3.70 [8–27] 0.680 (Z = –0.41) 14.21 ± 3.48 [8–28] 14.32 ± 3.76 [8–27] 0.853 (Z = –0.19)
Unemployment [n (%)] 217 (44.7) 76 (44.7) 0.990 (χ2 = 0.00) 214 (44.2) 75 (46.6) 0.601 (χ2 = 0.27)
Substance use
Alcohol use disorder according to DSM-IV-TR [n (%)] 221 (42.3) 84 (45.7) 0.435 (χ2 = 0.61) 217 (41.6) 82 (47.4) 0.180 (χ2 = 1.80)
Cannabis use disorder according to DSM-IV-TR [n (%)] 218 (41.8) 83 (45.1) 0.430 (χ2 = 0.62) 224 (42.9) 75 (43.4) 0.919 (χ2 = 0.01)
Clinical
PANSS positive score (mean ± SD [range]) 13.55 ± 6.04 [7–36] 14.02 ± 6.41 [7–38] 0.427 (Z = –0.79) 13.53 ± 6.03 [7–36] 14.23 ± 6.50 [7–38] 0.249 (Z = –1.15)
Chlorpromazine equivalents (mean ± SD [range]) 707.90 ± 694.69 689.45 ± 568.91 0.678 (Z = –0.42) 701.33 ± 688.16 712.11 ± 592.75 0.424 (Z = –0.80)
[0–6,324.29] [0–3,238.00] [0–6,324.29] [0–3,238.00]
GAF score (mean ± SD [range]) 45.70 ± 16.04 [10–90] 45.35 ± 16.88 [5–90] 0.862 (Z = –0.17) 45.75 ± 16.05 [10–90] 44.90 ± 16.89 [5–90] 0.619 (Z = –0.50)
Females n = 223–269b n = 75–92 b n = 229–273b n = 71–83b
Target variables
Benzo use disorder [n (%)] 12 (4.7) 6 (7.0) 0.406 (χ2 = 0.69) 12 (4.6) 6 (7.7) 0.281 (χ2 = 1.16)
Anxiety composite score (mean ± SD)c,d –0.02 ± 0.77 0.19 ± 0.80 0.028 (F = 4.91) –0.02 ± 0.78 0.21 ± 0.77 0.017 (F = 5.81)
Sociodemographic
Age (at examination) (years) (mean ± SD [range]) 42.36 ± 12.92 [18–79] 44.86 ± 12.52 [21–76] 0.893 (T = 1.61) 42.52 ± 12.90 [18–79] 44.49 ± 12.60 [20–76] 0.221 (T = 1.23)
Education (years) (mean ± SD [range])e 14.56 ± 3.95 [7–31] 14.12 ± 3.54 [8–27] 0.447 (Z = –0.76) 14.52 ± 3.94 [7–31] 14.13 ± 3.62 [8–27] 0.454 (Z = –0.75)
Unemployment [n (%)] 76 (31.9) 20 (25.0) 0.243 (χ2 = 1.37) 74 (30.5) 20 (28.2) 0.712 (χ2 = 0.14)
Substance use
Alcohol use disorder according to DSM-IV-TR [n (%)] 59 (22.4) 14 (15.7) 0.178 (χ2 = 1.82) 60 (22.4) 13 (16.0) 0.219 (χ2 = 1.51)
Cannabis use disorder according to DSM-IV-TR [n (%)] 30 (11.4) 8 (9.0) 0.525 (χ2 = 0.40) 29 (10.8) 9 (11.1) 0.941 (χ2 = 0.01)
Clinical
PANSS positive score (mean ± SD [range]) 13.84 ± 6.66 [7–37] 14.41 ± 6.38 [7–33] 0.288 (Z = –1.06) 13.87 ± 6.69 [7–37] 14.32 ± 6.24 [7–32] 0.366 (Z = –0.91)
Chlorpromazine equivalents (mean ± SD [range]) 636.37 ± 776.51 704.59 ± 762.50 0.612 (Z = –0.51) 634.40 ± 771.10 718.83 ± 788.67 0.616 (Z = –0.50)
[0–7,375.00] [0–4,370.00] [0–7,375.00] [0–4,370.00]
GAF score (mean ± SD [range]) 46.34 ± 19.42 [8–90] 44.22 ± 17.59 [12–84] 0.435 (Z = –0.78) 46.22 ± 19.25 [8–90] 44.88 ± 18.07 [12–84] 0.645 (Z = –0.46)
SD, standard deviation.
aFor statistical methods, Mann-Whitney U or χ2 tests and for normally distributed variables t tests were used. Bolded values: p < 0.05.
bBecause of missing data, sample sizes vary.
cResults after multiple imputations (10).
dAnalysis of covariance with age, positive symptoms (PANSS) and medication status (chlorpromazine equivalent) as covariates.
eTotal years spent in education system; patients currently in school or educational training were excluded.
azepam withdrawal-related seizures, the
susceptibility to PTZ-induced seizures
was first evaluated in diazepam-naive
mice. The seizure response of Baiap3 KO
mice of both sexes to PTZ (50 mg/kg IP)
was higher than that in WT animals,
with the difference just failing to reach
significance in males (Figures 3D, E). To
assess the effect of genotype on benzodi-
azepine withdrawal, the diazepam an-
tagonist flumazenil (15 mg/kg IP) was
injected on d 11, after 10 d of daily di-
azepam treatment, immediately followed
by PTZ injection (50 mg/kg IP) to trigger
withdrawal seizures (Figure 3A). Upon
flumazenil-induced diazepam with-
drawal, the response to PTZ in male
Baiap3 KO and WT mice did not differ
appreciably from the one found in di-
azepam-naive mice of both genotypes
(Figure 3F). In contrast, the genotype-
 dependent differences in diazepam-naive
females regarding seizure scores disap-
peared under conditions of diazepam
withdrawal (Figure 3G), which could be
explained by a ceiling effect. Thus, fe-
male and male Baiap3 KO mice are more
seizure-prone than their WT littermates,
and this propensity is not further in-
creased by benzodiazepine withdrawal.
Drug Self-administration and Basic
Behaviors Do Not Differ between
Baiap3 Genotypes upon Chronic
Addiction
To assess whether Baiap3 KO mice,
once addicted, would also be more
likely to orally self-administer benzodi-
azepines, we performed an experiment
on chronic midazolam addiction, where
self-application was assessed after
forced long-term exposure to escalating
doses of midazolam (Supplementary
Figure S6). We detected no genotype or
gender differences in the clear prefer-
ence for midazolam. Moreover, no geno-
type effects on body weight or basic be-
havior in the chronically addicted state
were noted (Supplementary Figure S6).
These data indicate that the Baiap3
genotype gender specifically affects the
development of tolerance, that is, drug
abuse at an early stage. In chronic ad-
diction, genotype effects are no longer
detectable.
Lack of Homeostatic Adaptation to
Diazepam in Baiap3 KO
Hypothalamus Slices
One hypothesis regarding predisposi-
tion to the development of addiction at
the cellular level is an altered response
to the addiction-inducing substance and
its withdrawal. Because Baiap3 KO mice
showed an increased seizure propensity
and an altered development of tolerance
to diazepam, we investigated whether
lack of Baiap3 leads to a measurably al-
tered response to diazepam treatment
and withdrawal in neurons in vitro. Be-
cause Baiap3 expression is highest in the
hypothalamus, we cultured organotypic
hypothalamus slices prepared from
male P5/P6 Baiap3 KO and WT animals
in the presence of either 10 µmol/L di-
azepam or vehicle (DMSO) and re-
corded from neurons in the ventrome-
dial hypothalamus in the presence of
the diazepam antagonist flumazenil to
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Figure 3. Diazepam tolerance and withdrawal in Baiap3 KO and WT mice. (A) Experimen-
tal design scheme. (B) Male diazepam-treated Baiap3 KO mice showed significantly
faster improvement of performance on the rotarod, consistent with a more rapid devel-
opment of tolerance to diazepam. (C) Rotarod performance of female mice was com-
parable between WT and KO. (D, E) Diazepam-naive Baiap3 KO mice display a higher
PTZ-induced seizure propensity compared with WT (significant in females, strong tendency
in males). (F, G) Flumazenil-induced diazepam withdrawal does not further increase PTZ-
 induced seizure propensity in Baiap3 KO mice. Seizure propensity of female mice became
comparable between genotypes, pointing to a ceiling effect. Numbers tested: males, 
WT = 25, KO = 25; females, WT = 21, KO = 23, except for (D) and (E), where males, WT = 7,
KO = 7; females, WT = 8; KO = 10. Mann-Whitney U test (D–G) and two-way repeated-
measures ANOVA (B, C), including Bonferroni, testing applied. Means ± SEM are presented.
mimic diazepam withdrawal conditions
in vitro. We hypothesized that diazepam
treatment would lead to a homeostatic
adaptation in the GABAAR-mediated
mIPSCs (Figure 4A) that would become
apparent under diazepam withdrawal
conditions. Although we observed no
diazepam treatment–dependent differ-
ences that reached statistical signifi-
cance, there was a significant genotype-
dependent effect under diazepam
withdrawal conditions. Here, WT
mIPSC amplitudes were 27% smaller
(Figure 4B) and rise times 13% longer
than in KO neurons (Figure 4C), which
is suggestive of a homeostatic adapta-
tion to diazepam treatment in WT but
not in KO slices. No significant differ-
ences in mIPSC decay times and fre-
quencies were observed (Supplementary
Table S2). Because the sudden with-
drawal of diazepam should lead to an
increase in overall network activity, we
recorded action potential (AP) frequen-
cies in ventromedial hypothalamus
slices in the presence of flumazenil. Sur-
prisingly, KO slices already showed sig-
nificantly higher AP frequencies than
WT slices under control conditions, with
no further increase under diazepam
withdrawal conditions. By contrast, in
WT slices, we observed a significant in-
crease in AP frequency under diazepam
withdrawal conditions compared with
vehicle-treated WT slices (Figure 4D).
There was no significant difference in
the resting membrane potentials (Fig-
ure 4E), AP rise times, decay times and
half-widths (Supplementary Table S2).
IPSCs were recorded in the same cells 
at a holding potential of –20 mV to be
able to isolate spontaneous GABAAR-
mediated currents without drug appli-
cation. In WT slices, we observed a sig-
nificant effect of diazepam withdrawal,
with an increase in IPSC amplitude and
frequency compared with vehicle-
treated WT slices (Figures 4F, G), which
is in keeping with the overall higher fir-
ing rate and which was not apparent in
KO slices. In summary, these data show
that neurons in Baiap3 KO hypothala-
mus slices have higher AP firing rates,
likely consistent with the higher seizure
propensity found in vivo, and that
Baiap3 KO slices show no obvious
homeostatic adaptation to diazepam
treatment and withdrawal.
DISCUSSION
In this study, we identify two human
BAIAP3 risk genotypes that are associ-
ated with anxiety in women and benzo-
diazepine use disorder in men. We fur-
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Figure 4. Increased basal network activity and lack of homeostatic adaptation to di-
azepam treatment in Baiap3 KO hypothalamus slices. (A) Sample traces of mIPSC record-
ings from WT and KO hypothalamus slices that were cultured in the presence of di-
azepam or under vehicle control conditions with DMSO. Under diazepam withdrawal
conditions, Baiap3 WT mIPSC amplitudes were significantly smaller than in KO slices (B),
and WT mIPSC rise times were longer than in KO slices (C). (D) Baiap3 WT slices showed an
increase in AP frequency in response to diazepam withdrawal when compared with
DMSO-treated WT slices, whereas no such increase was apparent for Baiap3 KO slices,
which already showed an increased AP frequency under DMSO control conditions when
compared with WT slices. (E) The resting membrane potential was not affected by experi-
mental condition or Baiap3 genotype. IPSC amplitudes (F) and IPSC frequencies (G) were
increased in Baiap3 WT slices under diazepam withdrawal compared with DMSO-treated
WT slices. Mann-Whitney U test was used for AP and IPSC frequencies; Student t test was
used for all other parameters. Means ± SEM are presented.
ther show that Baiap3 deficiency in mice
leads to (i) elevated seizure propensity;
(ii) increased anxiety in both genders,
with a more pronounced effect in fe-
males; and (iii) a faster development of
tolerance to benzodiazepines in male
mice. In vitro analysis of hypothalamic
slices revealed an increase in neuronal
baseline activity in the absence of Baiap3.
Withdrawal from chronic benzodi-
azepine application in vitro results in a
genotype-specific response pattern.
To the best of our knowledge, no other
genetic risk marker that is associated
with anxiety and benzodiazepine abuse
has been reported to date. We are aware
that, pending replication in nonschizo-
phrenic individuals, we cannot be sure
that our findings can be applied to the
general population. In spite of this limi-
tation, our findings suggest a role for
BAIAP3 and potential interaction part-
ners in the development of anxiety and
drug dependence.
Unfortunately, similar data from sam-
ples of equally well-phenotyped healthy
individuals or even other disease
groups are not available. This is particu-
larly true with regard to benzodiazepine
abuse, since short-term exposure is a
primary goal of controlled and med-
ically surveyed indications. Even look-
ing at other rare situations of long-term
exposure (for example, intractable
epilepsies), a homogeneous sample
comparable to the GRAS collection
would be difficult to imagine. In the
GRAS sample, there are no differences
between BAIAP3 genotypes regarding
benzodiazepine exposure or daily dose
(in case of exposure). This constellation
allowed us to analyze the specific ge-
netic risk of developing benzodiazepine
use disorder in a setting close to an ex-
perimental condition.
Importantly, the present study was
purely hypothesis-driven. Our hypothe-
ses for performing a human phenotype-
based genetic association study of
BAIAP3 were based on the anxiety phe-
notype we observed during basic behav-
ioral characterization of Baiap3 KO mice
as well as on the distinctive Baiap3 ex-
pression pattern in brain, which includes
regions relevant for addictive behaviors.
We find that in humans, female carriers
of the homozygous BAIAP3 risk geno-
types (AA for SNP rs2235632; TT for SNP
rs1132358) are more likely to meet crite-
ria for an anxiety disorder, whereas male
carriers of the same risk genotypes are
more likely to fulfill criteria for benzodi-
azepine use disorder. Neither SNP was
associated with schizophrenia in our
case control analysis. Furthermore, no as-
sociations with substance use disorder
other than benzodiazepine use disorder
were observed. In general, both genetic
linkage and candidate gene studies suf-
fer from lack of replicability (12). How-
ever, in our study, the parallel identifica-
tion of a gender-specific association of
BAIAP3/Baiap3 with anxiety and an al-
tered response to benzodiazepines in
both mice and men, lends strong support
to a causal link between BAIAP3 and the
observed phenotypes.
As for other genetic variations associ-
ated with anxiety disorders (11,12) or
substance use disorders (13–15), the im-
pact of BAIAP3 genotypes on anxiety
disorders or benzodiazepine use disorder
is likely to be small. However, the ob-
served effects and their gender speci-
ficity (across two species) are intriguing.
While we currently have no mechanistic
insight into this gender specificity, part
of the explanation may lie in the fact that
Baiap3 is expressed in sexually dimor-
phic brain regions such as the hypothala-
mus, amygdala and the bed nucleus of
the stria terminalis (38,39).
Given the higher prevalence of both
anxiety disorders and benzodiazepine use
disorder in women (9,40) the present find-
ings were surprising at first glance, but
the similarity of gender differences in
mice and humans underlines their signifi-
cance, encouraging follow-up work on
this gender effect. Admittedly, the gender
effects in humans may ultimately turn out
to be less prominent, since the total num-
ber of individuals with benzodiazepine
abuse in the GRAS sample is low, result-
ing in moderate significance levels only
for men. It cannot be excluded that, in a
larger sample, an association of benzodi-
azepine use disorder with the genotypes
investigated here might reach significance
for women as well. Furthermore, research
focusing on gender differences and social
desirability in self-reported anxiety sug-
gests an underreporting of fear and dis-
tress in men (41–43). Therefore, our use of
three self-reported measures in the calcu-
lation of the anxiety composite score
might partly explain the lack of associa-
tion of the BAIAP3 risk genotypes with
anxiety in men. Nevertheless, gender dif-
ferences in BAIAP3/Baiap3 genotype-phe-
notype associations most likely exist and
are worth pursuing.
Benzodiazepines are positive allosteric
modulators of GABAAR and thus en-
hancers of inhibitory GABAergic neuro-
transmission. Their sedative, anti-convul-
sive and amnesic effects are largely
mediated by the GABAARα1 subunit, the
anxiolytic effect by the α2 subunit and
muscle relaxation by α2, α3 and α5 sub-
units (44). To date, no specific risk associ-
ation of these obvious candidate genes
has been identified. At present we have
no evidence that would suggest that
Baiap3 interacts with GABAAR subunits.
However, the increased seizure propen-
sity observed in Baiap3 KO mice of both
sexes, which is already apparent without
prior diazepam treatment and with-
drawal, is indicative of an altered bal-
ance of excitatory and inhibitory sys-
tems. Our comparison of neuronal firing
rates in hypothalamus slices under base-
line and diazepam withdrawal condi-
tions uncovered an increase in basal net-
work activity in the absence of Baiap3.
This finding was unexpected, and al-
though presently limited to the hypothal-
amus, is consistent with the increased
seizure propensity observed in vivo. Even
though we do not know whether the
seizures observed in our PTZ-induction
model originate in the subcortical re-
gions that express Baiap3, subcortical
epileptogenesis with origins in the hypo-
thalamus is a feature seen in hypothala-
mic hamartomas (45), and the amygdala,
which also expresses Baiap3, is known to
play a key role in epileptogenesis (46).
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Interestingly, the human BAIAP3 gene is
located on chromosome 16p13.3, which
has been linked to electroencephalo-
graphic traits of idiopathic epilepsy syn-
dromes (47,48). We would thus argue
that further investigation of BAIAP3 as a
candidate gene for epilepsy-related phe-
notypes is warranted. Because we found
that Baiap3 did not colocalize with mark-
ers of GABAergic or glutamatergic pre-
and postsynapses to a significant degree
(Supplementary Figures S1C–G), the in-
creased seizure propensity in Baiap3 KO
mice of both sexes and the altered re-
sponse to benzodiazepines in males is
unlikely to be due to a direct effect of
Baiap3 at GABAergic or glutamatergic
synapses.
The neuronal circuitry underlying the
addictive properties of benzodiazepines
is less well understood than their molec-
ular mechanism of action. Unlike many
other addictive substances, benzodi-
azepines do not appear to increase
dopamine levels in the nucleus accum-
bens (49–51), although electrophysiologi-
cal studies suggest that benzodiazepines
increase firing of dopaminergic neurons
in the VTA through disinhibition of these
neurons via inhibition of nearby in-
hibitory interneurons (52,53). Additional
mechanisms, such as neuroendocrine re-
sponses to benzodiazepine treatment,
may play a critical role in the develop-
ment of benzodiazepine use disorder
(54). Furthermore, because expression of
Baiap3 in both the VTA and in the nu-
cleus accumbens is low (Allen Brain
Atlas), a direct effect of Baiap3 on the
mesolimbic dopamine pathway does not
appear be the most likely explanation for
the observed interaction between Baiap3
genotypes and the response to benzodi-
azepines. Instead, our findings support
the interpretation that the altered re-
sponse to benzodiazepines could be a
consequence of a local or global change
in neuronal excitability. Because all other
members of the Munc13 protein family
have been shown to be regulators of
SNARE-mediated exocytosis (25,29),
Baiap3 may regulate the release of one or
more modulatory neurotransmitters or
neuropeptides that influence the balance
between GABAergic and glutamatergic
neurotransmission. Baiap3 immuoreac-
tivity appears punctate (Supplementary
Figures S1C–G) and may localize to pep-
tidergic release sites, some of which may
also contain VGLUT2 or Viaat. Although
we presently cannot exclude the possibil-
ity that Baiap3 might have a postsynaptic
function, given what is know about the
function of all other members of the
Munc13 protein family, we think that a
pre-synaptic function is more likely. We
can furthermore not exclude the possibil-
ity that alterations in the hypothalamic-
pituitary-adrenal axis may play a role in
the anxiety phenotype or the altered re-
sponse to benzodiazepines seen in Baiap3
KO mice. We are currently investigating
whether Baiap3 is involved in regulating
exocytosis of dense core vesicles and/or
intracellular trafficking events that could
influence neuropeptide release or ex-
trasynaptic GABAARs.
CONCLUSION
To conclude, BAIAP3 had not previ-
ously been considered a candidate gene
for either psychiatric disorders or
epilepsy. Our study links BAIAP3/Baiap3
genotypes to anxiety and an altered re-
sponse to benzodiazepines in both mice
and men and thus strongly argues for
an involvement of BAIAP3 in these neu-
ropsychiatrically relevant phenotypes.
The identification of human genetic var-
iations that influence the risk for the de-
velopment of pathological phenotypes
as well as the response to pharmacologi-
cal treatments may pave the way for
more efficient treatments with fewer
side effects. Rodent models are usually
only imperfect representations of
human psychiatric conditions; however,
the simultaneous identification of Baiap3
as a biomarker for anxiety and the re-
sponse to benzodiazepines in mouse
and humans suggests that Baiap3 KO
mice will be a valuable tool in further
elucidating the genetic, physiological
and neuroanatomical underpinnings of
anxiety disorders and benzodiazepine
use disorder.
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Supplementary Table S1. Benzodiazepine use (%) and dose (lorazepam equivalents) in GRAS patients sorted by BAIAP3 genotypes.
BAIAP3 rs2235632 BAIAP3 rs1132358
p value p value
Males (GRAS sample) GC AG AA (χ2 value) a CC TC TT (χ2 value) a
N=181 N=351 N=187 N=184 N=347 N=175
Receiving benzodiazepines, No. (%) b 22 (12.2) 57 (16.2) 30 (16.0) .427 (χ2 =1.70) 20 (10.9) 57 (16.4) 30 (17.1) .165 (χ2 =3.60)
N=21d N=52d N=30 N=19d N=52d N=30
Benzodiazepine dose, mg, Mean±SD b, c 3.14±4.14 2.64±3.11 3.04±3.31 .833 (χ2 =0.37) 2.95±4.31 2.67±3.11 3.00±3.32 .979 (χ2 =0.04)
p value p value
Females (GRAS sample) GC AG AA (χ2 value) a CC TC TT (χ2 value) a
N=101 N=167 N=92 N=105 N=167 N=83
Receiving benzodiazepines, No. (%) b 28 (27.7) 34 (20.4) 23 (25.0) .363 (χ2 =2.02) 30 (28.6) 34 (20.4) 20 (24.1) .298 (χ2 =2.42)
N=27d N=33d N=21d N=29d N=33d N=18d
Benzodiazepine dose, mg, Mean±SD b, c 2.51±1.51 2.13±2.35 2.33±2.28 .227 (χ2 =2.97) 2.44±1.49 2.08±2.37 2.52±2.40 .234 (χ2 =2.90)
a For statistical methods Chi2 or Kruskal-Wallis test was used. 
b Refers to benzodiazepines as daily medical treatment. 
c Calculation of lorazepam equivalents according to Bezchlibnyk-Butler, K. Z. & Jeffries, J. J. (Eds) (2003) Clinical Handbook of Psychotropic
Drugs (13th ed). Cambridge (MA): Hogrefe & Huber. 
D Discrepancies in N due to missing information on benzodiazepine compound or daily dose. 
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Supplemental Data
Supplementary Table S2. The mIPSC frequencies and decay times and the AP rise times,
decay times and half-width were not affected by experimental condition or Baiap3
genotype.
WT DMSO KO DMSO WT Diazepam KO Diazepam
mIPSC Decay Time 20.27±4.35 ms 21.01±4.94 ms 21.40±4.22 ms 20.36±4.21 ms
mIPSC Frequency 3.99±3.26 Hz 5.59±5.78 Hz 4.43±3.74 Hz 3.61±2.80 Hz
AP Rise Time 0.97±0.36 ms 1.02±0.45 ms 1.05±0.37 ms 1.12±0.34 ms
AP Decay Time 1.17±0.17 ms 1.14±0.24 ms 1.14±0.24 ms 1.21±0.36 ms
AP Half-Width 1.22±0.19 ms 1.22±0.29 ms 1.20±0.26 ms 1.27±0.39 ms
Mann-Whitney U test for mIPSC frequencies and Student’s t-test for all other parameters.
Mean±SD presented.
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Supplementary Figure S1. Targeting strategy and expression of mouse Baiap3. (A) Targeting strategy for the mouse Baiap3 gene. The first
3 coding exons were replaced with a neomycin selection cassette (Neo). The targeting vector further contained 2 thymidine kinase cas-
settes (TK) for negative selection. (B) Western blot analysis of the expression of Baiap3, in P0, P7, P14, P21 and adult Baiap3 WT and KO ani-
mals. In Baiap3 KO pups, we detected a truncated Baiap3-immunoreactive product that decreased after P7 and was not detectable in
adult mice. An antibody to the valosin-containing-protein (VCP) ATPase was used as a loading control. (C-E) Immunostaining analyses in
the hypothalamic medial preoptic area show that Baiap3 largely does not co-localize with markers of glutamatergic and GABAergic
synapses. (C) Baiap3 (red) shows no co-localization with the vesicular glutamate tranporter (VGLUT)1 (green). (D) Baiap3 (red) shows
only limited co-localization with VGLUT2 (green) (E) Baiap3 (red) shows only limited co-localization with the vesicular inhibitory amino
acid transporter (Viaat) (green). (F) In organotypic hypothalamus slices Baiap3 (red) does not show significant co-localization with pre-
synaptic (Viaat, blue) or post-synaptic (Gephyrin, green) markers of GABAergic synapses or (G) with pre-synaptic (VGLUT2, blue) or post-
synaptic (postsynaptic-density-protein 95, green) markers of glutamatergic synapses. Scale bars equal 10μm. 
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Supplementary Figure S2. Anxiety composite score. Shown are variables composing the
anxiety composite score, their intercorrelations and internal consistency. Pearson's correla-
tion coefficients and Cronbach’s α given. 
Supplementary Figure S3. Baiap3 genotype does not affect activity level, exploratory behavior, motor function or body weight. (A,B) The
distance traveled during a 7-min session in the open field and (C,D) 5-min session in the elevated plus-maze was comparable among
genotypes and genders. (E,F) Exploratory behavior measured in the hole board, (G,H) motor coordination and learning, evaluated by ro-
tarod, as well as (I,J) body weight were comparable for both genders between Baiap3 KO and WT littermates. Numbers tested: males,
WT=16-25, KO=16-25; females, WT=18-23, KO=10-28. Mann-Whitney U test (A-F, I,J) and 2-way repeated measures ANOVA (G,H), including
Bonferroni testing, were applied. Mean±s.e.m. presented.
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Supplementary Figure S4. BAIAP3 genotyping strategy and case-control analyses. (A) Location of the selected single nucleotide poly-
morphisms (SNPs) in the BAIAP3 gene. Kb, kilobases. (B) Linkage disequilibrium map for N=1086 schizophrenic and schizoaffective patients
and (C) Linkage disequilibrium map for N=1142 healthy blood donors indicating a high degree of linkage between the 3 selected SNPs
in both groups. (D) Case-control comparisons reveal a similar distribution of the BAIAP3 SNP genotypes for patients and healthy individu-
als, thus excluding the selected BAIAP3 markers as risk factors for schizophrenia. 
Supplementary Figure S5. BAIAP3 mRNA expression in PBMCs. (A) SNP rs2235632: The risk genotype AA is associated with lower BAIAP3
mRNA levels in male but not in female patients. (B) SNP rs1132358: The risk genotype TT is associated with lower BAIAP3 mRNA levels in
male but not in female patients. Mann-Whitney U test applied, due to non-normal data distribution (A,B). 
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Supplementary Figure S6. High oral self-administration of midazolam (as readout of addiction), body weight, and basic behaviors in the
chronic addicted state are not affected by Baiap3 genotype. (A) Experimental design scheme. (B,C) Baiap3 KO and WT mice of both
genders displayed significant and comparable preference for midazolam over sucrose. (D,E) Chronic midazolam intake did not affect
body weight of male, but increased that of female mice independently of genotype. (F,G) Locomotion duration in LABORASTM remained
unaffected across genotypes and genders. (H,I) Scratching frequency in LABORASTM tended to be increased upon chronic high-dose mi-
dazolam across genotypes and genders. Numbers tested: males, WT= 6-8, KO=10-16; females, WT=6-10, KO=10-13, except for (B) and (C),
males, WT=8, KO=4; females, WT=5; KO=4; 2-way repeated measures ANOVA (B,C) as well as 2-way ANOVA (D-I), including Bonferroni test-
ing, where applicable. Mean±s.e.m. presented. 
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4. MOUSE MODEL TARGETING A TRANSCRIPTIONAL 
REGULATOR, MECP2 (I):  
Mild overexpression of Mecp2 in mice causes a higher 
susceptibility toward seizures 
 
a. Overview of project II 
An intriguing finding about the transcriptional regulator MECP2 (methyl-CpG-binding-
protein 2) gene is that the loss-of-function mutations are attributable to Rett syndrome 
(RTT) (Amir, Van den Veyver et al. 1999), while the gain-of-function causes another 
neurological disorder, termed MECP2 duplication syndrome (Ramocki, Tavyev et al. 
2010), indicating that MECP2 is dosage-sensitive (Collins, Levenson et al. 2004; 
Ramocki, Tavyev et al. 2010; Chao and Zoghbi 2012). This is also evident from 
mouse studies. Previously, a transgenic mouse model that overexpresses Mecp2 at 
twice the level of endogenous Mecp2 was generated and characterized (Collins, 
Levenson et al. 2004). The phenotypes of the mice are reminiscent of the human 
MECP2 duplication syndrome, with the onset of the phenotypes at around 10 weeks 
of age, when these mice started showing stereotyped and repetitive movements, 
motor dysfunctions, hypoactivity, ataxia, spasticity, epilepsy and 30% of them died by 
1 year of age (Collins, Levenson et al. 2004). Interestingly, in another study, 
evaluation of a Mecp2flox allele revealed a reduced expression of Mecp2 by 50% 
(Samaco, Fryer et al. 2008). These Mecp2flox/Y mice manifested a milder spectrum of 
disabilities, such as learning and motor deficits, decreased anxiety, and breathing 
dysfunction (Samaco, Fryer et al. 2008). 
 
Overall, there is accumulating evidence that the central nervous system is highly 
sensitive to the functional level of Mecp2: certain levels of Mecp2 are required for the 
neuronal system to maintain its inhibitory and excitatory balance (Ramocki and 
Zoghbi 2008). Consequently, any gain or loss of Mecp2 over a narrow threshold level 
can lead to postnatal neurological impairment (Chao and Zoghbi 2012). This precise 
regulation of MECP2 expression to maintain the balance has important impacts, for 
example in the evaluation of potential therapeutic strategies for correcting the 
expression level of MECP2 in patients with MECP2 dysfunctions. To study the 
pathological mechanism underlying the neurological impairment of gain-of-function of 
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MECP2, we established a transgenic mouse model with only mild overexpression of 
Mecp2. We aimed to identify and characterize the earliest pathologies elicited due to 
gain-of-function properties of MECP2. 
 
To evaluate Mecp2 dosage effects, a Mecp2WT_EGFP transgenic (TG) mouse was 
generated in which total Mecp2 (endogenous plus TG) was only mildly overexpressed 
at ~1.5fold WT level. The TG Mecp2 protein which showed a similar expression 
pattern to endogenous Mecp2 in the hippocampus, was biologically functional, as 
cross breeding of these mice with Mecp2 null-mutant mice rescued major phenotypes 
in the null mutant mice.  To assess the effect of mild overexpression of Mecp2 on 
neurons, neuronal parameters of cultured neurons were studied. TG neurons showed 
a reduction in the number of tertiary branching, but increased spine density and 
altered calcium homeostasis. 
 
To study the phenotypical consequences of mildly overexpressing Mecp2 at ~1.5fold 
WT level, we performed a detailed behavioral characterization during early postnatal 
period and adulthood of male TG and WT mice. First, TG and WT control mice 
underwent neonatal assessments which comprised (1) maturation measures targeting 
physical development, (2) neurodevelopmental measures targeting the development 
of neurological reflexes and (3) the development of neuron-motor-coordination. The 
TG mice did not differ from their WT littermates on cursory neonatal observation, 
suggesting that mild Mecp2 overexpression at ~1.5fold WT level did not alter the 
neonatal development.  
 
The effect of mild Mecp2 overexpression was then investigated during adulthood. 
Adult TG and WT mice were tested to assess their basic behavior (activity, anxiety, 
exploratory), sensory (olfactory, vision and hearing), motor and sensorimotor gating 
functions, and social behavior (aggression) and also depression-like behavior 
(anhedonia). Most behavioral domains tested were not altered in TG mice. However, 
we found that TG mice displayed increased aggression towards intruder mice during 
the resident-intruder paradigm test for territorial aggression. This confirmed our 
observation that TG mice were more inclined to bite when handled. We also 
repeatedly observed spontaneous seizures in the TG mice. Thus, to assess seizure 
susceptibility, we induced seizures by pentylenetetrazole (PTZ) administration. Indeed, 
we detected increased susceptibility to PTZ-induced seizures in 30-week old TG mice. 
Interestingly, on the neuronal level, treatment of TG neurons with PTZ also led to a 
Mouse model targeting a transcriptional regulator, MECP2 (I) 
35 
marked increase in amplitude and frequency of calcium spikes. Spontaneous and 
elicited calcium spikes (indicators of spontaneous discharges of neurons) are usually 
considered as a correlate of epileptic seizures (DeLorenzo, Sun et al. 2007). In 
conclusion, the results of the second project suggest that epileptic seizure propensity 
is highly sensitive to the functional level of Mecp2 and it appears as the primary 
symptoms when Mecp2 is mildly overexpressed in mice. 
 
b. Original publication 
Bodda C*, Tantra M*, Mollajew R, Arunachalam JP, Laccone FA, Can K, 
Rosenberger A, Mironov SL, Ehrenreich H and Mannan AU (2013): Mild 
overexpression of Mecp2 in mice causes a higher susceptibility toward seizures. The 




I was responsible for the very detailed behavioral characterization of several cohorts 
of transgenic mice with mild Mecp2 overexpression and their wild-type littermates. 
This included adult male mice testing as well as neonatal testing. I investigated the 
domains of basic behavior, sensory and motor functions, and social behavior. Not 
only did I perform the experiments, I also analyzed and interpreted the behavioral 
data which I presented in the figures for the publication (see Table 1, figure 2, 
supplemental figure S1, S4 and supplemental table S1). Moreover, I was involved in 
the conception, design, drafting, revision and publication of the manuscript: under the 
supervision of Prof. Hannelore Ehrenreich and PD Dr. Ashraf Mannan, I wrote and 
cited appropriately the materials and methods and results (including the 
interpretations of the results for the discussion) sections of the behavioral 
experiments of the manuscript. I prepared the above mentioned figures and tables 
and wrote the corresponding figure legends. 
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An intriguing finding about the gene encoding methyl-CpG binding protein 2 (MeCP2) is that the loss-of-
function mutations cause Rett syndrome and duplication (gain-of-function) of MECP2 leads to another
neurological disorder termed MECP2 duplication syndrome. To ensure proper neurodevelopment, a precise
regulation of MeCP2 expression is critical, and any gain or loss of MeCP2 over a narrow threshold level may
lead to postnatal neurological impairment. To evaluate MeCP2 dosage effects, we generated Mecp2WT_EGFP
transgenic (TG) mouse in which MeCP2 (endogenous plus TG) is mildly overexpressed (approximately
1.5). The TG MeCP2WT_EGFP fusion protein is functionally active, as cross breeding of these mice with
Mecp2 knockout mice led to alleviation of major phenotypes in the null mutant mice, including premature
lethality. To characterize the Mecp2WT_EGFP mouse model, we performed an extensive battery of behavioral
tests, which revealed that these mice manifest increased aggressiveness and higher pentylenetetrazole
(PTZ)-induced seizure propensity. Evaluation of neuronal parameters revealed a reduction in the number
of tertiary branching sites and increased spine density in Mecp2WT_EGFP transgenic (TG) neurons. Treatment
of TG neurons with epileptogenic compound-PTZ led to a marked increase in amplitude and frequency of
calcium spikes. Based on our ex vivo and in vivo data, we conclude that epileptic seizures are manifested
as the first symptom when MeCP2 is mildly overexpressed in mice. (Am J Pathol 2013, 183: 195e210;
http://dx.doi.org/10.1016/j.ajpath.2013.03.019)
The MECP2 gene encodes for methyl-CpG-binding protein
2 (MeCP2). MeCP2 binds to methylated CpG DNA se-
quences and modulates transcription of genes in the vicinity
of the methylated sequence.1 The ability of MeCP2 to bind to
the methylated CpGs, and its predominant localization to the
highly methylated heterochromatin regions of the nucleus,2
led researchers to propose that MeCP2 may act as a global
transcriptional repressor.3 Subsequently, the majority of
studies substantiated the role of MeCP2 in repression of
transcription (reviewed in Chahrour and Zoghbi4 and Guy
et al5). Furthermore, MeCP2 was shown to interact with
Sin3A and HDAC (histone deacetylases).6 By recruiting
HDAC at the methylation loci, MeCP2 further represses
transcription at such sites. However, recent studies have also
highlighted the role of MeCP2 in transcriptional activation. It
was shown that MeCP2 associates with actively transcribed
genes.6,7 MeCP2 promotes activation of transcription by
associating with the transcriptional activator CREB1 (cAMP
responsive element binding protein 1) on an active but not
repressed form of the same gene.6 A multifaceted role of
MeCP2 was further corroborated by the discoveries of its
involvement in RNA splicing and chromatin compactions.8,9
Mutations in MECP2 gene have been shown to cause
a neurodevelopmental disorder known as Rett syndrome
(RTT).10 Classically, RTT patients develop normally until
the age of 6 to 18 months. After this normal phase of
development, RTT patients fall into a stage of developmental
stagnation, followed by rapid regression. The patients start
Supported by the Cluster of Excellence and Deutsche For-
schungsgemeinschaft Research Center Nanoscale Microscopy and Molec-
ular Physiology of the Brain (A.U.M., S.L.M., and H.E.).
C.B. and M.T. contributed equally to this work.
Copyright ª 2013 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2013.03.019
ajp.amjpathol.org
The American Journal of Pathology, Vol. 183, No. 1, July 2013
showing symptoms, such as progressive loss of motor skills,
stereotypic hand movements, breathing abnormalities,
microcephaly, epileptic seizures, and social interaction
impairments reminiscent of autism.11 Due to X-chromosome
inactivation, females are mosaics for MECP2 mutations,
which can have a mitigating effect, with phenotypes ranging
from classic RTT to asymptomatic individuals.12 However,
male patients carrying MECP2 mutations usually show
a very severe phenotype. They typically suffer from neonatal
encephalopathy and die in early childhood.13 Until now,
more than 700 MECP2 mutations have been reported for
RTT (https://portal.biobase-international.com/hgmd/pro/all.
php, HGMD Professional 2012.4, last accessed December
14, 2012). All types of mutations have been reported, such as
missense, nonsense, splice site, deletion, and insertion. This
wide spectrum ofMECP2mutations suggests loss-of-function
as the likely common pathomechanism for RTT.
In addition to these loss-of-function mutations in the
MECP2 gene, which cause RTT, until now more than 100
cases of copy number gains of the MECP2 gene have been
reported.14,15 In the majority of cases, duplication ofMECP2
locus was observed, however, in several instances, triplica-
tion was also detected.16,17 The gain of MECP2 lead to
a neurological disorder termed MECP2 duplication
syndrome, which primarily affects males who display vari-
able phenotypes. Common symptoms include infantile
hypotonia, severe mental retardation, autism or autistic
features, poor speech development, recurrent infections,
progressive spasticity, ataxia, and epilepsy.14,15,18 MECP2
duplication is 100% penetrant in males.14 The triplication of
theMECP2 locus causes a more severe phenotype.17,19Most
of the reported MECP2 duplications are inherited, however,
de novo cases have also been reported.18,20,21
Previously, a TG mouse (MECP2-Tg1) was generated that
overexpresses MeCP2 at twice the level of endogenous
MeCP2.22 The phenotypes of these mice are reminiscent of
the humanMECP2 duplication syndrome. Until the age of 10
to 12 weeks, these TG mice appear normal. Afterward, they
develop progressive neurological symptoms that include
stereotyped and repetitive movements, motor dysfunction,
epilepsy, spasticity, ataxia, hypoactivity, kyphosis, and
premature death.22 Increasing the copy numbers ofMecp2 in
the TG mice, resulting in higher MeCP2 levels, causes even
more severe phenotypes.22 Interestingly, in another study,
evaluation of a Mecp2flox allele revealed that due to the
modification of the 30UTR of Mecp2 by insertion of
a neomycin cassette, the expression of MeCP2 was reduced
by 50%.23 These Mecp2flox/Y mice manifest a spectrum of
disabilities, such as learning and motor deficits, decreased
anxiety, and breathing dysfunction.
Overall, it is evident that the central nervous system is
highly sensitive to the functional level of MeCP2 and any gain
or loss of MeCP2 over a narrow threshold level can lead to
postnatal neurological impairment. This precise regulation of
MeCP2 expression to ensure proper neurodevelopment
has important ramifications regarding devising potential
therapeutic strategies for correcting the expression level of
MeCP2 in RTT patients. To study the pathomechanism
underlying the neurological impairment in MECP2 duplica-
tion syndrome, a mouse model with only mild overexpression
of MeCP2 may help to identify and characterize the earliest
pathologies elicited due to gain-of-function properties of
MECP2. Therefore, we generated Mecp2
WT_EGFP TG mice,
which mildly overexpress MeCP2 (approximately 1.5).
Materials and Methods
Generation of Mecp2WT_EGFP Transgenic Mouse Line
A bacterial artificial chromosome (BAC) clone, plasmid
(p)BAC_B22804 containing approximately 120 Kb of murine
genomic fragment with intact Mecp2 gene and the flanking
Opsin1 and Irak1 genes was used for generating the TG
construct.24 To generate pBAC_Mecp2WT_EGFP construct,
the enhanced green fluorescent protein/kanamycin-resistant
gene (EGFP/Kan) cassette was PCR-amplified using
pEGFP1 vector as the template with primers containing 50 bp
flanking sequence from either side of the Mecp2 stop codon.
Furthermore, the endogenous stop codon was replaced by two
glycine residues in frame between the MeCP2 protein and the
EGFP protein to facilitate the two proteins to fold and function
independently. The amplified EGFP/Kan cassette was elec-
troporated into Escherichia coli harboring the BAC clone and
pGET recombination system25 to facilitate the homologous
recombination of EGFP/Kan cassette at the site of stop codon
of Mecp2. The correct insertion of EGFP/Kan cassette after
the recombination event into the BAC clone was confirmed
by sequencing. TheMecp2 flanking genes, Opsin1 and Irak1
were deleted from the modified BAC clone using additional
BAC recombineering with the Zeocin selection cassette
(containing the BAC homology arms and Zeocin (InvivoGen,
Toulouse, France) antibiotic marker gene driven by EM7
promoter from pSELECT vector) to avoid any additional
phenotype arising from the overexpression of these genes.
During the process of Opsin1 deletion, aMlu I restriction site
was introduced into the BAC clone.
The final BAC construct pBAC_Mecp2WT_EGFP was
linearized with the Mlu I restriction enzyme and micro-
injected into the male pronuclei of the fertilized mouse
oocytes derived from the FVB/N strain. Next, the injected
oocytes were transplanted into the uteri of the foster
mothers. The genomic DNA isolated from tail biopsies of
newborn pups were analyzed for the presence of the trans-
gene by PCR analysis, as previously described.24
Western Blot Analysis
For Western blot experiments, total protein extracts were
isolated from brain biopsies of fresh male adult mice. In
brief, the brain biopsies were collected in ice cold PBS
and transferred to cold lysis buffer (20 mmol/L PIPES
[piperazine-N,N0-bis(2-ethanesulfonic acid)], 2 mmol/L
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EGTA, 1 mmol/L EDTA, 1 mmol/L DTT, and 0.3 mmol/L
phenylmethylsulfonyl fluoride) containing protease inhibitors
(Roche, Mannheim, Germany) followed by homogenization
using tissue micromotor. The lysates were sonicated on ice
and the supernatant was collected after centrifugation at
12,000 g for 10 minutes at 4C. An aliquot of 50 mg protein
lysates were denatured by boiling in a buffer containing SDS
and dithiothreitol, which were resolved by SDS-PAGE using
a NuPAGE 4 to 12%Bis-Tris precast gel in 2-(N-morpholino)
ethanesulfonic acid buffer (Invitrogen, Karlsruhe, Germany).
The resolved proteins were electrotransferred onto a nitrocel-
lulose membrane (Amersham Biosciences, Braunschweig,
Germany). Afterward, the membrane was blocked in 5%
lyophilized milk powder in Tris-buffered saline-Tween (100
mmol/L Tris-Cl, pH 7.5; 150 mmol/L NaCl; 0.1% Tween 20)
and then incubated with either anti-MeCP2 antibody (dilution
1:8000) raised in rabbit using MeCP2-strep tag fusion protein
as antigen (Eurogentec, Cologne, Germany) or anti-GFP anti-
body (GeneTex, Eching, Germany) (dilution 1:5000) at 4C
overnight. The following day after washing, the immunoblot
was incubated with secondary antibody conjugated with alka-
line phosphatase (dilution 1: 10,000) (Sigma-Aldrich, Munich,
Germany) for 1 hour at room temperature. Finally,Western blot
analysis was developed by using nitroblue tetrazolium, 5-
bromo-4-chloro-3-indolyl phosphate (NBT/BCIP; Carl-Roth,
Karlsruhe, Germany). The intensity of the protein bands in
the Western blot analysis were quantified using ImageJ soft-
ware version 1.46 (NIH, Bethesda, MD).
RNA Preparation and RT-qPCR Analysis
Total RNA was extracted from the cerebellum and hippo-
campus of 6-week-old male mice using TRIzol reagent (Invi-
trogen, Karlsruhe, Germany) according to the manufacturer’s
instructions. The cDNA was synthesized from 2 mg of RNA
using the SuperScript II (Invitrogen, Karlsruhe, Germany) and
oligo-dT primer in a total volume of 20 mL. For real-time
quantitative RT-PCR (RT-qPCR) analysis, the cDNA was
further diluted (1:8) and was used as a template in Platinum
SYBR Green qPCR SuperMix-UDG with ROX system
(Invitrogen, Karlsruhe, Germany) with Mecp2 gene specific
primers (Mecp2_F; 50-TGGTAGCTGGGATGTTAGGG-30
and Mecp2_R; 50-CCTTCTTGTCTTTCTTCGCC-30). The
RT-qPCR reactions were run in 7900 Sequence Detection
System (Applied Biosystems, Darmstadt, Germany). The
housekeeping gene, b-actin amplicon was used for data
normalization. TheRT-qPCRexperimentswere repeated four
times with three technical replicate. The data were analyzed
by SDS software version 2.2 (Applied Biosystems, Darm-
stadt, Germany) using standard curve method and Microsoft
Excel version 2010 (Immeuble Laccolith, Luxembourg).
Immunohistochemistry
The adult male mice were transcardially perfused with 4%
paraformaldehyde in PBS for 3 hours at 4C. The whole brain
was dissected and submerged in 15% sucrose for 1 hour at 4C
followed by incubation in 30% sucrose solution for 3 days, and
then cryosectioned to 40 mm thickness. The brain sections
were washed three times with PBS for 5 minutes each and then
permeabilized with 0.2% Triton-X for 30 minutes at 4C.
Thereafter, the slides were washed again three times with PBS
for 5 minutes and incubated in 4% bovine serum albumin and
0.1%Tween-20 (Promega,Mannheim, Germany) for 1 hour at
room temperature. The brain sections were then incubated
with anti-MeCP2 antibody (1:200; Eurogentec, Cologne,
Germany) at room temperature for 1 hour in 2% bovine serum
albumin solution. After washing steps, the sections were
incubated with secondary antibody conjugated with Cy3
(Sigma-Aldrich) for 1 hour at room temperature in 2% bovine
serum albumin solution. After final washing, the slides were
air-dried and VectaShield solution (Linaris, Wertheim,
Germany) was applied before mounting the slides with
coverslips. The sections were observed under a BX60 fluo-
rescence microscope (Olympus, Hamburg, Germany).
Animal Management and Behavioral Analysis
All experiments have been approved by the local Animal
Care and Use Committee. Mice used for the experiments
were kept in our behavioral unit under a temperature-
controlled environment (21  2C) on a 12-hour light/dark
cycle with food and water ad libitum, unless stated other-
wise. A battery of behavioral tests were performed on
preweaning and postweaning stages of mice. In all experi-
ments, the experimenter (M.T.) was unaware (blinded) of
the genotype.
Drug Used in Animal Experiments
Pentylenetetrazole (PTZ; Sigma-Aldrich Chemie GmbH,
Taufkirchen, Germany), a noncompetitive GABA antagonist
with epileptogenic properties was dissolved in saline for
subcutaneous injection.
Preweaning (Neonatal) Assessments
Male TG mice were bred with FVB/N wild-type (WT) female
mice to obtainWT andMecp2 TG animals. A daily inspection
for the presence of new litters in the cages was carried out
twice a day, and the day a litter was first observed was scored
as day 0 for that litter. After birth, animals were kept untouched
in the home cage with their mothers until postnatal day (P) 3,
and at P3 animals feet were tagged. Neurodevelopmental
evaluation tests were performed daily starting from P4 until
P21. The battery of tests provides an assessment of develop-
ment throughout the neonatal period and the behaviors
measured are expressed at different periods throughout the first
21 days of life. These tests have been extensively described
elsewhere26e28 and consist of observations covering the
maturation of physical landmarks, as well as developmental
milestones (Supplemental Figure S1). Weaning was per-
formed at 22 days of age. For the assessment of preweaning
behavior, 14 male WT and 18 male TG litters were used.
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Postweaning (Adult) Behavior
Breeding pairs of Mecp2 TG male and WT female FVB/N
mice were used to obtain WT and Mecp2 TG mice. Shortly
after weaning, mice were transferred to the behavioral unit
for testing. On arrival and during the whole period of
behavioral testing, mice were housed individually in stan-
dard plastic cages (26.5  20  14 cm). Adult behavioral
testing was performed starting at the age of 5 weeks. The
animal numbers of individual experiments are given in the
legend of each corresponding figure.
Experimental Design
Neonatal Assessments
Neonatal assessments were comprised of three domains: i)
maturation measures targeting physical development, ii)
neurodevelopmental measures targeting the development of
neurological reflexes, and iii) the development of neuro-
motor coordination.
Maturation Measures (Physical Development)
Body weight. The body weight of each pup was registered
daily, starting from P4 through P21.
Ear opening. The day when an opening in the ear was
visualized, the mouse was registered.
Eyes opened. The day when the eyes were opened, the
mouse was registered. An eye was considered open when
any visible break in the membrane was noticed.
Neurodevelopmental Measures
Surface righting reflex. Animals were restrained on their
back on a table and then released. The time needed for each
pup to right itself was recorded and the performance was
monitored for 3 consecutive days, starting from P4. Score
0 was assigned when pup did not show surface righting
reflex and score 1 when surface righting reflex was present.
Postural reflex. Starting on P7 onward, animals were put
in a small box and shaken up and down, left and right.
Animals were tested until an appropriate response (animals
splaying their four feet) was observed and scored as 1.
Cliff avoidance. Observed daily from P6 until each test
pup, when placed on an edge with forepaws and nose just
over the edge, showed retraction within 10 seconds. Then
score 1 was assigned.
Negative geotaxis reflex. Observed daily from P7 onward,
animals were put in a head-down position on a 30 inclined
surface. The response of each pup was observed for 30
seconds and registered as shown in Supplemental Figure S1.
Neuromotor Coordination Measures
Wire suspension. The animals were forced to grasp a 3
mm wire and hang from it on their forepaws. Mice were
tested starting on P10 onward until all test pups were able to
hold the wire for 30 seconds.
Swimming ability. Mice were tested on P8, P12, and P14.
On each observation day, one at a time, test pups were placed
in a tank of water (30C) for a period of 5 to 15 seconds and
observed for three aspects of swimming: i) direction, ii) head
position relative to water surface, and iii) use of limbs.
Scoring for direction was: sank, 0; floated, 1; swam in circle
or arch, 2; straight, 3. Scoring for angle: submerged, 0; nose
at the surface, 1; nose and top head at or above the surface but
ears still below the surface, 2; similar to the last except for
waterline is now at mid-ear level, 3; nose and top of head and
ears above the surface, 4. Scoring for limb usage: no
paddling, 0; paddling with all four limbs, 1; paddling with
hind limbs only and forelimbs held stationary, 2.
Adult Behavior
Elevated Plus Maze
The mouse was placed in the central platform, facing an
open arm of the plus maze inside a room with light intensity
set to 130 lx. Behavior was recorded by an overhead video
camera and a computer equipped with Viewer software
version 2 (Biobserve GmbH, Sankt Augustin, Germany) to
calculate the time each animal spends in open or closed
arms. The proportion of time spent in open arms was used
for estimation of open arm aversion (fear equivalent).
Open Field
Spontaneous activity in the open field was tested in a gray
Perspex arena (120 cm in diameter, 25 cm high) (Max Planck
Institute for Biophysical Chemistry, Göttingen, Germany)
placed inside a room with light intensity set to 130 lx. The
mouse was positioned in the center and allowed to explore the
open field for 7 minutes. The behavior was recorded by
a computer-linked overhead video camera. Viewer software
was used to calculate velocity, distance traveled, and time spent
in central, intermediate, or peripheral zones of the open field.
Hole Board
The hole board test measures exploratory activity. The
apparatus consisted of a transparent Perspex chamber (21 
21  36 cm) with a nontransparent floor raised 5 cm above
the bottom of the chamber with 16 equally spaced holes (2
cm in diameter). Mice were allowed to explore the chamber
for 5 minutes and the number of explored holes (head dips)
was monitored by 2 layers of infrared photo beams con-
nected to a computer with ActiMot software version 2 (TSE
Systems GmbH, Bad Homburg, Germany). The light
intensity was set to 5 lx during the test phase.
Pre-Pulse Inhibition Test
In this test of sensorimotor gating, individual mice were placed
in small metal cages (90  40  40 mm) to restrict major
movements and exploratory behavior. The cages were equip-
ped with a movable platform floor attached to a sensor that
records verticalmovements of the floor. The cages were placed
in four sound-attenuating isolation cabinets (TSE Systems
GmbH). Startle reflexes were evoked by acoustic stimuli
delivered from a loudspeaker that was suspended above the
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cage and connected to an acoustic generator. The startle
reaction to an acoustic stimulus, which evokes a movement of
the platform and a transient force resulting from this move-
ment of the platform, was recorded with a computer during
a recording window of 260 msec (beginning with the onset of
prepulse) and stored for further evaluation. The recording
window was defined from the onset of the acoustic stimulus.
An experimental session consisted of a 2-minute habituation to
65 dB background white noise (continuous throughout the
session), followed by a baseline recording for 1 minute at
background noise. After baseline recording, 6 pulse-alone
trials using startle stimuli of 120 dB intensity and 40 msec
duration were applied to decrease influence of within-session
habituation. These data were not included in the analysis of the
prepulse inhibition. For tests of prepulse inhibition, the 120
dB/40 msec startle pulse was applied either alone or preceded
by a prepulse stimulus of 70 dB, 75 dB, or 80 dB intensity at 20
msec duration. An interval of 100 ms with background white
noise was used between each prepulse and pulse stimulus. The
trials were presented in a pseudorandom order with an interval
ranging from 8 to 22 seconds. The amplitude of the startle
response (expressed in arbitrary units) was defined as the
difference between the maximum force detected during
a recording window and the force measured immediately
before the stimulus onset. Amplitudes were averaged for each
individual animal, separately for both types of trials (ie,
stimulus alone or stimulus preceded by a prepulse). Prepulse
inhibition was calculated as the percentage of the startle
response using the following formula:
Prepulse inhibition %Z 100  ½ðstartle amplitude after pre-
pulse and pulseÞ=ðstartle amplitude after pulse onlyÞ  100:
ð1Þ
Rota-Rod
Rota-rod is a test for motor function, balance, and coordi-
nation, and comprises a rotating drum (Ugo Basile Srl,
Comerio, Italy) that is accelerated from 4 to 40 revolutions
per minute over the course of 5 minutes. Each mouse was
placed individually on a drum and the latency of falling
from the drum was recorded using a stopwatch. To assess
motor learning, the rota-rod test was repeated 24 hours later.
Grip Strength
Agrip strength meter (TSE Systems GmbH) was used to assess
forelimb grip strength. Mice were lifted and held by their tail so
that their forepaws could grasp a wire grid. The mice were then
gently pulled backward by the tail with their posture parallel to
the surface of the table until they released the grid. The peak
force applied by the forelimbs of the mouse was recorded in
pond. Each mouse performed the test three times, and the
average of the three trials was used for statistical analysis.
Assessment of Hearing
Individual mice were placed in small metal cages (90 40
40 mm) to restrict major movements and exploratory
behavior. The cages were equipped with a movable platform
floor attached to a sensor that records vertical movements of
the floor. The cages were placed in four sound-attenuating
isolation cabinets (TSE Systems GmbH). Startle reflexes
were evoked by acoustic stimuli delivered from a loud-
speaker that was suspended above the cage and connected
to an acoustic generator. The startle reaction to an acoustic
stimulus (pulse), which evokes a movement of the platform
and a transient force resulting from this movement of the
platform, was recorded with a computer during a recording
window of 100 msec and stored for further evaluation. The
recording window was defined from the onset of the
acoustic stimulus. An experimental session consisted of a 2-
minute habituation to 65 dB background white noise
(continuous throughout the session), followed by a baseline
recording for 1 minute at background noise. After baseline
recording, stimuli of different intensity and fixed 40 msec
duration were presented. Stimulus intensity was varied
between 65 dB and 120 dB, such that 19 intensities from
this range were used with 3 dB step. Stimuli of the each
intensity were presented 10 times in a pseudorandom order
with an interval ranging from 8 to 22 seconds. The ampli-
tude of the startle response (expressed in arbitrary units)
was defined as the difference between the maximum force
detected during a recording window and the force measured
immediately before the stimulus onset. Amplitudes of
responses for each stimulus intensity were averaged for
individual animals. Mean values for each experimental
group were plotted on the graph to provide the stimulus-
response curves.
Visual Cliff Test
This test was used to assess more profound visual defi-
ciencies (eg, in contrast perception).29 The test apparatus
consisted of an open-topped box (70  35 cm floor, 30 cm
high). The walls of the box were made from white
Perspex, and the base was made from clear Perspex. The
box was positioned on the edge of a laboratory bench so
that half of the base was placed on the bench (ground
side), and the other half over the edge of the bench, sus-
pended 1 m above the floor (air side). Mice were placed in
the middle of the base at the edge of the cliff, and their
activity was monitored for 5 minutes by a computer and the
video-tracking system Viewer 2 (Biobserve GmbH). The
percentage of time each mouse spent on the ground and the air
side of the box was calculated. The light intensity inside the
room was set to 150 lx.
Olfaction Test
In the first 3 days mice were habituated to the test cages
(29.5  18.5  13 cm); mice were placed in the cages for 2
 20 minutes per day. On day 3, mice were deprived of
food for 24 hours before testing, with water ad libitum and
a chocolate cookie was placed within the home cage. From
days 4 to 6, mice were again placed into test cages with
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a chocolate cookie inside (2  20 minutes). After habitua-
tion was finished on each day, mice received food for 1 hour
per day within their home cages. On day 7, the test took
place, and individual mice were placed into test cages, in
which a piece of a chocolate cookie was hidden under 1.5
cm standard bedding at the end of the cage. The mouse was
positioned in the right corner at the opposite end of the cage,
and the food-finding time (ie, the time from the moment the
mouse was placed into the cage to the time it located the
cookie and initiated burrowing) was recorded. As soon as
the cookie was uncovered, the mouse was not allowed to
consume it and was removed from the cage. To control for
other sensory, motor, or motivational deficiencies that might
influence the food-finding latency, the test was repeated as
previously described with a piece of chocolate cookie
clearly visibly placed on the bedding. A fresh cage and
bedding was used for each trial, and all mice were subjected
to identical testing procedures. Cut off time was set to 3
minutes.
Sucrose Preference Test
The evaluation of anhedonia-like behavior was assessed
using the sucrose preference test, which was performed
using a two-bottle procedure. During the sucrose prefer-
ence test, mice have free access to both water and a sucrose
solution. Animals were first habituated for 48 hours to
consume water from the two small (100 mL) bottles. After
habituation, mice were deprived of water and the sucrose
preference was measured during the next 3 days. The first
two days served as a habituation to sucrose solution. The
results of day 3 were used for the evaluation of sucrose
preference. Each day, single-housed mice were presented
for 60 minutes with two bottles (one with tap water and
one with 2% sucrose solution) in the home cage.
Consumption of water or sucrose solution was measured
by weighing the bottles before and after the session.
Bottles were counterbalanced across the left and the right
sides of the cage, and their position was alternated from




sucrose solution intake ðmLÞ




Intermale aggression was studied in the resident-intruder
paradigm. As standard opponent males, we used group-
caged males of the same age, also from the same FVB/N
strain. A standard opponent was introduced into the home
cage of the tested resident male and observation started
when a tested resident male sniffed the opponent for the first
time. The observation was stopped immediately after the
first attack (an attack being defined as a bite) to prevent
wounding, but lasted 5 minutes if no attack occurred. The
latency of attack was recorded by a stop watch.
PTZ-Induced Seizure
The method used here has been previously described by
Ferraro et al.30 Seizure activity was induced in wakeful
mouse using a single subcutaneous injection of 50 mg/kg
body weight PTZ. After injection of the compound, the
mouse was placed in a small, clear home cage and was
closely observed for 30 minutes. Latencies to focal [partial
clonic (PC)], generalized [generalized clonic (GC)], and
maximal [tonic-clonic (TC)] behavioral seizures were
recorded. Furthermore, four phases in the continuum of
behavioral response to subcutaneous PTZ injection were
defined as follows: i) hypoactivity (a progressive decrease
in motor activity until the animal came to rest in
a crouched or prone position with the abdomen in full
contact with cage bottom); ii) partial clonus (PC) (clonus
seizure activity affecting face, head, and/or forelimb or
forelimbs); iii) generalized clonus (GC) (sudden loss of
upright posture, whole body clonus involving all four
limbs and tail, rearing and autonomic signs); and iv) tonic-
clonic (TC) (maximal) seizure (generalized seizure char-
acterized by tonic hind-limb extension, also associated
with death).
Finally, latencies to PC, GC, and TC seizures were
summed to assign each mouse a seizure score that was used





















The weighing factors (0.2, 0.3, and 0.5) in the equation
were included as means of incorporating a measure of the
progressive nature of the PTZ-induced seizure phenotype
into the severity rating because GC is regarded as a more
significant event than PC, and TC (hind-limb extension) is
regarded as the most severe component of the phenotype.
Therefore, the seizure score reflects the degree of progres-
sion of the seizure phenotype in each mouse.30
Hind Limb Clasping Test
To quantify hind-limb clasping,31 P40 stage mice were
picked up from the cage by tail and suspended 10 cm above
the cage for 30 seconds to allow the clasping of the hind
limbs. During this time mice were videotaped. The video
was analyzed, and the duration of hind-limb clasping was
calculated for each mouse.
Primary Neuronal Culture and Immunocytochemical
Analysis
For neuronal cell preparation, brains from three P7 stage
male mice were collected and put into dissection solution
(0.72 g bovine albumin, 0.347 g MgSO4 in 240 mL Hanks
Bodda et al
200 ajp.amjpathol.org - The American Journal of Pathology
medium) on ice. The hippocampus was dissected from the
whole brain, the meninges were removed, and the tissue
samples were cut into small pieces and incubated in Hanks
solution for 5 to 10 minutes on ice.
The tissue samples were then digested at 37C for 10
minutes with 6 mg of trypsin and 60 mg of DNAase (2000
U/mL) in 2 mL of digestion solution (0.8 g NaCl, 35 mg
NaHCO3, 37 mg KCl , 99 mg Na2HPO4 in 100 mL of H2O,
pH approximately 7.3 to 7.4). The reaction was stopped by
addition of 2.4 mg of trypsin inhibitor (Sigma-Aldrich) in 4
mL of dissection solution and incubated at room tempera-
ture for 10 minutes. The samples were then incubated in
a solution of 0.5 mL of horse serum and 2.5 mL of
dissection solution for 10 minutes at room temperature. The
digested hippocampal cells were triturated with three
different sizes of pipettes coated with Sigmacote (Sigma-
Aldrich).
The homogenate was centrifuged at 100  g at 4C for 10
minutes. The cells obtained were resuspended in 1 mL of
culture medium A [0.5 g D-glucose, 0.2 mL (12.5 mg/mL)
insulin (Sigma-Aldrich), 1 mL (200 mmol/L) GLUTAMAX
(Gibco, Paisley, UK), 50 mL (10 mg/mL), gentamicin, 10 mg
transferring, and 10 mL horse serum up to 100 mL with
minimal essential medium Eagle (Sigma-Aldrich). The cell
suspension was seeded (4000 to 8000 cells per well) in pre-
incubated culture plates with coverslips coated with poly-D-
lysine and laminin (BD Bioscience, Heidelberg, Germany) in
culture medium A and incubated at 37C in 5% CO2. The
medium was replaced after overnight incubation. After 4 days,
culture media was changed to medium B [50 mL gentamicin
(Sigma-Aldrich), 125 mL bFGF (Invitrogen, Karlsruhe,
Germany), 250 mL L-Glutamine, 2 mL B27 supplement
(Gibco, Darmstadt, Germany), 125 mL cytosine arabinoside (4
mmol/L) up to 100 mL with Neurobasal medium (Gibco,
Darmstadt, Germany)]. Themediumwas changed every 2 days
until the day of neuronal cell analysis, when cells were fixed
and immunostained with antiemicrotubule-associated protein
2 (MAP2) antibody (Cell Signaling, Frankfurt, Germany)
(dilution 1: 500) (Abcam, Cambridge, UK) and visualized by
the BX60 fluorescence microscope (Olympus, Hamburg,
Germany).
The evaluation of neuronal parameters, such as cell soma
area and number of primary, secondary, and tertiary branch
sites, was performed by ImageJ software32 and the total
neurite lengths were measured by NeuronJ software version
1.4.233 (http://www.imagescience.org/meijering/software/
neuronj, last accessed March 2012). The analysis was per-
formed with the experimenter (C.B.) being unaware (or
blinded) of the genotype. The average data were derived
from WT and TG mice (9 to 10 each).
Sholl Analysis
To evaluate the complexity of a neuron, such as dendrite
distribution and arborization, we performed Sholl analysis34
on captured images of primary neurons. In brief, concentric
circles (Scholl lines) were drawn at 5 mm increments up to
a radius of 250 mm from the centroid of the neuron soma
until the tip of the longest neurite. The numbers of crossings
made by neurites originating from soma through each Scholl
line were calculated by ImageJ software. The crossings of
neurites at each Scholl line were summed and the means and
SD were calculated.
Measurements of Calcium Influx in Primary Neurons
Primary culture of hippocampal neurons was prepared as
previously described. The coverslips with neurons were
placed on the microscope stage (at room temperature) in
a chamber continuously superfused at 34C at 1 mL per
minute with HEPES-buffered salt solution (136 mmol/L
NaCl, 5 mmol/L KCl, 1.25 mmol/L CaCl2, 0.8 mmol/L
MgCl2, 6 mmol/L glucose, 10 HEPES, pH 7.4). The
experimental solutions were produced by adding aliquots of
corresponding stock solutions directly to the chamber
solution. The neurons were treated with 1 mmol/L fura-
2-AM (calcium indicator dye, Invitrogen, Karlsruhe,
Germany) for 20 minutes. The cells were viewed through
a 40 objective in an upright Axioscope2 microscope
(Zeiss, Goettingen, Germany). Excitation (380 nm) was
generated by light-emitting diode and the fluorescence (520
 19 nm) was recorded with a cooled CCD camera. Images
were captured at intervals of 0.5 seconds, and analyzed
using MetaMorph software (Roper Scientific, Planegg/
Martinsried, Germany). Free calcium values (C ) were ob-





where the dissociation constant for calcium binding to
fura-2 is K Z 0.22 mmol/L,35 f Z F/Fmax. The maximal
fluorescence Fmax was measured after application of 1
mmol/L ionomycin in calcium-free solution and Fmin was
obtained after introduction of 5 mmol/L calcium into the
chamber. The calibration gave R Z Fmin/Fmax Z 0.21 
0.02.
To examine slow calcium buffering in neurons, we
induced calcium loads by depolarization-activated calcium
influx with 50 mmol/L KCl and followed calcium
recovery to the basal levels. The time-constants of calcium
recovery, together with depolarization-induced calcium
increases and resting calcium levels allow to assess the
contribution of mechanisms involved in calcium regula-
tion.36 The mean values of time-constants, resting, and
elevation of calcium were determined in the WT and TG
cells. PTZ tests were applied to examine responses of
neurons to epileptogenic stimuli. Calcium changes were
recorded for 12 to 16 neurons in the image field. We
determined the amplitude and frequency of calcium
spikes, counted the number of active neurons, and aver-
aged the data for six biological replicates of WT and
Mecp2
WT_EGFP TG neuron.
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Golgi-Cox Staining
The whole mouse brains were dissected from 3 weeks old
mice and Golgi staining was performed using the FD Rapid
GolgiStain Kit (FD Neurotechnologies, Columbia, MD).
The dissected brains was rinsed with double distilled water
and then immersed in a Solution A/B mixture (impregna-
tion) for 6 to 7 days at room temperature. Afterward, the
brains were incubated in Solution C (cryoprotection) for 2
days and thereafter frozen in anisopentane/dry ice bath. The
brains were immediately sectioned into 100 to 150 mm slices
using a CM 1900 cryostat (Leica, Wetzlar, Germany) and
the slices were mounted on slide pre-coated with 0.4%
gelatin (Sigma-Aldrich). After the samples were dried, they
were dehydrated by immersing them in solution with
incremental proportion of ethanol. The staining procedure
for development of the black precipitate was performed
using kit reagents according to the manufacturer instruction.
Afterward, coverslips were mounted using Eukitt quick
hardening mounting medium (Fluka, Neu Ulm, Germany)
and the slides were visualized using the BX60 microscope
(Olympus, Hamburg, Germany).
The morphology of pyramidal neurons was traced from
the captured images through a graph pad by using NeuronJ
software and neuronal parameters were evaluated as
described above. The spine density was calculated as
average number of spines sprouting from a block unit of 10
mm of neurite. The average data were derived from WT and
TG mice, 5 to 6 each.
Statistical Analysis
For neuronal parameters evaluation, the differences between
WT and Mecp2WT_EGFP transgenic neurons were calculated
by applying Wilcoxon’s Rank sum statistics or, if appro-
priate, by using the Student’s t-test. We set the overall level
of significance to 5%. For the number of branching sites as
the mainly focused phenotypes were corrected for multiple
testing according to Bonferroni assuming four independent
tests (area, length, number of spines per 10 mm, and
branching points). Data are represented as means  SD in
both the figures and text.
In the preweaning behavior assessment, regression
analyses were used to compare the performance between
TG and WT littermate control mice: variables scored 0 or 1
were analyzed by logistic regression. Additionally, Fisch-
er’s exact test for categorical data on each observation day
and two-way repeated measures analysis of variance
including Bonferroni post hoc test were used where
applicable.
Statistical significance for adult behavioral phenotyping
was evaluated using the U-test and two-way repeated
measures analysis of variance including the Bonferroni post
hoc test where applicable. A critical value for significance of
P < 0.05 was used throughout the study. Data are repre-
sented as means  SEM in both the figures and text.
For RT-qPCR data, the statistical significance between
WT and Mecp2WT_EGFP TG mice were calculated by
Student’s t-test.
All statistical analyses were performed with either
GraphPad Prism 4.0 (La Jolla, CA) or SAS Version 9.2,
SAS Institute Inc. (Cary, NC) or SPSS for Windows,
version 17.0 (Chicago, IL).
Results
Reducing Expression of MeCP2 from Mecp2WT_EGFP Allele
The Mecp2WT_EGFP TG mouse was generated by micro-
injection of linearized pBAC_Mecp2WT_EGFP construct
(Figure 1A) into fertilized oocytes of FVB/N mice. For the
generation of the pBAC_Mecp2WT_EGFP construct, we
used a BAC clone (B22804). This BAC contains approx-
imately 120 kb of a mouse genomic fragment, which
consists of the complete Mecp2 gene including all fours
exons, as well as flanking/regulatory sequences.24 The
BAC clone also contains the complete transcriptional unit
of Opsin1 gene, which is 50 upstream of Mecp2 and part of
the Irak1 gene, which is located downstream 30 end of the
Mecp2 gene. The sequences of Opsin1 and Irak1 genes
were deleted from the BAC clone by GET recombina-
tion,24 using the Zeocin selection cassette to exclude any
toxic effect in the TG animals due to duplication of these
genes (Figure 1A).
The pups obtained after microinjection were tested for the
integration of the transgene into the genomic sequence by
PCR genotyping using a primer pair specific for the trans-
gene.24 Through PCR genotyping, several founders were
identified, however, subsequent breeding and transmission
analysis of Mecp2WT_EGFP allele among the founders led to
the establishment of one successful TG line. From the
breeding of this TG line with FVB/N mice, we obtained
equal numbers of male and female mice suggesting that the
transgene was integrated into an autosomal chromosome.
The Mecp2WT_EGFP TG mouse line was maintained in
a heterozygote state (TWT/-) by backcrossing with FVB/N
mice. From such breeding, we obtained 50% TG mice
(TWT/-) and 50% WT littermates.
To determine whether the MeCP2WT_EGFP is expressed
in the TG mice, we performed Western blot analysis with
total protein extracted from the brain biopsies from the
adult Mecp2WT_EGFP TG male mice. The immunoblot with
antibody against MeCP2 revealed expression of two
MeCP2 proteins. In addition to the endogenous MeCP2
(approximately 70 kDa) band, a TG MeCP2WT_EGFP band
of approximately 100 kDa in size was detected in the brain
of TG mice. In contrast, only endogenous MeCP2 was
detectable in WT mice (Figure 1B). Moreover, immuno-
blot analysis with green fluorescent protein antibody
detected the approximately 100 kDa MeCP2WT_EGFP
protein, only in TG mice (Figure 1B). From Western blot
analysis, it is obvious that the intensity of MeCP2WT_EGFP
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TG protein is remarkably lower as compared to endoge-
nous MeCP2 band. This observation prompted us to
quantify the relative intensity of the TG protein to
endogenous protein by ImageJ software. Densitometrical
quantification of the protein bands intensities from five
independent immunoblots revealed that relative expres-
sion of MeCP2WT_EGFP was approximately 40  4.1% to
that of endogenous MeCP2 (Figure 1C). To determine
whether the reduced expression MeCP2WT_EGFP protein
from the transgene was due to lower amount of mRNA,
we performed quantitative real-time PCR analysis. Indeed,
we also detected a reduced level of TG mRNA
(Figure 1D).
To determine the cellular expression pattern of the
MeCP2WT_EGFP protein, we performed immunohistochem-
ical analysis of brain sections. MeCP2WT_EGFP protein was
Figure 1 Expression analysis of MeCP2 from the BAC transgene. A: Schematic diagram illustrating the generation of the pBAC_Mecp2WT_EGFP
construct using GET recombination in the BAC clone. An EGFP/Kan cassette was inserted in frame at stop codon of Mecp2 in exon 4 and was replaced
with two glycine residues in the BAC clone. The sequences of Opsin1 and Irak1 genes were deleted from the BAC clone by GET recombination using the
Zeocin selection cassette. B: Western blot analysis using MeCP2 antibody on the total protein extract isolated from brain samples revealed in addition to
the endogenous MeCP2 (70 kDa) an additional MeCP2 protein corresponding to MeCP2WT_EGFP of size approximately 100 kDa in the TG adult mice.
Additionally, immunoblots with anti-GFP antibody confirmed that the approximately 100 kDa size protein was indeed MeCP2WT_EGFP. Furthermore,
Western blot analysis with brain extract of rescued mice (TWT/-: -/y), generated by breeding Mecp2WT_EGFP TG mice with Mecp2 knockout mice revealed
only expression of MeCP2WT_EGFP of size of approximately 100 kDa. C: Quantification of the protein bands intensities from at least five immunoblots
revealed that relative expression of MeCP2WT_EGFP was approximately 40  4.1% to that of endogenous MeCP2. D: Quantitative real-time PCR analysis
suggests that reduced expression of TG MeCP2WT_EGFP is due to the diminished level of mRNA. E: Immunohistochemical analysis of hippocampus showed
a similar expression pattern for the TG MeCP2WT_EGFP protein as compared to endogenous MeCP2. KO, knockout mice adult mice. Scale bars: approxi-
mately 10 kb (A); 50 mm (E).
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visualized by green fluorescent protein fluorescence and
MeCP2 antibody staining, which also detected endogenous
MeCP2 protein. The expression pattern of MeCP2WT_EGFP
protein was similar to that of endogenous MeCP2
(Figure 1E and Supplemental Figure S2).
Prolonging Lifespan of Mecp2 Null Mutant Mice on
Expression of Mecp2WT_EGFP Allele
We bred Mecp2WT_EGFP TG mice with Mecp2 knockout
mice31 to express the TG allele in Mecp2 null background
(TWT/-; -/y). Western blot analysis withMeCP2 antibody using
total protein extracted from the brain revealed expression of
MeCP2WT_EGFP protein only (approximately 100 kDa)
(Figure 1B). Remarkably, the premature lethality at the age of
approximately 10 weeks, reported for null mutants, was
rescued by the expression of the TG allele. These mice have
a prolonged life span, as our observation over a period of
approximately 9 months did not detect any early deaths. Hind-
limb clasping, a typical feature of Mecp2 null mutant mice,
was also absent in these mice (Supplemental Figure S3).
Mecp2WT_EGFP Transgenic Mice Exhibit Increasing
Aggressiveness and Seizure Propensity
The TG mice appeared normal on cursory observation. To
characterize the behavioral phenotype of Mecp2WT_EGFP TG
mice, we performed a series of behavioral tests at both
preweaning (0 to 3 weeks) and postweaning (after 5 weeks
onward) stages.
Pre-Weaning Behavior Analysis
The number of animals used in the analysis of maturation
markers and neurodevelopmental measures was: Mecp2 TG
(TG) male (n Z 18), WT littermate male (n Z 14).
Maturation Measures
Body Weight
Body weight of animals was taken daily from P4 through P21
and the data were analyzed with two-way repeated
measurement analysis of variance. We did not find any
significant differences between genotypes in the body weight
measured (Supplemental Table S1). As expected, all mice
progressively increased their body weight as we observed
from P4 through P21 (data not shown), indicating a compa-
rable growth rate between TG and WT littermates.
Ear and Eye Opening
The day when at least one eye was open and the day an
aperture was seen in the ear was registered daily starting from
P4. No differences existed between genotypes regarding the
day of the ear and the eye opening (Supplemental Table S1).
All test mice have their ears and eyes fully opened on P14
(data not shown).
Neurodevelopmental Measures (Neurological Reflexes
and Neuromotor Coordination)
There were no significant differences observed between
groups in terms of the neurological reflexes tested in
surface righting, postural, cliff avoidance, and negative
geotaxis reflex (Supplemental Table S1). We also observed
a comparable performance between groups during the
acquisition of neuromotor coordination assessed from wire
suspension and neonatal swimming activity (Supplemental
Table S1).
Postweaning (Adult) Behavior Analysis
Adult behavioral phenotyping of male TG mice with mild
Mecp2 overexpression, as well as their WT littermates, was
performed beginning at the age of 5 weeks (Table 1).
Behavioral analysis was performed with less stressful tests at
the beginning and more stressful tests toward the end in the
following order: elevated plus maze, open field, hole board,
prepulse inhibition, rota-rod, hearing, visual cliff, sucrose
preference, grip strength, olfaction, resident intruder, and
finally, PTZ-seizure induction. The number of animals used
in the adult behavioral analysis is given in the corresponding
figure legends of each read out. For behavioral analyses, we
used 10 to 27 WT and 6 to 22 TG mice (dependent on the
complexity of the test, lower or higher numbers of mice are
needed).
Table 1 Summary of Phenotypes in Adult Mecp2WT_EGFP
Transgenic Mice
Domain Behavioral tests WT versus TG
Basic behavioral functions
Activity (locomotion) Open filed P > 0.05
Anxiety Elevated plus maze P > 0.05
Exploratory Hole board P > 0.05
Anhedonia Sucrose preference P > 0.05




Rota-rod P > 0.05
Muscle strength Grip strength P > 0.05
Sensory functions
Olfaction Food finding P > 0.05
Vision Visual cliff P > 0.05
Hearing Hearing (PPI set up) P > 0.05
Social behavior




Prepulse inhibition P > 0.05
Mild MeCP2 overexpression does not alter basic behavior, motor, sensory,
or sensorimotor gating readouts in mice, but leads to alterations in social
behavior (aggression) and seizure activity. Wild-type (WT) mice Z 10 to
27; transgenic (TG) mice Z 6 to 22. Data are presented as means  SEM.
PPI, prepulse inhibition; PTZ, pentylenetetrazole.
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Mild Overexpression of Mecp2 Selectively Influences
Behavioral Alterations
Although basic behavior, sensory, and motor functions, as
well as sensorimotor gating remain unchanged by mild over-
expression ofMecp2, our results revealed that social behavior
and seizure propensity of TG animals overexpressing Mecp2
were altered (Table 1, Figure 2, and Supplemental Figure S4).
During daily handling of the animals, we observed that mice
displayed a higher tendency to bite when handled. We per-
formed the resident-intruder paradigm to investigate whether
mild Mecp2 overexpression was associated with an increased
aggressive behavior. Indeed, tested at the age of 8 weeks, we
found that TGmiceweremore aggressive compared to theWT
littermates (Figure 2A). The latency of the first attack of TG
mice toward the intruder was significantly reduced, compared
to their WT littermates (PZ 0.048).
We also repeatedly observed spontaneous seizures in the
TG mice. Thus, to assess seizure susceptibility, we induced
seizures by administering PTZ (50 mg/kg s.c. of body
weight).30 We detected increased PTZ-induced seizure
activity in 30-week-old TG mice (P Z 0.042) compared to
their WT littermates (Figure 2B).
Mild Mecp2 Overexpression Causes Increase in Soma
Size and Fewer Branching Sites in Cultured Neurons
The ex vivo cultured hippocampal neurons are considered
a well-characterized model for the evaluation of neuronal
development.37 We cultured hippocampal neurons from P7
Mecp2WT_EGFP TG and WT male mice to determine the
effect of mild overexpression of Mecp2 during the process
of neuronal development and differentiation. The primary
neurons were cultured for 14 days, then immunostained
with anti-MAP2 antibody (Figure 3, A and B). MAP2 is
a neuron-specific cytoskeletal protein that is enriched in
dendrites.38 The stained neurons were traced and analyzed
by ImageJ software for calculating the soma size. The
neuronal parameters, such as total length of neurites,
number of neuritis, and number of primary, secondary, and
tertiary branch sites, were evaluated by NeuronJ software.
The mean soma size of 91 TG neurons was slightly larger
compared to those of 83 WT neurons (P Z 0.0008)
(Figure 3C). However, no significant difference could be seen
for the total length of neurites projecting from TG neurons (P
Z 0.1536) (Figure 3D). Analysis of branching sites of neurites
revealed an average lower number of branching sites in TG
neurons, although this was clearly significant only for tertiary
sites (primary sites:PZ 0.6000, secondary sites: PZ 0.0496,
and tertiary sites: P < 0.0001) (Figure 3, E and G). To further
evaluate the complexity of neurons, we performed Sholl
analysis on the traced images.
34 Sholl analysis is used to
evaluate the morphological complexity of imaged neurons by
counting the number of neurite intersections for concentric
circles of increasing radius arising from the cell soma
(Supplemental Figure S5). This quantitative analysis revealed
diminished apical neurite branching in TG neurons.
Pyramidal Neurons of Mecp2WT_EGFP Transgenic Mice
Show Higher Spine Density
To evaluate the effect of mild Mecp2 overexpression on
neurons in vivo, we visualized the hippocampal neurons
by Golgi-Cox staining of tissue sections. The Golgi-Cox
staining allows high resolution visualization of dendrites
and spines in the histological section, thus enabling us to
calculate the qualitative and quantitative parameters of
neurons.39e41 The stained pyramidal neurons (Figure 4A)
were reconstructed by semiautomatic tracing using NeuronJ
software (Figure 4B) and were analyzed similarly, as previ-
ously described for cultured neurons. We did not observe
significant difference in soma size between TG and WT
neurons (Figure 4C), although the total length of TG neurites
was increased (Figure 4D). To determine the spine density of
neurites, we used higher magnification images of basal
dendrites from CA1 region (Figure 4E). Spine density for
neurite unit length of 10 mm revealed, on average, a slightly
higher density of spines in TG neurites (mean, 14.4 mm) than
WT neurites (mean, 13.6 mm; PZ 0.0324) (Figure 4F).
Calcium Homeostasis in Mecp2WT_EGFP Transgenic
Neurons
Calcium responses of cultured primary hippocampal neurons
were evaluated by applying depolarization-induced calcium
influx (50 mmol/L KCl) and IP3-mediated calcium release
from endoplasmic reticulum after activation of P2Y receptors
with 1 mmol/L ATP.42 Our measurements revealed that TG
neurons in comparison to WT neurons, had higher levels of
resting calcium (0.075  0.05 mmol/L versus 0.052  0.03
mmol/L), calcium elevations due to depolarization were also
higher (0.34  0.08 mmol/L versus 0.25 0.06 mmol/L), and
the amplitudes of ATP-driven calcium release were smaller
Figure 2 Phenotypic characterization of Mecp2WT_EGFP TG mice. A: To
test aggressiveness, we performed the resident-intruder paradigm. The
latency of the first attack of 8-week-old TG mice toward the intruder was
significantly reduced, compared to their littermates, the WT mice. B: The
30-week-old TG mice also manifested increased sensitivity to PTZ-induced
seizures. Mice (WT Z 10 to 27; TG Z 6 to 22). Data are presented as
means  SEM. *P < 0.05.
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(0.21 0.04 mmol/L versus 0.31 0.05 mmol/L) (Figure 5, C
and D). The time course of calcium recovery in TG neurons
was distinctly slower, both after depolarization and calcium
release (Figure 5). Themean time constant of calcium recovery
in WT was 6.1  0.4 seconds (Figure 5A), and in TG cells it
was approximately three times longer (18.6  1.2 seconds)
(Figure 5B). We further observed that TG neurons were more
prone to spontaneous calcium oscillations that may indicate
intrinsic differences in the vulnerability toward external
stimuli. Spontaneous calcium spiking was seldom observed in
WT neurons (6 of 97 cells [6%]), whereas in TG neurons,
spontaneous activity was encountered more frequently (12 of
98 cells [12%]).
In the behavioral test, the TG mice manifested a higher
propensity toward PTZ-induced seizure activity (Figure 2C),
we evaluated the response of cultured hippocampal neurons
to PTZ. Spontaneous and elicited calcium spikes (indicators
of spontaneous discharges of the neurons) are usually
considered as a correlate of epileptic seizures.43,44 The WT
neurons rarely showed spontaneous calcium transients and
10 mmol/L PTZ-induced only a weak effect (Figure 5E). The
TG neurons frequently demonstrated spontaneous calcium
spikes whose amplitude and frequency were markedly
increased after PTZ treatment (Figure 5F).
Discussion
Evaluation of the quantitative effect of MeCP2 expression
level on phenotypes is highly relevant, as duplication of
Figure 3 Evaluation of neuronal
parameters of cultured (14 days)
neurons fromhippocampus of postnatal
7-day-old mice. A: Immunostaining of
the TG Mecp2WT_EGFP primary neuronal
cells with MAP2 (red), the MeCP2WT_EGFP
expression was visualized by green
fluorescence. B: The stained neuron
images were traced by ImageJ and
NeuronJ software and neuronal param-
eters were analyzed. C: The soma size of
TGneuronswas slightly larger compared
toWT neurons.D: The total length of TG
neurons was slightly smaller. EeG: The
numbers of branch siteswere reduced in
TG neurons, especially a significant
reduction in tertiary branch sites was
observed in TG neurons. Number of
neurons (WT Z 83; TG Z 91); 10,
primary; 20, secondary; 30, tertiary
branch sites; Scale bar Z 50 mm (A).
*P < 0.05, ***P < 0.001.
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MECP2 causes severe neurological impairment,14,18,22 and
on the contrary, loss of function mutations causes Rett
syndrome.10 It is evident that precise regulation of MeCP2
expression is essential for proper neurodevelopment. To
determine the consequence of MeCP2 dosage, we generated
a TG Mecp2WT_EGFP mouse model mildly overexpressing
MeCP2. The BAC construct used for the generation of
Mecp2WT_EGFP TG mice consist of complete promoter and
regulatory elements necessary for the spatiotemporal expres-
sion pattern of MeCP2.22,24 In addition, to exclude the possi-
bility of interference in the phenotype of Mecp2WT_EGFP mice
due to overexpression of Opsin1 and Irak1, we deleted both
genes in the BAC construct. When expression pattern of
MeCP2WT_EGFP from the transgene was compared with
endogenous MeCP2, we observed a similar expression
pattern, thus confirming that the BAC transgene mimics the
endogenous MeCP2 expression. Additionally, in a previous
study, we showed that expression pattern of a TG MeC-
P2270_EGFP (generated from the same BAC clone) was
comparable to the endogenous protein.24 In the pBAC_
Mecp2270_EGFP construct, the EGFP/Kan cassette was
inserted after 270 amino acids into exon 4 of Mecp2.
Overall, the MeCP2270_EGFP TG protein is equivalent to
human p.R270X mutation.24
Interestingly, using Western blot analysis, the intensity of
TG MeCP2WT_EGFP protein band was much weaker than
endogenous MeCP2. Quantification of protein bands inten-
sity revealed that the expression level of TG protein was
nearly half (40  4.1%) as compared to the endogenous
MeCP2 protein. To determine whether the reduced expres-
sion from the transgene was due to lower level of mRNA or
post-transcriptional regulation, we performed RT-qPCR
analysis. Our data indicates that the diminished level of
mRNA may be the underlying reason for lower level of TG
MeCP2WT_EGFP protein. A previous study has shown that
modification of 30 UTR ofMecp2 by insertion of a neomycin
cassette and polyadenylation sequence in Mecp2flox allele
causes 50% reduction of expression as compared to the
endogenous level in these mice.23 During the generation of
Mecp2WT_EGFP TG mice, we also modified the 30 untrans-
lated region ofMecp2 by insertion of an EGFP/Kan cassette,
which could be the underlying cause for reduced expression.
However, a regulatory inhibition (at least partially) at the site
of TG integration cannot be completely excluded.
Figure 4 Characterization of pyramidal neu-
rons in hippocampal sections by histological
staining. A: The pyramidal neurons in the hippo-
campal sections of 3-week-old mice were visualized
by Golgi-Cox staining. B: The neurons morphology
reconstructed by semiautomatic tracing using
NeuronJ software and neuronal parameters. C and
D: The cell soma size were comparable between TG
and WT neurons, total length of TG neurites was
slightly longer. E: The spine density was calculated
from higher magnification images. F: The spine
density for neurite unit length of 10 mm was higher
in TG neurons. The spine density was plotted as
mean value per unit length of 10 mm for neurite
length of approximately 2500 mm. Number of
neurons (WTZ 50; TGZ 50). Scale bars: 100 mm
(A and B); 10 mm (E). *P < 0.05.
Mecp2 Overexpression Causes Seizures
The American Journal of Pathology - ajp.amjpathol.org 207
To determine whether MeCP2WT_EGFP protein expressed
from the TG locus is functionally active, we crossed
Mecp2WT_EGFP TG mice with Mecp2 knockout mice. An
expression level of approximately 50% of MeCP2WT_EGFP
in the null background was able to rescue the premature
lethality reported in these mice. We did not detect any
indication of early death in these mice over a period of 9
months. In addition, the hind limb clasping phenotype of
null mice was alleviated by transgene expression. Overall,
these findings clearly indicate that MeCP2WT_EGFP protein
is functional and C-termini fusion of EGFP protein does not
interfere with biological function of MeCP2 in the trans-
gene. Nevertheless, we wish to stress that approximately
50% of MeCP2WT_EGFP expression might not necessarily
rescue all of the progressive phenotypes of null mutant mice
and further investigation will be necessary to exclude any
late stage symptoms.
Mecp2WT_EGFP TG mice appear phenotypically normal
and were negative for hind limb clasping (observation over
a 9-month period). To identify any relevant behavioral
symptoms in these mice, we performed a battery of tests
involving basic and social behavior, motor performance,
sensory functions, and sensorimotor gating. Our investiga-
tion revealed that in most behavioral parameters the perfor-
mance of TG mice were comparable to that of WT siblings,
and with the progression of age, there was no deterioration in
the symptoms. However, the animals showed increased
aggression and propensity toward PTZ-induced seizures. The
phenotype ofMecp2WT_EGFP TG mice (approximately 1.5)
was in stark contrast to the previously reported MECP2-Tg1
mice (2) that manifested severe neurological phenotypes.22
MECP2-Tg1 mice display stereotyped and repetitive move-
ments, motor dysfunction, epilepsy, spasticity, ataxia,
hypoactivity, kyphosis, and premature death.22 In MECP2-
Tg1 mice, the phenotypes appear at an early stage (10 to 12
weeks) and deteriorate progressively. Overall, by means of
our generated mouse model expressing approximately 1.5
the level of MeCP2, we could reinforce the notion that the
effect of MeCP2 on neurodevelopment is quantitative.
Furthermore, unlike doubling of MeCP2 dosage, which
causes severe neurological impairment, only approximately
1.5 the level of overexpression of MeCP2 elicits a milder
phenotype.
The expression level of MeCP2 is critical for early
neuronal development and MeCP2 function is vital even at
a single-neuron level.45 To assess the effect of mild over-
expression (approximately 1.5) of MeCP2 on neurons, we
evaluated neuronal parameters of cultured neurons. We
observed a slight but statistically significant increase in
soma size. The reduced number of tertiary branching sites in
Mecp2WT_EGFP TG as compared to WT neurons was also
statistically significant. When we analyzed the neuronal
parameters of Golgi-Cox stained, we observed no difference
in soma size. This discrepancy could be due to sensitivity of
two different experimental systems used for neuronal
parameters. The morphological features of neurons are
explicitly visible in primary culture; therefore, even subtle
changes can be calculated. However, exogenous conditions
in the primary culture can also create distortion, which
might not be representative to an in vivo form. Remarkably,
in Golgi-Cox stained neurons, we detected a slight increase
(statistically significant) in spine density in the TG neurons.
Previous studies have shown that loss of MeCP2 leads to
substantial reduction in spine density,46e48 thus, it is
reasonable to expect enhanced spine density during MeCP2
overexpression. Overall, it seems that mild overexpression
of MeCP2 subtly deters the maturation of neurons.
Furthermore, we observed an impaired calcium homeo-
stasis with a slower time course of calcium decay in
Mecp2
WT_EGFP TG neurons, which was manifested by an
increase in basal calcium levels, prolongation of calcium
Figure 5 Impaired calcium response in hippocampal neurons, cultured
for 14 days. A and B: Each panel shows calcium responses to membrane
depolarization in 12 to 16 neurons. The depolarization with 50 mmol/L KCl
was followed by calcium recovery to basal levels. The mean time constant
of calcium recovery was approximately three times longer in TG neurons
than WT. C and D: Calcium release after activation of P2Y receptors with
1 mmol/L ATP led to a smaller amount of calcium release in the TG neurons.
E: Epileptogenic stimulation with 10 mmol/L PTZ-enhanced spontaneous
calcium spikes substantially in the TG neurons. F: The amplitudes and
frequencies of spontaneous calcium spikes and the number of active cells
after PTZ exposure. The values were distinctly higher in TG neurons. White
bars, WT; grey bars, TG. *P < 0.05, **P < 0.01.
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recovery to basal levels after brief depolarization, and
a smaller amount of calcium released from intracellular
stores in TG neurons. The calcium imbalance could be the
underlying cause for the observed exaggerated response of
the TG neurons to epileptogenic compound-PTZ.30,44
Improper calcium handling can make these neurons more
vulnerable to external stimuli encountered during early
development. A similar disturbance in calcium homeostasis
was also observed in Mecp2 null mutant neurons,49 which
suggest that both lack and overexpression of MeCP2 may
lead to deleterious effect.
It is interesting to note that epileptic seizures are a major
phenotype reported both in RTT and MECP2 duplication
syndrome. Remarkably, MECP2 disruptions also lead to
neuropsychiatric disorder, such as Angelman-like syndrome,
and in many instances these patients also manifest epileptic
seizures.50,51 In this context, it is noteworthy that the primary
phenotype observed in the Mecp2WT_EGFP TG mice was an
increased propensity to epileptic seizures, as observed in our
behavioral tests, as well as at the resolution of single neurons
(ex vivo). In both in vivo and ex vivo settings, the seizure
activity was induced by epileptogenic compound-PTZ, and
in the TG condition, the induction was remarkably stronger.
In conclusion, it is evident from our study that epileptic
seizure propensity is highly sensitive to the functional level
of MeCP2 and it appears as a primary phenotype in the
mouse due to mild overexpression of MeCP2. In future gene
therapy approaches to correct the MeCP2 expression either
in RTT or MECP2 duplication syndrome, the optimum
dosage of the treatment may have to be determined so that
epilepsy does not occur as a consequence.
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Neonatal assessments were done covering the domains of physical development (body weight, 
the day of ear and eye opening), neurobehavioral development (surface righting, postural, cliff 
avoidance, and negative geotaxis reflex), and the development of neuromotor coordination (wire 
suspension and swimming activity).  
Mice (WT= 14, TG= 18).  
 
Domain Behavorial Tests WT vs TG 
Early postnatal physical 
development 
Body Weight p>0.05 
Ear Opening p>0.05 
Eye Opening p>0.05 
Early postnatal 
neurodevelopment 
Surface righting reflex p>0.05 
Postural reflex p>0.05 
Cliff avoidance p>0.05 
Negative geotaxis reflex p>0.05 
Early postnatal neuromotor 
coordination 
Wire suspension p>0.05 
Swimming activity p>0.05 
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5. MOUSE MODEL TARGETING A TRANSCRIPTIONAL 
REGULATOR, MECP2 (II):  
Mild expression differences of MECP2 influencing 
aggressive social behavior 
  
a. Overview of project III 
Results from mouse models carrying different Mecp2 mutations, ranging from loss-of-
function to reduced or enhanced expression reveal a correlation between the dosage 
of Mecp2 and phenotype severity of the mutants, indicating a narrow threshold of the 
expression range, with deviance in both directions being disadvantageous (Chahrour 
and Zoghbi 2007; Chao and Zoghbi 2012). Previously shown in project I, mild 
overexpression of Mecp2 in the amount that exceeds wild-type levels by ~1.5fold 
induced higher seizure propensity and aggression in male FVB/N mice, together with 
alterations in neuronal branching sites and augmented spine density (Bodda, Tantra 
et al. 2013). Also in vitro application of an epileptogenic compound, 
pentylenetetrazole to transgenic neurons led to a marked increase in amplitude and 
frequency of calcium spikes (Bodda, Tantra et al. 2013). Our findings are in line with 
the observation that the severity of the induced phenotypes increases not only as 
Mecp2 function decreases, but also as Mecp2 level increases beyond normal levels, 
delineating the necessity of a tight regulation of Mecp2 level to ensure proper 
functions (Chao and Zoghbi 2012). 
 
While epileptic seizures are a well established pathological consequence of 
alterations in Mecp2 function/ expression (Collins, Levenson et al. 2004; Chahrour 
and Zoghbi 2007; Chao, Chen et al. 2010), the information on the functional 
consequences of mild overexpression on behavior is still sparse. Recent studies have 
shown that increasing the endogenous Mecp2 level up to two- and three-fold of 
physiological levels resulted in deficits in social interaction (Samaco, Mandel-Brehm 
et al. 2012).  Along these lines, it has been shown that disturbed neuronal 
homeostasis across different Mecp2 mouse models has consistent social behavioral 
consequences (Pearson, Defensor et al. 2012). Here, the most common phenotypes 
observed are abnormal (enhanced/ impaired) social interaction, deficits in nest 
building and increased aggression (Shahbazian, Young et al. 2002; Moretti, 
Bouwknecht et al. 2005; Fyffe, Neul et al. 2008; Kerr, Alvarez-Saavedra et al. 2008; 
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Samaco, Mandel-Brehm et al. 2009; Chao, Chen et al. 2010; Pearson, Defensor et al. 
2012; Samaco, Mandel-Brehm et al. 2012). All together, there is growing evidence 
that Mecp2 regulates the expression/ function of genes involved in social behavior 
(Moretti, Bouwknecht et al. 2005). 
 
It is worthwhile mentioning that the phenotypes observed across different mouse 
models arose from different genetic backgrounds of mutant mice carrying different 
type of Mecp2 mutations and therefore did not consider basic phenotypical 
differences among mouse strains. Behavioral studies on basic behavior, social and 
cognitive domains have revealed considerable phenotypical differences between 
different mouse strains (Wolfer and Lipp 2000; Moy, Nadler et al. 2009; Pietropaolo, 
Guilleminot et al. 2011; O'Leary, Gunn et al. 2013; Samaco, McGraw et al. 2013). For 
example, a strain-comparison study on FVB/N and C57BL/6N mice revealed that 
FVB/N mice showed higher frequency of bouts during the resident-intruder paradigm 
for aggression (Mineur and Crusio 2002; Pugh, Ahmed et al. 2004). It is therefore 
very likely that the genetic background could determine or modulate phenotypical 
changes induced by alterations in Mecp2 expression, and that particular phenotypes 
might be unique to a specific genetic background. 
 
Being aware of the fact that genetic background might modulate the behavioral 
phenotype of mutant mice (Wolfer and Lipp 2000; Pietropaolo, Guilleminot et al. 2011; 
Samaco, McGraw et al. 2013), in the frame of the third project, transgenic mice with 
~1.5fold Mecp2 expression of the FVB/N were backcrossed for 10 generations to the 
C57BL/6N background to create a congenic strain. We then asked the question 
whether the symptoms that arose upon mild overexpression of Mecp2 are conserved 
across genetic backgrounds (FVB/N versus C57BL/6N) and genders. Including now 
female mice in behavioral analysis, we found that, independent of genetic 
backgrounds and genders, a marked increased in susceptibility to PTZ-induced was 
persistent in Mecp2 overexpressing mice. We also found that while mildly 
overexpressing Mecp2 at ~1-5fold WT level in both FVB/N and C57BL/6N genetic 
backgrounds of both genders left most basic behavioral unaltered, it modulated 
spontaneous home cage activity.  
 
Interestingly, we found that the territorial aggression of male mice with mild Mecp2 
overexpression is genetic background-dependent. The marked reduction of the attack 
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latency towards the intruder mice during the resident-intruder paradigm for territorial 
aggression was displayed only by transgenic mice of the FVB/N, but not the 
C57BL/6N background. We then investigated the pattern of territorial behavior of male 
transgenic mice of the C57BL/6N background and we found indicators of reduced 
territorial social interest in transgenic mice, compared to their WT littermates. 
However, observed in a neutral non-territorial arena (the 3-partite chamber), 
transgenic male mice of the C57BL/6N background showed normal pattern of social 
interaction. Furthermore, these transgenic male mice of the C57BL/6N background 
displayed reduced nest building and lower ultrasound vocalization response to an 
anesthetized female intruder, and signs of social inferiority as assessed by social 
dominance test. Together, these data indicated that also in Mecp2 overexpressing 
mice of C57BL/6N background, territorial social behavior was a target phenotype. In 
contrast to TG mice of the FVB/N background, in these intrinsically less aggressive 
mice, however, aggression seemed to be dampened rather than intensified by Mecp2 
overexpression. Thus, it appeared that while social behavior is susceptible to changes 
in Mecp2 level, the phenotypical alterations (i.e. more or less aggressive) depend on 
the behavioral traits of each genetic background. 
 
Despite accumulating evidence on the importance of MECP2 for development and 
further maintenance of neuronal function (Guy, Cheval et al. 2011; McGraw, Samaco 
et al. 2011; Minh, Du et al. 2012), studies addressing the effect of common genetic 
variations of this gene on human behavior remain scarce. An association study on 
two collections of families showed a significant association between SNP single 
markers at the 3’ end of MECP2 with autism/ autism spectrum disorder (Loat, Curran 
et al. 2008). Despite the necessity of further investigations, this study indicates that 
one/more functional variants of MECP2 existing at significant frequency in the 
population might influence the risk for autism/ autism spectrum disorders (Loat, 
Curran et al. 2008). In the acknowledgement of an overlap in behavioral phenotypes 
of RTT, MECP2 duplication syndrome and autistic individuals, there is the possibility 
that MECP2 variants might be involved in modulating behavioral domains affected 
across these disorders, such as social behavior. In the framework of the present 
project, we aimed to investigate whether slight MECP2 expression differences 
mediated by common genetic variations would be associated with behavioral 
phenotypes relevant for aggression, as observed in transgenic mice with mild 
overexpression of Mecp2. 
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Our mouse studies revealed aggression as a central phenotype modulated by mild 
increased of Mecp2 expression. Accordingly, a phenotype-based genetic association 
study was conducted on two variants of MECP2: SNP rs2734647 (C/T) and 
rs2239464 (G/A). Phenotypical readouts such as poor impulse control, aggression, 
excitement and uncooperativeness were selected from the GRAS data collection 
(Ribbe, Friedrichs et al. 2010). We established that the selected readouts were 
substantially intercorrelated with each other, implying the likelihood of these items to 
represent behavioral expressions of overlapping neuronal circuitries. Significant 
associations between these readouts and both SNPs were found in male, but not 
female patients: male C-carriers of SNP rs2734647 and G-carriers of SNP rs2239464 
were more aggressive. 
 
To study the functional implications of the 3’UTR SNP rs2734647 (C/T) on microRNA 
(miR-) dependent posttranscriptional regulation of gene expression, in silico analyses 
were performed. Four miRs with seed binding sites including the 3’UTR SNP position 
were predicted. We found that in vitro luciferase assays using HEK293 cells 
demonstrated a significant reduction of luciferase activity upon co-transfection of the 
plasmid carrying the T-allele with miR-4711-3p and miR-511. When luciferase assays 
were performed using N2a cells, similar positive results were obtained for miR-511. 
Additionally, we further investigated whether allele-specific down-regulation of 
MECP2 expression would also be visible in peripheral blood mononuclear cells 
(PBMC) of male T-carriers of SNP rs2734647. Here we found a lower MECP2 
expression (of about 50%) in PBMC of male carrying T-allele, compared to C-carriers. 
All together, results from the third project suggest a role of Mecp2/MECP2 as a 
regulator of aggressive behavior in mouse and man, with genetic variations acting as 
a modifier. 
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The X-chromosomal MECP2/Mecp2 gene encodes methyl-CpG-binding protein 2, a 
transcriptional activator and repressor regulating many other genes. We discovered in 
male FVB/N mice that mild (~50%) transgenic overexpression of Mecp2 enhances 
aggression. Surprisingly, when the same transgene was expressed in C57BL/6N mice, 
transgenics showed reduced aggression and social interaction. This suggests that 
Mecp2 modulates aggressive social behavior. To test this hypothesis in humans, we 
performed a phenotype-based genetic association study (PGAS) in >1000 
schizophrenic individuals. We found MECP2 SNPs rs2239464 (G/A) and rs2734647 
(C/T; 3’UTR) associated with aggression, with the G- and C-carriers, respectively, being 
more aggressive. This finding was replicated in an independent schizophrenia cohort. 
Allele-specific MECP2 mRNA expression differs in peripheral blood mononuclear cells 
by ~50% (rs2734647: C>T). Notably, the brain-expressed, species-conserved miR-511 
binds to MECP2 3’UTR only in T-carriers, thereby suppressing gene expression. To 
conclude, subtle MECP2/Mecp2 expression alterations impact aggression. While the 
mouse data provides evidence of an interaction between genetic background and mild 
Mecp2 overexpression, the human data convey means by which genetic variation 














The X-chromosomal MECP2/Mecp2 gene encodes for methyl-CpG-binding protein 2, 
which can act both as a transcriptional activator and repressor (Chao & Zoghbi, 2012). 
Indeed, hundreds of genes have been estimated to be regulated, directly or indirectly, 
by this protein (Chahrour et al, 2008; Cohen et al, 2008). Complete or partial loss-of-
function mutations of MECP2 lead to Rett syndrome, characterized by a gender-
dependent array of symptoms, ranging from early loss of acquired speech and motor 
skills to severe mental retardation and neonatal encephalopathy, amongst many others 
(Amir et al, 1999; Bienvenu & Chelly, 2006). Interestingly, gene duplication can cause 
very similar symptoms (Ramocki et al, 2010), and both down- and upregulation of 
MECP2 are associated with behavioral core features of autism spectrum disorders 
(ASD) (Peters et al, 2013). 
Diverse genetic mouse models, ranging from complete loss-of-function to reduced or 
enhanced expression, have been generated to study consequences of Mecp2 mutations 
(Bodda et al, 2013; Chen et al, 2001; Collins et al, 2004; Guy et al, 2001; Moretti et al, 
2005; Samaco et al, 2008; Shahbazian et al, 2002). In fact, there is a correlation 
between Mecp2 'dosage' and phenotype severity, indicating a narrow normal expression 
range, with deviance in both directions being disadvantageous (Chao & Zoghbi, 2012). 
Along these lines, we have previously shown that mild overexpression of Mecp2 of 
~1.4-1.5 times the wildtype (WT) level induces increased seizure propensity and 
aggression in male FVB/N mice, together with alterations in neuronal branching sites 
and augmented spine density (Bodda et al, 2013). Application of an epileptogenic 
compound, pentylenetetrazole, to transgenic (TG) neurons in vitro leads to a marked 
increase in amplitude and frequency of calcium spikes (Bodda et al, 2013). 
While epileptic seizure susceptibility is a well-established result of alterations in MECP2 
expression (Bodda et al, 2013; Chahrour & Zoghbi, 2007; Chao et al, 2010; Chao & 
Zoghbi, 2012; Collins et al, 2004; Shahbazian et al, 2002), information on the behavioral 
consequences of mild overexpression is still rather limited. Doubling the Mecp2 
expression level in mice resulted in impaired social interaction (Samaco et al, 2012). 
Mecp2 deficiency, however, also led to abnormal social behavior such as deficits in nest 
building, altered social interaction and enhanced aggression (Chao et al, 2010; Fyffe et 
al, 2008; Kerr et al, 2008; Moretti et al, 2005; Pearson et al, 2012; Samaco et al, 2008; 
Samaco et al, 2009; Shahbazian et al, 2002). Taken together, tightly regulated Mecp2 
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expression is obviously critical for normal function of genes involved in social behavior 
(Moretti et al, 2005). 
Importantly, the reported phenotypes arose from diverse genetic backgrounds of mice 
carrying Mecp2 mutations, not considering basic phenotypical differences among 
mouse strains (Moy et al, 2009; O’Leary et al, 2013; Pietropaolo et al, 2011; Samaco et 
al, 2013; Wolfer & Lipp, 2000). For example, behavioral comparisons between FVB/N 
and C57BL/6N strains revealed that FVB/N mice showed a higher frequency of bouts 
during behavioral paradigms of aggression (Mineur & Crusio, 2002; Pugh et al, 2004). 
Thus, the genetic background might well mask or modulate phenotypical changes 
induced by alterations in Mecp2 expression.  
In humans, data on aggression/impulsivity in Rett or MECP2 gene duplication syndrome 
are scarce. A family study characterizing neuropsychiatric phenotypes of 9 males and 9 
females with MECP2 duplications revealed a high prevalence of hostility (63%) in 
female carriers. Moreover, an asymptomatic Rett mutation carrier with the mutation 
located in the deletion hotspot of the MECP2 3’ region has been reported to experience 
episodes of uncontrolled aggression (Huppke et al, 2006).  
The present study has been designed (1) to explore the role of gender and genetic 
background (FVB/N versus C57BL/6N) for behavioral phenotypes associated with mild 
Mecp2 overexpression in mice, i.e. altered aggression, spontaneous home cage 
behavior and predisposition to epileptic seizures, and (2) to translate these findings to 
humans by searching for social behavioral consequences of common single nucleotide 
polymorphisms (SNPs) within MECP2 and (3) to strive for mechanistic insight into SNP-






Mild Mecp2 overexpression in FVB/N and C57BL/6N mice of both genders leaves 
most basic behaviors unaltered but modulates spontaneous home cage activity 
To estimate the expression of the TG protein Mecp2WT_EGFP (~100kDa) compared to 
endogenous Mecp2 (~70kDa) in TG mice, we performed Western blot analysis with total 
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protein extracted from hippocampus and cerebellum. As described previously for FVB/N 
mice (Bodda et al, 2013), the relative expression of Mecp2WT_EGFP in brain amounts to 
40-50% of endogenous Mecp2 in both strains, leading to a subtle overexpression of 
~1.4-1.5-fold compared to WT. Mecp2WT_EGFP TG mice of both genders and strains 
(FVB/N and C57BL/6N) develop and reproduce normally, and are devoid of any 
immediately obvious phenotype. Also, upon comprehensive testing of several 
independent cohorts of both genotypes and genders at different ages, all major domains 
of basic behavior, i.e. general activity, anxiety, motor functions, exploratory behavior, 
sensory and cognitive functions were unaltered when compared to the respective WT 
littermate controls (Table1a,b), thus confirming and extending our earlier report on male 
FVB/N TG mice (Bodda et al, 2013).  
 
We wondered whether subtle behavioral differences upon mild overexpression of 
Mecp2 are perhaps not captured by the usual behavioral test battery. Therefore, 
spontaneous home cage behavior was monitored continuously overnight using 
LABORASTM. Indeed, we found significant differences between TG and WT mice. There 
was an overall tendency of reduced locomotion, including climbing, and increased 
immobility in TG as compared to WT, noticeable across strains and genders, except for 
male FVB/N mice that failed to show significant changes in locomotion (Figure1).  
 
Male Mecp2 transgenic mice of both genetic backgrounds exhibit altered 
territorial social behavior and aggression as compared to their WT littermates 
  
Based on the unexpected observation that mild overexpression of Mecp2 leads to 
increased territorial aggressive behavior of male TG versus WT FVB/N mice when 
exposed to FVB/N intruders (Bodda et al, 2013), we started here a series of new 
experiments on the resident-intruder paradigm: (1) We aimed at testing reproducibility of 
this phenomenon in FVB/N mice exposed to younger intruder males of C57BL/6N 
background, i.e. per se less aggressive intruders (Mineur & Crusio, 2002; Pugh et al, 
2004). This experiment yielded similar results (Figure2A), i.e. increased territorial 
aggression in TG FVB/N. (2) We were interested to see whether another genetic 
background, C57BL/6N, would modify the effect of Mecp2 overexpression. However, 
using the same resident-intruder protocol as in FVB/N males, no attack by C57BL/6N 
males was observed (Table1b). As male C57BL/6N mice are generally less aggressive 
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compared to male FVB/N (Mineur & Crusio, 2002; Pugh et al, 2004), the resident-
intruder protocol had to be slightly modified by extending the cut-off time to 10min and 
increasing the basal level of aggression using warming (Gaskill et al, 2012; Greenberg, 
1972). Even though the necessary increase in surrounding temperature (<38°C) is far 
below the temperature used to test pain sensitivity (hot plate test; temperature set to 
55°C), we note here that the pain threshold in TG and WT mice was identical (Table1b). 
Prior to testing, the home cage of the resident mouse was placed under a heat-emitting 
red lamp for 20min to obtain mild prewarming. Further, during testing, the home cage of 
the resident was positioned on a warming pad (set to 38°C). Surprisingly and opposite 
to FVB/N mice, the attack latency of TG C57BL/6N was longer, pointing to reduced 
territorial aggression as compared to WT littermates. In fact, within the 10min 
observation, 30% of WT and 55% of TG residents of the C57BL/6N background did not 
attack the intruder at all (Figure2A). In contrast to the clear alteration of territorial 
aggression in TG versus WT male mice of both strains, the sociability test (mouse 
preferred over empty cage) revealed entirely normal behavior, indistinguishable 
between TG and WT (Figure2B). 
 
The unforeseen result of reduced aggression in male TG C57BL/6N prompted us to 
investigate the pattern of their territorial behavior during the resident-intruder test. We 
measured frequency and duration of agonistic encounters of the resident mouse for the 
first 3min upon introducing the intruder. Whereas the latency to initiate the first contact 
was comparable between male WT and TG C57BL/6N mice (8.5±1.3s versus 
10.7±1.9s; p=0.35), TG mice exhibited lower frequency and duration of follow/chase 
behavior, as well as sniffing of facial and anogenital areas of the intruder mice than their 
WT littermates (Figure3).  
 
Since this territorial behavioral pattern of male C57BL/6N TG mice indicated somewhat 
reduced social interest, we hypothesized that these mice might also display other signs 
of changed social interest/competence. Indeed, nest building capacity/quality, social 
dominance measured by the tube test, and ultrasound vocalization in response to an 
anesthetized female intruder, revealed inferiority or at least a strong tendency thereof in 
TG animals (Figure3). Together, these data indicate that also in Mecp2 overexpressing 
mice of C57BL/6N background, territorial aggressive behavior is a central target 
phenotype. In these intrinsically non-aggressive mice, however, the direction of change 
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is exactly opposite to the FVB/N strain and accompanied by reduced social interest and 
competence. 
 
Seizure propensity is increased upon mild Mecp2 overexpression, independent of 
genetic background and gender 
 
A common characteristic neurological phenotype found in different mouse models of 
mutant Mecp2, ranging from complete loss-of-function to overexpression, are epileptic 
seizures (Chahrour & Zoghbi, 2007; Collins et al, 2004; Guy et al, 2001; Shahbazian et 
al, 2002). We previously reported in male FVB/N TG mice a higher susceptibility to 
seizure induction by the GABAA receptor antagonist, pentylenetetrazole (PTZ) (Bodda et 
al, 2013). This work could now be expanded to female FVB/N TG as well as to male and 
female C57BL/6N TG mice. Indeed, PTZ-induced seizure propensity is increased 
across genetic backgrounds and genders (Figure4), pointing to a strong overall 
phenotypical consequence of mild Mecp2 overexpression.   
 
The startle response to acoustic stimulation is augmented upon mild Mecp2 
overexpression in female mice of both genetic backgrounds  
 
Deletion of Mecp2 in GABAergic neurons resulted in reduction of the startle response to 
acoustic stimuli of 120db (Chao et al, 2010), but nothing has been known regarding a 
potential influence of mild Mecp2 overexpression on startling. Since Mecp2 TG mice of 
both genetic backgrounds exerted an exaggerated seizure reaction to a GABAA receptor 
antagonist, PTZ, we wondered whether mild overexpression of Mecp2 might also alter 
the startle reflex and/or the prepulse inhibition of the startle response (PPI). Indeed, we 
found enhanced startling in female but not male Mecp2 TG mice of both FVB/N and 
C57BL/6N background (Figure4). No changes in the percentage of PPI were observed 
in any strain or gender (Table1a,b). Similar findings that the startle response at 120db 
does not necessarily affect overall PPI were reported in the context of a study on mouse 
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MECP2 SNP distribution is comparable in healthy and schizophrenic individuals  
 
Since our mouse studies revealed aggressive social behavior as a central phenotype 
modulated by subtle Mecp2 overexpression, we started a hypothesis-driven analysis on 
subjects of the GRAS (Göttingen Research Association for Schizophrenia) data 
collection (Ribbe et al, 2010). Genotyping for association analyses was performed for 4 
SNPs located in the X-chromosomal MECP2 gene with reasonably high minor allele 
frequency (Figure5A). At first, a potential genetic risk condition of the selected SNPs for 
schizophrenia was assessed: A case-control study comparing allele frequencies of the 4 
genotyped SNPs rs2239464, rs3027933, rs2075596, and rs2734647 in 1052 GRAS 
patients versus 1248 healthy controls was performed separately for men and women. 
All markers fulfilled Hardy-Weinberg criteria, and no significant associations with 
diagnosis were detected (Figure5B,C). Due to strong linkage disequilibrium (LD) 
between markers, only rs2239464 and rs2734647 were considered for the phenotype-
based genetic association study (PGAS, inclusion criterion r²<0.8) (Figure5D). 
 
Normal genetic variation of MECP2 influences aggression and impulsivity in man 
 
Translating our findings in mild Mecp2 overexpressing mouse models to humans, we 
selected aggression-related variables from the GRAS phenotypical data collection and 
tested their association with the 2 selected MECP2 SNPs separately in men and 
women. Poor impulse control and a further trait reflecting behavioral expression of 
impulsive aggression (excitement) were chosen. For both, SNP rs2734647 in the 3’UTR 
(Table2), as well as for SNP rs2239464 (Table3), significant associations with these 
traits were found in men, with C-carriers and G-carriers (the major alleles), respectively, 
being more aggressive. Sociodemographic and clinical measures potentially 
confounding these results did not differ between genotype groups. The nominally 
significant result for years of education in males (SNP rs2734647) was accounted for by 
including it as a covariate in all models with target measures as dependent variables. In 
contrast, for women, no statistically significant results were obtained. The phenotype-
genotype relationships could be reproduced in a small independent sample of 
schizophrenic men (Table4).  Taken together, the association of MECP2 genotypes with 
readouts of aggression, as detected in mice, was confirmed in two independent cohorts 
of men.  
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SNP rs2734647 in the 3'UTR affects miR-511 binding and gene expression 
 
To examine possible functional implications of SNP rs2734647 in the 3’UTR on 
microRNA (miR)-dependent regulation of gene expression, in silico analyses were 
performed using TargetScan (Release 6.2) (Grimson et al, 2007; Lewis et al, 2005) and 
PITA (Kertesz et al, 2007), resulting in the prediction of 4 miRs with seed binding sites 
comprising the SNP rs2734647 position (i.e. c.*3638A>G). Allele-specific differences of 
the predicted   G values, indicating strength of miR binding, are summarized in 
Figure6A. While miR-4711-3p and miR-511 are predicted to show preferential binding in 
case of the presence of the T-allele, miR-515-3p has a strong negative   G only in 
case of the C-allele, and miR-519e lacks a strong allele preference. In vitro luciferase 
assays using HEK293 cells revealed significantly reduced luciferase activity in case of 
co-transfection of the plasmid carrying the T-allele with both miR-4711-3p and miR-511 
(Figure6B). Co-transfection with miR-515-3p or miR-519e did not lead to luciferase 
activity reduction for either rs2734647 T or C (Figure6B). In luciferase assays using N2a 
cells, the positive result was only replicated for miR-511 (Figure6C). In summary, these 
data strongly suggest miR-511 as rs2734647 genotype-dependent candidate for 
MECP2 regulation in humans. For the sake of completeness, we determined 
endogenous expression of miR-511 in the cell lines used for transfection. Whereas 
mmu-miR-511 levels were under the detection limit in N2a cells, hsa-miR-511 was 
clearly expressed in HEK293 cells (3.59*10-3). However, since we always used 
negative, i.e. non-miR-transfected controls, Luciferase assay results are unlikely to have 
been affected.  
 
miR-511 is expressed in aggression-relevant human brain regions  
 
Since miR-511 seems to be an important modulator of rs2734647 genotype-dependent 
MECP2 expression, we asked whether this miR would be detectable in brain regions 
relevant for impulsivity and aggression (frontal and pre-frontal cortex, temporal cortex, 
occipital cortex, hippocampus, and amygdala). Placenta was used as developmental 
control tissue. In all regions examined, miR-511 expression was found (Figure6D). 
Importantly, the same holds true for MECP2 using primers amplifying either MECP2_e2 
only or both isoforms (Figure6E). In contrast, miR-4711-3p expression was not detected 
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(data not shown), at least questioning a role of this miR for MECP2 regulation in the 
adult human brain. In the adult C57BL/6N versus FVB/N mouse brain, the expression of 
miR-511 was low and comparable between strains in cortex (2.39*10-5 versus 3.71*10-
5), hippocampus (6.45*10-5 versus 3.78*10-5), and cerebellum (2.22*10-5 versus 2.36*10-
5). Strong expression was found in embryonic tissue (C57BL/6N embryo head E17: 
1.83*10-3; embryo body: 2.26*10-3), and highest in cultured microglia (13.02*10-3). 
 
Peripheral blood mononuclear cells (PBMC) of male rs2734647 T-carriers show 
lower MECP2 expression 
 
Since miR-511 was shown to be expressed in dendritic cells and macrophages (Tserel 
et al, 2011), we investigated the hypothesized allele-specific down-regulation of MECP2 
expression in PBMC of male subjects. Indeed, a significantly lower expression in T-
carriers versus C-carriers (amounting to around 50%) was detected with primers 
amplifying both MECP2 isoforms, whereas MECP2_e2 alone showed no expression 
difference dependent on the rs2734647 genotype (Figure6F). This result may indicate 
that in T-carriers mainly the MECP2_e1 isoform is affected, at least in PBMC, potentially 
related to isoform-specific different lengths of the MECP2 3’UTR (Coy et al, 1999). 
 
Sequence variation of miR-511 in mouse and man underlines the importance of 
an interaction with the MECP2 3’UTR 
 
A perfect seed match of human hsa-miR-511 with the MECP2 3’UTR in carriers of 
rs2734647-T is the most likely reason for the difference in luciferase activity in contrast 
to the C-allele, which results in a mismatch in the seed binding region. C is the 
conserved ancestral allele, found in multiple other mammalian species, including 
mouse. Strikingly, the seed sequence of mouse mmu-miR-511 differs from hsa-miR-511 
exactly regarding the nucleotide complementary to the SNP position (Figure6G). Thus, 
mmu-miR-511 shows an ideal seed match to the mouse 3’UTR, whereas hsa-miR-511 
perfectly fits to the human 3’UTR carrying the T-allele. This observation may emphasize 
the importance of the miR-511 interaction with MECP2.  
 
Notably, screening of available data from Jackson Laboratories (http://www.jaxlab.org) 
revealed that the two mouse lines employed here are not polymorphic for the Mecp2 
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3’UTR allele or the miR-511 sequence. It would, however, be interesting to investigate 






The present study, extending from mouse to man, shows that mildly increased MECP2 
expression leads to alterations in male social aggression. Using C57BL/6N versus 
FVB/N mice (with their known inherent strain differences in aggressive behavior) 
(Mineur & Crusio, 2002; Pugh et al, 2004) as models, we demonstrate that the direction 
of change upon mild Mecp2 overexpression in this behavioral target domain is subject 
to modification by the genetic background. In other words, the resulting lower or higher 
social aggression depends on the basic genetic make-up of a particular subject. The 
discovery of MECP2 influencing aggressive behavior could also be reproduced in two 
independent cohorts of schizophrenic men, with a polymorphism in the 3'UTR of the 
gene co-determining both the level of MECP2 expression as well as of aggression. The 
genotype-dependent expression difference in men found in PBMC (around 50%) is in 
the range of the transgenic overexpression in both mouse strains, emphasizing the 
physiological significance of these findings as well as of our mouse models for studying 
behavioral consequences of the normal 'Mecp2 dose range'.  
 
Even though in both schizophrenia samples, higher expression of MECP2 (3’UTR SNP 
rs2734647 C carriers lack suppressability by miR-511) was associated with higher 
aggression, it has to be considered that also humans are not an isogenic population. 
One might thus, in analogy to our observation in different mouse strains, predict a 
human population with reduced aggression as suggested by the C57BL/6N data (i.e. a 
bimodal aggression distribution when combining different genetic backgrounds). 
 
Although the results for women show a similar tendency for poor impulse control and 
excitement as aggression readouts, they are far from reaching significance, likely due to 
the smaller number of individuals, but certainly also to the fact that MECP2 is X-
chromosomal. Homozygous T carriers in the female sample are therefore expectedly 
very rare. 
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In our translational PGAS approach, we had the chance to explore the aggression 
association of MECP2 genotypes in a phenotypically very well characterized large 
sample of schizophrenic individuals (Ribbe et al, 2010), and we replicated the 
association findings in a second, independent cohort of schizophrenic men. Therefore, 
we cannot state with certainty at this point, that the phenotype association holds true in 
the same way for healthy individuals. Nevertheless, apart from the supporting data 
obtained for healthy mice, it has to be emphasized that aggression is not a specific or 
unique symptom in schizophrenia. Also, the range of aggressive features in the whole 
GRAS patient sample follows a normal distribution, extending from very low to very high 
aggression scores.  
 
Along the same lines, the case-control study presented here, including 1052 cases and 
1248 controls, fails to attribute to MECP2 any schizophrenia risk gene role. In some 
contrast, a recent study reported in a Han Chinese population an association of 
rs2734647 C with the disease (498 cases versus 2025 controls, replicated in 1027 
cases versus 1005 controls) (Wong et al, 2013). Although we did not even find a 
respective trend (Figure5C), we cannot entirely exclude limited power of our case-
control approach. On the other hand, the association might well be population-specific. 
In any case, a potential risk gene status, even if confirmed by future GWAS including X-
chromosomal genotypes, will not be dramatic considering the large number of 
individuals needed for its demonstration. Instead, MECP2 is most likely disease-
independently involved in the regulation of a basic mammalian behavioral phenotype, 
i.e. aggression. Interestingly, carriers of the minor allele of MECP2 SNP rs2239464 
were previously shown to have decreased cortical surface area in brain regions such as 
the cuneus (Joyner et al, 2009), which is associated with inhibitory control in patients 
with bipolar disorder (Haldane et al, 2008). 
 
In further support of an association between MECP2 and aggression, impulse control 
alterations in individuals with MECP2/Mecp2 gene duplication syndrome have been 
reported (Ramocki et al, 2009), even though the findings of the present study are more 
relevant for the understanding of physiological gene-dose effects on social behavior. 
Importantly, Mecp2/MECP2 functions as transcriptional regulator targeting hundreds of 
other genes (Ben-Shachar et al, 2009; Bird, 2008; Chahrour et al, 2008; Chen et al, 
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2003; Sun & Wu, 2006; Wu et al, 2010). Thus, it is most likely a whole pattern of genes - 
directly or indirectly influenced by this regulator - that primes nuances of aggressive 
social behavior. As an example, changes in the expression of a Mecp2 regulated gene, 
Prom1, are associated with domestication and aggressive behavior in animals (Albert et 
al, 2012; Gopisetty et al, 2012). Furthermore, Mecp2 is known to control expression of 
brain-derived neurotrophic factor (Bdnf) (Martinowich et al, 2003), which in turn is 
involved in the regulation of aggression (Ito et al, 2011). 
 
Aggression seems to be a strong target phenotype of mild Mecp2/MECP2 
overexpression independent of the genetic background, since these expression 
changes did not lead to alterations in basic behavior, including motor, sensory and 
cognitive functions. Male and female TG mice of both the FVB/N and C57BL/6N genetic 
backgrounds displayed basic behavior comparable to their WT littermates. Apart from 
aggression, only home cage activity, seizure propensity and startle response were 
influenced by mild Mecp2 overexpression in a fashion widely independent of the genetic 
background.  
 
There have been reports on sexual dimorphism with respect to Mecp2 expression and 
function in the brain. For instance, in amygdalae and ventromedial hypothalamus, male 
rats express less Mecp2 as compared to females ((Kurian et al, 2008; Kurian et al, 
2007). Furthermore, conditional knockout of Mecp2 during amygdala development 
caused subtle modifications of juvenile play behavior in male but not female rats (Kurian 
et al, 2008). These findings may indicate a role of Mecp2 in gender-specific modulation 
of behavior. In the present work, however, sexual dimorphism was consistently 
observed only with the startle response in a genotype and genetic background 
independent manner.  
 
Even though the explicit situations are still unknown in which miR-511 regulated 
MECP2/Mecp2 expression might be of particular physiological relevance, any kind of 
inflammation in the brain for instance could play a pivotal role, considering the relatively 
high expression found here in mouse microglia. The distinct suppression of MECP2 
expression by miR-511 in SNP rs2734647-T carriers reported here may even be 
considered as a future treatment target in MECP2 gene duplication syndrome. In any 
case, the high conservation of the interaction between miR-511 and MECP2 in both 
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mouse and man makes a specific significance of their interplay very likely. This 
significance is further supported by the here demonstrated co-expression of MECP2 
and miR-511 in human brain areas pivotal for aggression and impulsivity regulation 
(Bauman et al, 2006; Berlin et al, 2004; Brower & Price, 2001; Horn et al, 2003; Siever, 
2008; Whelan et al, 2012; Zetzsche et al, 2007). Interestingly, miR-511 expression was 
found here also in different mouse brain areas, with levels comparable across both 
genetic backgrounds.  
 
 
To conclude, MECP2/Mecp2 has been shown here to be a regulator of social 
aggressive behavior in mouse and man, with the genetic background playing an 




MATERIALS & METHODS 
Mice  
All mouse experiments have been approved by the Animal Care and Use Committee of 
Lower Saxony, Oldenburg, Germany. The generation of Mecp2WT_EGFP  TG mice with a 
1.4-1.5-fold Mecp2 overexpression on FVB/N background has been described in detail 
previously (Bodda et al, 2013). Briefly, a bacterial artificial chromosome (BAC) clone, 
pBAC_B22804, containing 120 Kb of murine genomic fragment with the intact Mecp2 
gene and the flanking Opsin1 and Irak1 genes was used for generating the transgenic 
construct (Kifayathullah et al, 2010). To generate the pBAC_Mecp2WT_EGFP 
construct, the enhanced green fluorescent protein/kanamycin-resistant gene 
(EGFP/kan) cassette was PCR amplified using pEGFP1 vector as template with primers 
containing 50bp flanking sequence from either side of the Mecp2 stop codon. The 
endogenous stop codon was replaced by two glycine residues inframe between the 
MeCP2 protein and the EGFP protein to facilitate the two proteins to fold and function 
independently. The amplified EGFP/Kan cassette was electroporated into E.coli 
harboring the BAC clone and pGET recombination system, to facilitate the homologous 
recombination of EGFP/Kan cassette at the site of stop codon of Mecp2. The correct 
insertion of EGFP/Kan cassette after the recombination event into the BAC clone was 
confirmed by sequencing. The Mecp2 flanking genes, Opsin1 and Irak1 were deleted 
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from the modified BAC clone using additional BAC recombineering with zeocin selection 
cassette (containing the BAC homology arms and zeocin antibiotic marker gene driven 
by EM7 promoter frompSELECT vector) (InvivoGen, Toulouse, France), to avoid any 
additional phenotype arising from the overexpression of these genes. During the 
process of Opsin1 deletion, a MluI restriction site was introduced into BAC clone. The 
final BAC construct pBAC_Mecp2WT_EGFP was linearized with MluI restriction enzyme 
and micro-injected into the male pronuclei of the fertilized mouse oocytes derived from 
the FVB/N strain. Next, the injected oocytes were transplanted into the uteri of the foster 
mothers. Genomic DNA isolated from tail biopsies was analyzed for the presence of the 
transgene by PCR. Because the transgene was not confirmed to be localized to the X 
chromosome, translational relevance with respect to modelling mosaicism resulting from 
X chromosome loss is limited. 
 
To create a comparator congenic strain for behavioral analyses, Mecp2 TG FVB/N mice 
were backcrossed for 10 generations to the C57BL/6N background. For experiments 
reported here, male and female Mecp2WT_EGFP TG (hemizygous) and their WT 
littermates on either FVB/N or C57BL/6N backgrounds were used. Tail biopsies were 
taken before weaning to obtain genomic DNA for genotyping (Bodda et al, 2013; 
Kifayathullah et al, 2010). Western blot and qPCR analyses for TG expression 
estimation was performed as described previously (Bodda et al, 2013). 
 
Behavioral analyses 
After weaning and during the whole period of behavioral testing, mice were housed 
individually in standard plastic cages (26.5x20x14cm) and kept under temperature-
controlled environment (21±2ûC) on 12h light/dark cycle with food and water ad libitum, 
unless stated otherwise. Single housing was necessary since male FVB/N mice 
exhibited extremely aggressive behavior in a group-housed setting. In order to avoid 
housing differences as confounding variables, we decided to single-house all mice, 
independent of gender and strain. All experiments were conducted by investigators 
unaware of the genotype ('blinded'), during the light phase of the day (between 8:00am 
and 6pm, except for automated home cage behavioral assessment. Several 
independent cohorts of mice (genders and strains tested separately, starting at 5 weeks 
of age) were run through a battery of tests covering altogether basic behavioral, 
sensory, motor, cognitive and social functions (for overview see Table1a,b). The order 
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of tests was always oriented toward increasing invasiveness and performed as 
published in detail earlier (Bodda et al, 2013; El-Kordi et al, 2012; Jamain et al, 2008): 
Elevated plus maze (anxiety), open field (spontaneous activity), hole board (exploratory 
behavior), grip strength and rotarod (motor force, balance and coordination), marble 
burying (stereotypies and obsessive–compulsive behaviors), prepulse inhibition of the 
startle response (sensorimotor gating), hearing test (startle curve upon random 
presentation of stimulus intensities from 65dB to 120dB), Y-maze (working memory), 
novel object recognition, visual cliff (vision), sociability (social preference, i.e. other 
mouse over object), buried food finding (olfaction), sucrose preference (anhedonia), hot 
plate test (pain sensation), and hole board (working and reference memory). Moreover, 
automated home cage behavior analysis (LABORASTM), ultrasound vocalization 
recording, nest building (social competence), social tube (dominance), resident-intruder 
paradigm (aggression) and seizure propensity (seizure induction by pentylenetetrazole) 
were performed as indicated (Table1a,b). In the following, the here relevant tests (with 
significant results) will be described in detail, while for the other tests the reader is 
politely referred to previous publications of ourselves and others (Bodda et al, 2013; El-
Kordi et al, 2012; Jamain et al, 2008; Kuc et al, 2006; Mandillo et al, 2008). 
 
Automated home cage behavior analysis was performed using LABORASTM system 
(Metris b.v., Hoofddorp, The Netherlands) which consists of a triangular shaped sensor 
platform (Carbon Fiber Plate 1000mm×700mm×30mm), positioned on 2 orthogonally 
placed force transducers (Single Point Load Cells) and a third fixed point attached to a 
heavy bottom plate (Corian Plate 980mm×695mm×48mm). The whole structure stands 
on 3 spikes, which are adjustable in height and absorb external vibrations. Mice are 
housed in clear polycarbonate cages (Makrolon type II cage, 22cm×16cm×14cm) with 
wood-chip bedding covered floors. The cage is placed directly onto the sensing 
platform, with the upper part of the cage (including top, food hopper and drinking bottle) 
suspended in a height-adjustable frame separate from the sensing platform. Resultant 
electrical signals caused by mechanical vibrations as induced by movement of the 
mouse are transformed by each force transducer, amplified to a fixed signal range, 
filtered to eliminate noise, digitized and stored on a computer. Stored signals are 
classified into separate behavioral categories like locomotor activity, immobility and 
climbing, and quantified by the LABORASTM software. Prior to each session, 
LABORASTM was calibrated. Spontaneous mouse behavior was assessed from 6:00pm 
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until 9:00am, with 1h cage habituation prior to initiation of recording. Male (FVB/N: 
10TG, 10WT; C57BL/6N: 12TG, 24WT) and female mice (FVB/N: 10TG, 10WT; 
C57BL/6N: 13TG, 28WT) were tested. 
 
Ultrasound Vocalizations (USVs) were recorded using a microphone 
(UltraSoundGateCM16) connected to a preamplifier (UltraSoundGate116), which was 
linked to a computer. At the day of recording, mice in their home cage (single housed) 
were placed in the recording room for 60s. Subsequently, the intruder mouse was put 
into the resident's cage, and vocalization behavior recorded for 3min. The intruder 
mouse was an anaesthetized unfamiliar female (anesthetic: intraperitoneal injection of 
0.25% tribromoethanol, 0.1ml/10g body weight). Number of calls per recording session 
was counted and USVs were separated from other sounds using the whistles detection 
algorithm of Avisoft-SASLab 5.2 with following selection criteria: Possible changes per 
step=4 (4687Hz), minimal continuity=8ms, possible frequency range=35–150kHz. 
These criteria had been tested in former studies of mouse USVs (El-Kordi et al, 2012; 
Hammerschmidt et al, 2012). Avisoft Bioacoustics, Berlin, Germany, delivered all sound 
recording hardware and software. Male C57BL/6N mice (12TG and 23WT) were tested. 
 
The resident-intruder test was used to study inter-male aggression in various 
independent cohorts of TG and WT mice of both genetic backgrounds (FVB/N and 
C57BL/6N) and different age groups, ranging from 8-32 weeks (Bodda et al, 2013; 
Jamain et al, 2008). As standard opponents (intruders), group-housed males (4 weeks 
younger than resident test males) of C57BL/6N background were employed (Charles 
River, Sulzfeld, Germany). An intruder was introduced into the home cage of the test 
resident. Observation started when the resident first sniffed the opponent and stopped 
(stop watch) at first attack (defined as bite) to prevent wounding, but lasted for 300s 
(FVB/N) or 600s (C57BL/6N) if no attack occurred (cut-off) (Mineur & Crusio, 2002; 
Pugh et al, 2004). Male mice (FVB/N: 12TG, 22WT; C57BL/6N: 10TG, 13WT) were 
tested. Over the first 180s (unless mice attacked before), frequency and duration of 
following behaviors was additionally quantified in C57BL/6N (10TG, 11WT): nose/snout 
and anogenital sniff, following/chasing.  
 
The social tube test measures social dominance (Garfield et al, 2011; Messeri et al, 
1975; Moretti et al, 2005). The test apparatus comprises a 30cm long transparent acrylic 
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tube with an internal diameter of 3cm. Two mice are placed from opposite ends in the 
tube and gently pushed to the middle, where they face each other closely. Single-
housed TG and WT C57BL/6N mice were challenged with unrelated group-housed mice 
of C57BL/6N background. A subject was declared 'winner' when its opponent 
completely retreated from the tube ('out') within 300s (cut-off). To account for both, 
winning/losing and time to win/lose, dominance values are calculated using the following 
formulas: winner dominance value=100/time to out and loser dominance value = 
1/(300–time to out). Male C57BL/6N mice (10TG, 16WT) were tested in this paradigm. 
 
Nest building is an important behavior in rodents, reflecting social competence in 
reproduction (Deacon, 2006; El-Kordi et al, 2012; Satoh et al, 2011). Two hours before 
dark phase, the nesting towel was removed from home cages of single-housed mice 
and replaced by a nestlet (pressed 2.7g cotton square). Nest building quality was 
scored in the morning (Deacon, 2006; El-Kordi et al, 2012). Male C57BL/6N mice 
(10TG, 16WT) were tested. 
 
The pentylenetetrazole-induced seizure protocol has been described in detail 
previously (Bodda et al, 2013; Ferraro et al, 1999; Wojcik et al, 2013). Seizure activity 
was induced in wakeful mice by a single intraperitoneal (i.p.) injection of 
pentylenetetrazole (PTZ) (50mg/kg body weight) followed by close observation for 
30min in a small, clear homecage. Latencies to focal (partial clonic), generalized clonic 
and maximal tonic-clonic behavioral seizures were recorded. Furthermore, 4 phases in 
the continuum of behavioral response to PTZ injection were defined as follows: (1) 
Hypoactivity (progressive decrease in motor activity until resting in a crouched or prone 
position with abdomen in full contact with cage bottom); (2) Partial clonus (clonus 
seizure activity affecting face, head, and/or forelimb or forelimbs); (3) Generalized 
clonus (sudden loss of upright posture, whole body clonus involving all 4 limbs and tail, 
rearing and autonomic signs); (4) Tonic-clonic (maximal) seizure (generalized seizure 
characterized by tonic hindlimb extension – also associated with death). Finally, 
latencies to partial clonus (PC), generalized clonus (GC), and tonic-clonic (TC) seizures 
were summed to assign each mouse a seizure score that was used as a quantitative 
trait measure for mapping according to the following equation: Seizure score = 
[(0.2)(1/PC latency)+(0.3)(1/GC latency)+(0.5)(1/TC latency)] x1000. The weighting 
factors (0.2, 0.3 and 0.5) in the equation were included as means of incorporating a 
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measure of the progressive nature of the PTZ-induced seizure phenotype into the 
severity rating because generalized clonus is regarded as a more significant event than 
partial clonus, and tonic hind limb extension is regarded as the most severe component 
of the phenotype. Therefore, the seizure score reflects the degree of progression of the 
seizure phenotype in each mouse.(Ferraro et al, 1999) The test was performed on adult 
Mecp2 TG of FVB/N and C57BL/6N background (30-40 weeks old). Male (FVB/N: 6 TG, 
10 WT; C57BL/6N: 12 TG, 10 WT) and female mice (FVB/N: 14 TG, 14 WT; C57BL/6N: 
10 TG, 11 WT) were tested. 
 
Human sample 
Schizophrenic patients (discovery sample) 
The GRAS (Göttingen Research Association for Schizophrenia) data collection(Ribbe et 
al, 2010) was approved by the ethics committee of the Georg-August-University 
Göttingen (master committee) and respective review boards of collaborating centers. 
The project complies with the Helsinki Declaration. Patients fulfilling DSM-IV criteria for 
schizophrenia or schizoaffective disorder were included regardless of disease stage 
(acute, chronic, residual, or remitted). All study participants (European Caucasian 
95.3%; other 2.0%; unknown 2.7%) and, if applicable, their legal representatives gave 
written informed consent. Of the included 1052 patients, 68.2% were male (N=717) and 
31.8% female (N=335). Average age was 39.14±12.56 years (range 17 to 78). 
 
Healthy controls 
Healthy voluntary blood donors were recruited by the Department of Transfusion 
Medicine at the Georg-August-University of Göttingen according to national guidelines 
for blood donation. As such, they widely fulfill health criteria, ensured by a broad pre-
donation screening process including standardized health questionnaires, interviews, 
and assessment of hemoglobin concentration, blood pressure, pulse, and body 
temperature. Of the N=1248 successfully genotyped control subjects (European 
Caucasian 97.8%; other 2%; unknown 0.2%), 61.5% were male (N=768) and 38.5% 
female (N=480). Average age was 37.44±13.23 years (range 18 to 69). 
 
 
Independent schizophrenia sample (replicate sample) 
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To replicate in an independent sample the phenotype-genotype associations found in 
male schizophrenic GRAS patients, data from male schizophrenic subjects (N=385) of 
the Munich/Halle collection of Dan Rujescu could be analysed (Van den Oord et al, 
2006). Also in this replicate sample, written informed consent had been obtained from 
all subjects after detailed and extensive description of the study, which was approved by 
the local ethics committee and carried out in accordance to the ethical standards laid 
down in the Declarations of Helsinki.  
 
Phenotyping - Target variables 
All schizophrenic patients of the GRAS data collection were comprehensively 
phenotyped (Ribbe et al, 2010). To prove our hypothesis that MECP2 genotypes 
modulate aggressive behavior in human subjects, we selected target variables closely 
related to (poor impulse control) or predicting (excitement) aggressive behavior in 
schizophrenic individuals (Arango et al, 1999; Colasanti et al, 2010; Soyka et al, 2007). 
To assess the severity of poor impulse control, item 14 of the positive and negative 
syndrome scale (PANSS) (Kay et al, 1987) was used (‘disordered regulation and control 
of action on inner urges, resulting in sudden, unmodulated, arbitrary or misdirected 
discharge of tension and emotions without concern about consequences’). From the 
subscale covering positive symptomatology, item 4 assessing excitement (‘hyperactivity 
as reflected in accelerated motor behavior, heightened responsivity to stimuli, 
hypervigilance or excessive mood lability’) was employed (Tables2,3). Both PANSS 
readouts were also available in the independent sample of schizophrenic individuals 
(replicate sample). The choice of items is supported by the literature: Cheung and 
colleagues compared aggressive and non-aggressive schizophrenia patients 
(aggression assessed by the Staff Observation Aggression Scale) with respect to single 
items of the PANSS (Cheung et al, 1997). The largest group difference was found for 
the PANSS item ‘poor impulse control’. Strikingly, the aggressive group had an average 
score of 4 (range: 1-7) on this item. Even after controlling for the total level of 
psychopathology, the associations of ‘poor impulse control’ and aggressive behavior 
remained significant. Additionally, in a more recent prospective study, ‘poor impulse 
control’ as measured by PANSS was highly predictive of aggressive behavior (assessed 
by the Overt Aggression Scale)(Nolan et al, 2005). 
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Phenotyping - Control variables  
Control variables (and potential confounders) are also presented in Tables2,3. 
Sociodemographic data (age, years of education, unemployment rate), a cognition 
composite score and clinical variables describing disease severity were used to 
characterize the GRAS sample and exclude potential confounding effects explaining the 
target phenotype-genotype associations. The cognition composite score(Begemann et 
al, 2011) represents the mean of 3 z-standardized neuropsychological measures of 
higher cognitive functioning: reasoning ability (Leistungsprüfsystem subtest 3 (Horn, 
1983)), executive functioning  (Trail-Making Test B (Reitan, 1958)) and verbal learning 
and memory (Verbal Learning and Memory Test (Helmstaedter et al, 2001)). As further 
clinical variables, the general, positive and negative scores of the PANSS (target 
variables excluded from respective scores), chlorpromazine equivalents (standardized 
dosage of antipsychotic medication) (Rijcken et al, 2003; Woods, 2003) and GAF 
(Global assessment of functioning (Wittchen et al, 1997)) as measure of impaired 
psychological, social and occupational performance were used. 
 
DNA extraction, normalization and genotyping 
Genomic DNA was purified from whole blood using JETQUICK Blood & Cell Culture 
DNA Spin Kit (Genomed GmbH, Löhne, Germany) according to the manufacturer's 
protocol. Resulting DNA samples were aliquoted and stored at -80°C. For further 
analysis, DNA was normalized to 50ng/µl with an automated robotic platform (Microlab 
Star, Hamilton, Bonaduz, Switzerland). For quality control, each sample was analyzed 
with a 0.8% agarose gel. Genotyping was performed using SimpleProbes (TIB Molbiol, 
Berlin, Germany) on LightCycler 480 (Roche Diagnostics, Basel, Switzerland), 
according to the manufacturer’s instructions. 
 
Transfection studies  
Cell lines 
Human embryonic kidney 293 (HEK293) and mouse neuroblastoma (N2a) cells were 
maintained in DMEM supplemented with 1g/l glucose, L-glutamine (Glutamax), 5% fetal 
calf serum, 100U/ml penicillinG sodium and 100µg/ml streptomycin sulfate. For 
luciferase assays, cells were seeded into 12-well plates (220,000 cells/well/2ml 
medium), cultured for 24h and co-transfected using Lipofectamine 2000 (Invitrogen, 
Karlsruhe, Germany), following the manufacturer’s instructions. 
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Luciferase reporter constructs and detection assay 
The reporter plasmids phRL-TK rs2734647C, or rs2734647T, respectively, were 
constructed by cloning a 3’UTR fragment of 346 bp and including the SNP downstream 
of the Renilla luciferase open reading frame, making use of the XbaI restriction site of 
phRL-TK (forward primer: 5’-ATTATCTAGACCAGGTCTACCCCTCCCGGC-3’, reverse 
primer: 5’-ATTATCTAGAGGCTGCTCCCTGTCCCAGGT-3’). Sequence integrity was 
verified using Sanger sequencing. Of the Renilla luciferase reporter construct (phRL-TK 
rs2734647C, or rs2734647T, respectively), 1µg (per well), plus 1µg (per well) of the 
reference construct pCMV-LacZ (Clontech, Mountain View, CA, USA) were co-
transfected in the presence of 10pg of mirVana miRNA mimic hsa-miR-4711-3p, hsa-
miR-511, hsa-miR-515-3p, hsa-miR-519e-3p, negative control #2 (all Life Technologies, 
Darmstadt, Germany), or no miRNA, respectively. After 24h, cells were split in 96 well 
plates, creating four technical replicates for each condition, and separately for luciferase 
and beta-galactosidase measurement. Enzyme activity was determined using a Mithras 
LB 940 Plate Reader (Berthold, Bad Wildbad, Germany). Renilla luciferase activity was 
normalized to beta-galactosidase activity.  
 
RNA isolation and quantitative PCR 
Peripheral blood mononuclear cells (PBMC) were isolated from citrate blood of men with 
rs2734647C or rs2734647T genotype (X-chromosomal gene), applying a standard 
isolation procedure (Ficoll-Paque Plus, GEHealthcare, München, Germany). Human 
RNA was extracted from deep-frozen human brain samples of adult male subjects who 
had been free of neuropsychiatric diseases, from placenta or PBMC, respectively, using 
a miRNeasy Mini kit (Qiagen, Hilden, Germany). The same kit was employed for 
isolation of mouse RNA from whole E17 embryo (divided into body and head), 
hippocampus, amygdala, placenta, and cultured microglia. Synthesis of cDNA was done 
by the SuperScriptIII system (Invitrogen, Karlsruhe, Germany). Detection of MECP2 
cDNA was performed using SYBR green (Roche, Diagnostics GmbH, Mannheim, 
Germany) and specific primer pairs amplifying the MECP2_e2 isoform (NCBI reference 
sequence NM_004992), spanning exons 2–3 (forward primer: 5’- 
CAGCTCCAACAGGATTCCAT-3’, reverse primer: 5’- TGGAGGTCCTGGTCTTCTGA-
3’), or both isoforms (NM_004992 and NM_001110792), spanning exons 3–4 (forward 
primer: 5’- AGCTTAAGCAAAGGAAATCTGG-3’, reverse primer: 5’-
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GCTTTTCCCTGGGGATTG-3’). Specific Taqman microRNA assays were used to 
detect hsa-miR-511, hsa-miR-4711-3p, or mmu-miR-511 (Applied Biosystems, Foster 
City, CA, USA), following the manufacturer’s instructions. MECP2 expression levels 
were normalized to GAPDH, human miRNA expression levels to RNU43, and mouse 
miRNA expression levels to sno-142. 
 
Statistics 
All experimental data acquisition was done by experimenters unaware of group 
assignment ('blinded'). Mouse behavioral data were analyzed by Mann-Whitney U test 
or 2-way analysis of variance including posthoc Bonferroni testing, where applicable, 
using Prism4 (GraphPad Software, San Diego, CA, USA). All data are presented as 
mean±SEM, unless stated otherwise. Luciferase assay results from each experiment 
were normalized to the relative luciferase activity without miRNA co-transfection and 
analyzed using one-tailed t-tests. qPCR results were normalized to the respective 
control genes and analyzed using one-tailed t-tests. PLINK (v1.07) (Purcell et al, 2007) 
was used for the analysis of statistical association between single SNPs and case or 
control status (allelic test), and to test for deviations from Hardy-Weinberg equilibrium. 
Statistical analyses of phenotype-genotype associations in the human samples (both 
GRAS and replicate sample) were performed using SPSS for Windows version 17.0 
(SPSS Inc., Chicago, IL, USA; http://www.spss.com). As MECP2 is X-linked, analyses 
were performed separately for men and women. Genotype differences with respect to 
the target variables were assessed by analysis of covariance. Covariates age at 
examination, years of education, chlorpromazine equivalents and severity of negative 
symptoms (PANSS) were used, as these parameters are likely to influence the extent to 
which impulsive aggressive behavior becomes obvious in a social situation. For the 
cognition composite score, analysis of covariance with covariates age, chlorpromazine 
equivalents and severity of negative symptoms was applied as these variables have 
been widely reported to confound performance on neuropsychological tests(Bilder et al, 
1992; Hori et al, 2006). Genotype differences with respect to sociodemographic and 
clinical measures were tested non-parametrically using χ2 (nominal variables) or Mann-
Whitney-U/Kruskal-Wallis tests (continuous variables). All p-values derived from 
statistical models for the GRAS sample are two-sided (Tables2,3). For the replicate 
sample one-sided p-values are displayed (Table4). Nominal significance level for all 
analyses was set to p<0.05. 
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The paper explained 
Problem 
The transcriptional regulator methyl-CpG-binding protein2, MECP2, is renowned 
because of the devastating neurodevelopmental disorder Rett syndrome, caused by 
partial or complete loss of its function. The very same gene, when duplicated, induces a 
similar disorder, indicating the necessity of tight MECP2 regulation. Among the vast 
array of other genes influenced by MECP2, many are involved in modulating behavior. 
Surprisingly, nothing is known on the physiological (i.e. non disease-related) effects on 
behavior of subtle MECP2 expression differences.  
Results 
We present here a translational study, reaching from mouse to man to cell, that explores 
behavioral consequences of mildly increased MECP2 expression across species. In 
both man and mouse, we find that the behavioral target domain directed by MECP2 is 
male social aggression. This in turn is subject to modification by the genetic 
background, as we demonstrate by comparing an inherent aggressive with a less 
aggressive mouse strain. Likewise, we identify in two independent cohorts of 
schizophrenic individuals, i.e. a discovery and a replicate sample, a role of MECP2 in 
aggressive human behavior and show that a polymorphism in the untranslated region of 
the gene determines binding efficiency of another brain-expressed regulator, microRNA-
511. Notably, the genotype-dependent expression difference of 40-50% (rs2734647-
C>T) in man, at least partially mediated by microRNA-511, is comparable to the level of 
transgenic overexpression in our mice, emphasizing the physiological significance of 
these findings. 
Impact 
Genetic regulation of behavior is still poorly understood. We present here a translational 
study, extending from mouse to man to cell, that explores for the first time behavioral 
consequences of mildly (~50%) increased MECP2 expression across species. This is 
achieved by transgenic Mecp2 overexpression in mice and through genetic variation-
induced non-regulability of MECP2 gene expression (rs 2734647-C: no miR-511-mediated 
MECP2 downregulation) in humans. We find MECP2 to be a modulator of social 
aggression in mouse and man. While the mouse data shows an interaction between 
genetic background and Mecp2 expression on behavior, the human data provides 
means by which genetic variation may affect MECP2 expression and result in 
behavioral change. 
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Figure 1: Spontaneous home cage activity of FVB/N and C57BL/6N mice of both 
genders is modulated by mild Mecp2 overexpression. Results for male and female 
mice of both strains are presented. With the exception of male FVB/N mice, locomotion, 
immobility and climbing reveal similar TG effects across genders and genetic 
backgrounds. N=10-28; mean±SEM given. 
 
 
Figure 2: Territorial aggressive behavior in male mice is influenced by Mecp2 
overexpression and genetic background. A. Latency to attack in the resident-intruder 
test is significantly reduced in male FVB/N TG mice but increased in C57BL/6N. Note 
the different cut-off for the 2 strains.  B. Sociability testing in the tripartite chamber 
reveals a highly significant preference of male mice, independent of the genetic 




Figure 3: Male TG C57BL/6N mice show reduced territorial social interaction as 
well as inferior social competence. Upper 2 rows: Frequency and duration of 
determinants of territorial social interaction, i.e. follow/chase behavior, nose/snout sniff 
and anogenital sniff, are consistently reduced in TG carriers. Lower row: TG mice are 
inferior in nest building, social dominance behavior and ultrasound vocalization. N=10-
23; mean±SEM given. 
 
 
Figure 4: Pentylenetetrazole-induced seizure propensity is increased upon mild 
Mecp2 overexpression independent of strain and gender, whereas the startle 
response is augmented in females only. Upper row: Higher seizure scores are found 
in TG carriers across gender and genetic backgrounds. N=6-14; Lower row: Significant 
increase in the startle response is observed only in female mice of both genetic 
backgrounds. N=11-28; mean±SEM given. 
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Figure 5: Basic genetics of MECP2: Gene structure, Hardy-Weinberg statistics, 
linkage disequilibrium, and case-control analysis in schizophrenic (GRAS) 
patients and healthy individuals. A. Schematic overview of MECP2 isoforms e1 and 
e2, including SNP positions. Digits depict exon numbers, solid black lines exon usage 
for the respective isoform. Dashed lines denote SNP positions. Black fillings in boxes 
denote coding sequence, isoform-specific in exons 1 and 2.  B. Test for deviation from 
Hardy-Weinberg-Equilibrium (HWE) in females only due to X-chromosomal location of 
MECP2. C. Case-control association analysis - separate for both genders - reveals 
similar distribution of SNPs in patients and controls. D. Linkage disequilibrium for all 
included GRAS patients and controls.   
 
Figure 6: SNP rs2734647 in the 3'UTR of MECP2: Search for mechanistic insight 
A. Human miRNAs predicted to bind to the MECP2 3‘UTR in an rs2734647 allele-
specific manner. The bases corresponding to the SNP position are black-shadowed. 
Numbers left and right of the nucleotide sequence refer to its base-pair position within 
the miRNA sequence.  B, C. Luciferase assay results showing relative luciferase activity 
in HEK293 and N2a cells after co-transfection of candidate miRNAs with phRL-TK 
rs2734647C, or rs2734647T, respectively; mean±SEM; N=7 for all conditions. Statistical 
significance was calculated relative to the non-transfection control (100%) D, E. Relative 
expression of hsa-miR-511 and of MECP2 isoform 2 (MECP2_e2) or both isoforms 
(MECP2_e1&2) in aggression/impulsivity – relevant brain areas: FC=frontal cortex, 
PFC=prefrontal cortex, TC=temporal cortex, OC=occipital cortex, HC=hippocampus, 
AM=amygdala, as well as in placenta (N=1) as control tissue. Numbers of individual 
brains included in the analysis are given in brackets; mean±SEM. F. Relative 
expression of MECP2_e2 or MECP2_e1&2 in peripheral blood mononuclear cells 
(PBMC) of male patients dependent on rs2734647 genotype; N numbers of individuals 
in brackets; mean±SEM. G. Alignment of human and mouse MECP2 3‘UTRs around 
rs2734647 SNP position (black-shadowed) and human and mouse miR-511, illustrating 
a perfect species-specific seed match; hsa-miR-511 perfectly matches the human 
MECP2 3‘UTR in case of rs2734647 T. Additional mismatches are gray-shadowed.  
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Table 1a: FVB/N mice (first part)   
Behavioral paradigms 
(order according to domains) 
Cohort 1 Cohort 2 Cohort 3






































Anxiety-like behavior                      
Elevated plus maze (time in open 
versus closed arms [s]) 
4    Genotype: p=0.2, F=1.825 12 Genotype: p=0.3, F=1.120 Genotype: p=0.8, F=0.082 5 Genotype: p=0.4, F=0.567 Genotype: p=0.6, F=0.342 
Activity                      
Open field (total distance [m]) 4 73±6 80±5.6 n.s. 74±10 85±3 n.s. 12 78±6.3 69± 4.3 n.s. 72±5.6 71±3 n.s. 5 87±2.8 84±3.9 n.s. 94±3.7 89±3.4 n.s. 
Exploratory behavior                      
Hole board (holes visited [#])        12 12±1.4 10±1.4 n.s. 23±2.6 21±1.7 n.s. 6 15±1.2 15±1.7 n.s. 19±2.8 21±2.2 n.s. 
Impulsivity                      
Marble  burying and digging 
(marbles buried [#]) 
       14 3.9±0.5 4.6±0.6 n.s.    7 4.5±0.5 4.6±0.7 n.s. 3.8±0.9 4.3±0.7 n.s. 
              16 4.5±1 3.6±1 n.s. 1.5±0.7 3.5±1.0 n.s. 
Motor leaning and coordination                      
Rotarod (latency to fall [s])        13 Genotype: p=0.2, F=1.383 Genotype: p=0.4, F=0.834        
Motor strength                      
Grip strength (grip strength [P])        16 95±6.3 94±7.8 n.s. 97±4.3 97±3 n.s.        
Hearing                      
Hearing curve (startle amplitude 
[AU]) 
       13 
Genotype: p=0.003, F=15.53 
(TG: increased startle) 
Genotype: p=0.01, F=12        
(TG: increased startle) 
       
Vision                      
Visual cliff (preference for "ground" 
[%]) 
       15 52±0.7 55±1.3 n.s. 54±0.9 52±1 n.s.        
Olfaction                      
Food finding test (latency to find 
hidden cookie [s]) 
       18 83±29 114±33 n.s. 234±32 270±15 n.s.        
Food finding test (latency to find 
visible cookie [s]) 
       18 12±3.2 11±2 n.s. 14±2.2 16±2.4 n.s.        
Pain sensation                      
Hot plate (latency to lick [s])        24    18.6±1.3 16.5±1.2 n.s.        
Anhedonia-like behavior                      
Sucrose preference test (preference 
for sucrose [%]) 
       20 69±3.9 65±3.9 n.s. 70±2.1 64±2.5 n.s.        
Sociability                      
Social interaction: 3-partite chamber 
(sociability index [AU]) 
       16 5.4±2.3 5.8±4.3 n.s. 7.9±3.4 3.2±3.0 n.s. 8 17±4.4 13±5.2 n.s. 22±3.1 13±2.9 0.05 
Communication                      
Ultrasound vocalization (calls [#])               13    456±100 434±103 n.s. 
Social competence                      
Nest building (Nest score [AU])                      
Social dominance                      




Table 1a: FVB/N mice (second part) 
Behavioral paradigms 
(order according to domains) 
Cohort 1 Cohort 2 Cohort 3
































Aggression                      
Resident-intruder paradigm 
(latency to attack [s]); 5min 
session; FVB/N as intruder 
8  200±33 109±19 0.049    25 55±12 49±8.1 0.7 no attack 9 36±11 19±3.6 0.4    
Resident-intruder paradigm 
(latency to attack [s]); 5min 
session; C57BL/6N as intruder 
              16 209±22 84±33 0.002    
Resident-intruder paradigm 
(latency to attack [s]); 10min 
session with pre-warming; 
C57BL/6N as intruder 
                     
Sensorimotor gating                      
Startle reactivity - PPI set up (startle 
amplitude [AU]) 
              7 8.5±0.8 10.6±1.1 0.06 6±0.6 10±0.7 0.0003 
              16 9.6±1.2 15±2 0.05  5.4±1.3 12±1.2 0.005 
Prepulse inhibition (percentage 
inhibition [%]) 
       12 Genotype: p=0.3, F=1.314 Genotype: p=0.2, F=2.005 7 Genotype: p=0.9, F=0.036 Genotype: p=0.4, F=0.899 
              16 Genotype: p=0.5, F=0.499 Genotype: p=0.6, F=0.323 
Novel object recognition                      
no delay paradigm (preference for 
new object [%]) 
                     
30' delay paradigm (preference for 
new object [%]) 
                     
Working memory                      
Y-maze (percentage alternation [%])               7 55±3.0 61±2.8 n.s. 67±5.4 61±3.4 n.s. 
Hole board (errors [#])                      
Reference memory                      
Hole board (errors [#])                      
Home cage activity (LABORAS)                      






















Climbing frequency [#]               35 331±100 196±45 n.s. 451±78 277±115 n.s. 
Seizure propensity                      
PTZ- seizure induction (seizure score 
[AU]) 
       30 4.8±0.7 9.1±2 0.042 6±1 8±1 0.006        
Body weight [g] 6 25±0.5 25±0.3 n.s. 21±0.3 22±0.6 n.s. 16 30±0.5 30±0.7 n.s. 25±0.5 25±0.3 n.s. 6 21±0.5 21±0.7 n.s. 17±0.5 17±0.4 n.s. 










Table 1b: C57BL/6N mice (first part) 
Behavioral paradigms 
(order according to domains) 
Cohort 1 and 2 Cohort 3 





















Anxiety-like behavior            
Elevated plus maze (time in open 
versus closed arms [s]) 
5 Genotype: p=0.07, F=3.398  Genotype: p=0.6, F=0.244     
Activity            
Open field (total distance [m]) 5 55.3± 2  58.1 ± 3 n.s. 60±1.9  59±2.7 n.s.     
Exploratory behavior            
Hole board (holes visited [#]) 7 11±1 12±1.7 n.s. 18±2.5 20±2.9 n.s.     
Impulsivity            
Marble  burying and digging (marbles 
buried [#]) 
8 9.5±1.4 8.2±2.2 n.s. 5.9±0.8 7.7±1.2 n.s.     
Motor leaning and coordination            
Rotarod (latency to fall [s]) 6 Genotype: p= 0.4, F=0.552 Genotype: p= 0.8, F=0.054   
Motor strength            
Grip strength (grip strength [P]) 30 134±3.9 138±5.8 n.s. 123±3.2 117±5.3 n.s.     
Hearing            
Hearing curve (startle amplitude [AU]) 7 Genotype: p= 0.2, F=1.434 Genotype: p= 0.1, F=2.773   
Vision            
Visual cliff (preference for "ground" 
[%]) 
10 53±1.3 53±1.3 n.s. 52±1.3 56±3.4 n.s.     
Olfaction            
Food finding test (latency to find 
hidden cookie [s]) 
16 107±15 89±17 n.s. 96±14 113±30 n.s.     
Food finding test (latency to find 
visible cookie [s]) 
16 8.6±1.5 12±3.5 n.s. 6.5±1.8 7.5±2.0 n.s.     
Pain sensation            
Hot plate (latency to lick [s]) 32 13±0.6 15±1.2 n.s. 16±0.7 15±1.2 n.s.     
Anhedonia-like behavior            
Sucrose preference test (preference 
for sucrose [%]) 
14 91±1.3 88±1.4 n.s. 75±2.6 71±4.9 n.s.     
Sociability            
Social interaction: 3-partite chamber 
(sociability index [AU]) 
12 6.4±1.8 6.2±3.2 n.s. 9.0±1.3 7.2±3.4 n.s.     
Communication            
Ultrasound vocalization (calls [#]) 13 126±33 26±12 0.03 345±57 150±62 0.08     
Social competence            
Nest building (Nest score [AU])        7 3.8±0.2 2.4±0.5 0.02 
Social dominance            




Table 1b: C57BL/6N mice (second part) 
Behavioral paradigms 
(order according to domains) 
Cohort 1 and 2 Cohort 3


















Aggression            
Resident-intruder paradigm (latency 
to attack [s]); 5min session; FVB/N as 
intruder 
           
Resident-intruder paradigm (latency 
to attack [s]); 5min session; C57BL/6N 
as intruder 
32 no attack    13 no attack 
Resident-intruder paradigm (latency 
to attack [s]); 10min session with pre-
warming; C57BL/6N as intruder 
       14 349±52 460±53 0.06 
Sensorimotor gating            
Startle reactivity - PPI set up (startle 
amplitude [AU]) 
7 7.7±0.5 7.7±0.6 n.s. 6.8±0.4 8.9±0.6 0.01     
Prepulse inhibition (percentage 
inhibition [%]) 
7 Genotype: p= 0.7, F= 0.135 Genotype: p= 0.7, F= 0.115   
Novel object recognition            
no delay paradigm (preference for 
new object [%]) 
8 56±3.9 66±3.7 n.s. 53±2.4 56±3.5 n.s.     
30' delay paradigm (preference for 
new object [%]) 
8 57±2.9 51±4.4 n.s. 54±2.5 62±3.7 n.s.     
Working memory            
Y-maze (percentage alternation [%]) 10 64±2.0 63±4.2 n.s. 63±2.1 66±2.6 n.s.     
Hole board (errors [#]) 20 
Genotype: p= 0.07, F= 3.511 
(TG: more errors) 
Genotype: p= 0.8, F= 0.0228     
Reference memory            
Hole board (errors [#]) 20 
Genotype: p= 0.09, F= 3.174 
(TG: more errors) 
Genotype: p= 0.6, F= 0.262     
Home cage activity (LABORAS)            










0.009     










P<0.0001     
Climbing frequency [#] 37 105±10 49±12 0.004 349±73 75±21 0.0003     
Seizure propensity            
PTZ- seizure induction (seizure score 
[AU]) 
40 6.7±1.1 10±0.8 0.03 7.7±0.8 8.1±1 0.02     
Body weight [g] 12 27±0.4 27±0.4 n.s. 23±0.3 23±0.4 n.s. 14 29±0.6 30±1.3 n.s. 
Note: gray-shaded cells denote experiments that are presented in the figures. 
a
age in weeks. 
 









 C  T 
P value
(F/Z/χ2  value)b 
Target variables
c
 N=491-608  N=73-109 
     Poor impulse control, Mean±SD [range] 1.72±1.12 [1-6] 1.39±0.76 [1-4] 0.0001 (F= 14.65) 
     Excitement, Mean±SD [range] 2.05±1.30 [1-7] 1.82±1.13 [1-6] 0.034 (F= 4.52) 
Control variables    
Sociodemographic variables  
     Age (at examination), y, Mean±SD [range] 37.40±12.09 [17-78] 37.02±11.99 [21-71] 0.736 (Z = -0.34) 
     Education, y, Mean±SD [range]
d
 12.11±3.10 [0-24] 11.32±2.48 [8-18] 0.020 (Z= -2.33) 
     Unemployment, No. (%) 107 (17.8) 22 (21.0) 0.446 (χ2 = 0.58) 
Clinical variables  
     PANSS general score, Mean±SD [range]
e
 30.57±10.82 [15-81] 31.88±9.73 [16-55] 0.542 (Z = -0.61) 
     PANSS negative score, Mean±SD [range] 18.04±7.67 [7-46] 19.23±7.31 [7-40] 0.070 (Z= -1.81) 
     PANSS positive score, Mean±SD [range]
f
 11.61±5.25 [6-34] 11.39±5.15 [6-30] 0.667 (Z= -0.43) 
     Cognition composite score, Mean±SD [range]
 g
 0.09±0.84 [-2.4-2.2] 0.00±0.84 [-2.1-1.7] 0.543 (F= 0.37) 
     Chlorpromazine equivalents, Mean±SD [range] 688±644 [0-4511] 725±734 [0-6324] 0.394 (Z= -0.85) 
     GAF score, Mean±SD [range] 45.48±16.35 [5-90] 46.94±15.45 [15-85] 0.375 (Z= -0.89) 
Females (GRAS sample)
a





 N=194-234 N=73-91 N=8-10 
     Poor impulse control, Mean±SD [range] 1.73±1.15 [1-7] 1.57±0.94 [1-5] 1.60±1.07 [1-4] 0.729 (F=0.31) 
     Excitement, Mean±SD [range] 2.11±1.30 [1-7] 1.93±1.31 [1-7] 1.50±0.53 [1-2] 0.277 (F=1.29) 
Control variables    
Sociodemographic variables    
     Age (at examination), y, Mean±SD [range] 43.41±12.90 [18-76] 41.82±12.47 [19-72] 43.52±12.10 [20-58] 0.657 (χ2= 0.84) 
     Education, y, Mean±SD [range]
d
 12.61±3.36 [8-27] 12.14±2.83 [8-21] 12.15±3.76 [8-19] 0.750 (χ2= 0.58) 
     Unemployment, No. (%) 25 (10.9) 12 (13.6) 4 (40.0) 0.176 (χ2= 1.83) 
Clinical variables     
     PANSS general score, Mean±SD [range]
e
 33.04±12.10 [15-69] 32.38±12.25 [15-72] 31.30±10.64 [19-54] 0.872 (χ2= 0.28) 
     PANSS negative score, Mean±SD [range] 18.13±8.50 [7-44] 17.82±8.11 [7-36] 19.30±9.36 [7-39] 0.904 (χ2= 0.20) 
     PANSS positive score, Mean±SD [range]
f
 12.25±6.03 [6-32] 11.41±5.25 [6-30] 11.40±4.40 [6-18] 0.650 (χ2= 0.86) 
     Cognition composite score, Mean±SD [range]
g
 -0.02±0.83 [-2.0-1.9] -0.19±0.90 [-2.0-2.0] 0.08±0.83 [-1.5-1.1] 0.090 (F= 2.43) 
     Chlorpromazine equivalents, Mean±SD [range] 677±839 [0-7375] 608±685 [0-4375] 640±512 [150-1680] 0.614 (χ2= 0.98) 
     GAF score, Mean±SD [range] 45.44±19.07 [12-90] 47.07±18.60 [8-90] 48.80±14.73 [25-70] 0.472 (χ2= 1.50) 
All p-values   0.05 are set in boldface. 
 
a
 Due to missing data, sample sizes vary.  
b 
For statistical methods, Mann-Whitney U/Kruskal-Wallis test (women) or Chi
2
 tests and for models including covariates ANCOVAs (target variables and cognition composite score) were used. 
c
 ANCOVA with education, age at examination, negative symptoms (PANSS) and medication status (chlorpromazine equivalent) as covariates. 
d
 Years spent in education system; patients currently in school or educational training included (score 0). 
e
 Item 14 (target variable) excluded from sum score.  
f
 Item 4 (target variable) excluded from sum score. 
g
 ANCOVA with age, negative symptoms (PANSS) and medication status (chlorpromazine equivalent) as covariates. 
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 N=469-582  N=94-134  
     Poor impulse control, Mean±SD [range] 1.72±1.12 [1-6] 1.44±0.81 [1-4] 0.001 (F= 10.84) 
     Excitement, Mean±SD [range] 2.05±1.31 [1-7] 1.83±1.11 [1-6] 0.056
     
(F= 3.67)
        
Control variables    
Sociodemographic variables  
     Age (at examination), y, Mean±SD [range] 37.31±12.07 [17-78] 37.27±12.12 [21-71] 0.918 (Z= -0.10) 
     Education, y, Mean±SD [range]
d
 12.10±3.10 [0-24] 11.50±2.52 [8-20] 0.063 (Z= -1.86) 
     Unemployment, No. (%) 101 (17.6) 28 (21.5) 0.294 (χ2 = 1.10) 
Clinical variables  
     PANSS general score, Mean±SD [range]
e
 31.71±10.84 [15-81] 31.36±9.83 [16-55] 0.966 (Z= -0.04) 
     PANSS negative score, Mean±SD [range] 18.13±7.66 [7-46] 18.61±7.48 [7-40] 0.420 (Z= -0.81) 
     PANSS positive score, Mean±SD [range]
f
 11.67±5.29 [6-34] 11.20±4.99 [6-30] 0.358 (Z= -0.92) 
     Cognition composite score, Mean±SD [range]
 g
 0.09±0.83 [-2.4-2.2] 0.05±0.88 [-2.1-1.9] 0.842 (F=0.40) 
     Chlorpromazine equivalents, Mean±SD [range] 691±635 [0-4511] 688±700 [0-6324] 0.936 (Z=-0.08) 
     GAF score, Mean±SD [range] 45.11±16.26 [5-90] 45.27±15.7 [15-85] 0.045 (Z=-2.00) 
Females (GRAS sample)
a





 N=173-206 N=94-117 N=10-13 
     Poor impulse control, Mean±SD [range] 1.74±1.18 [1-7] 1.62±0.99 [1-5] 1.23±0.60 [1-3] 0.243 (F= 1.42) 
     Excitement, Mean±SD [range] 2.12±1.29 [1-7] 1.98±1.31 [1-7] 1.62±1.12 [1-5] 0.416 (F= 0.88) 
Control variables     
Sociodemographic variables     
     Age (at examination), y, Mean±SD [range] 43.65±13.11 [18-76] 42.01±12.15 [19-72] 42.66±12.37 [20-58] 0.665 (χ2= 0.82) 
     Education, y, Mean±SD [range]
d
 12.66±3.32 [8-27] 12.22±3.05 [8-21] 11.96±3.28 [8-19] 0.538 (χ2= 1.24) 
     Unemployment, No. (%) 20 (10.0) 17 (14.5) 4 (30.8) 0.056 (χ2= 5.77) 
Clinical variables    
     PANSS general score, Mean±SD [range]
e
 32.92±12.42[15-69] 33.11±11.79 [15-72] 30.23±11.42 [19-54] 0.690 (χ2= 0.74) 
     PANSS negative score, Mean±SD [range] 18.07±8.49 [7-44] 18.20±8.37 [7-39] 17.62±8.48 [7-39] 0.961 (χ2= 0.08) 
     PANSS positive score, Mean±SD [range]
f
 12.28±5.99 [6-32] 11.74±5.55 [6-32] 10.00±4.26 [6-18] 0.440 (χ2= 1.64) 
     Cognition composite score, Mean±SD [range]
 g
 0.01±0.84 [-2.0-1.9] -0.20±0.87 [-2.0-2.0] 0.03±0.75 [-1.5-1.4] 0.049 (F= 3.06) 
     Chlorpromazine equivalents, Mean±SD [range] 671±852[0-7375] 638±702 [0-4370] 650±504 [150-1680] 0.811 (χ2= 0.41) 
     GAF score, Mean±SD [range] 46.07±19.12 [15-90] 45.13±18.87 [8-90] 51.38±12.35 [25-70] 0.323 (χ2= 2.26) 
All p-values   0.05 are set in boldface. 
 
a
 Due to missing data, sample sizes vary.  
b 
For statistical methods, Mann-Whitney U/Kruskal-Wallis test (women) or Chi
2
 tests and for models including covariates ANCOVAs (target variables and cognition composite score) were used. 
c
 ANCOVA with education, age at examination, negative symptoms (PANSS) and medication status (chlorpromazine equivalent) as covariates. 
d
 Years spent in education system; patients currently in school or educational training included (score 0). 
e
 Item 14 (target variable) excluded from sum score.  
f
 Item 4 (target variable) excluded from sum score. 
g






Table 4: Phenotype comparison of replication sample patients by MECP2 SNPs rs2734647 and rs2239464 
Males (replication sample) rs2734647 genotypes P value 
(Z/χ2  value)a  C T 
Target variables
b
 N=322 N=63 
     Poor impulse control, Mean±SD [range] 3.16±1.91 [1-7] 2.86±1.93 [1-6] 0.05 (Z= -1.64) 
     Excitement, Mean±SD [range] 3.79±1.60 [1-7] 3.52±1.56 [1-7] 0.09 (Z= -1.33) 
Control variables    
     Age (at examination), y, Mean±SD [range] 35.34±10.91 [19-65] 36.63±10.80 [18-67] 0.16 (Z = -1.01) 
     Education rating, % low, intermediate, high education level 47.8%, 22.4%, 29.8% 42.9%, 30.2%, 27.0% 0.21 (χ2= 1.78) 
Males (replication sample) rs2239464 genotypes P value 
(Z/χ2  value)a  G A 
Target variables
b
 N=308 N=77  
     Poor impulse control, Mean±SD [range] 3.19±1.92 [1-7] 2.82±1.89 [1-6] 0.03 (Z= - 1.91) 
     Excitement, Mean±SD [range] 3.83±1.60 [1-7] 3.42±1.58 [1-7] 0.02 (Z= - 2.07) 
Control variables    
    Age (at examination), y, Mean±SD [range] 35.28±11.01 [19-65] 36.66±10.40 [18-67] 0.12 (Z= -1.23) 
    Education rating, % low, intermediate, high education level 48.7%, 22.1%, 29.2% 40.3%, 29.9%, 29.9% 0.14 (χ2= 2.53) 
 
All p-values   0.05 are set in boldface. 
 
a
For statistical methods, Mann-Whitney U or Chi
2
 tests were used (all p-values one-sided). 
b
 Mann-Whitney U tests with standardized residuals from linear regression with target variables as dependent variables and age at examination and negative symptoms  












































































































































































































































































Nose/snout sniff Anogenital sniff Follow/chase 
Nose/snout sniff Anogenital sniff Follow/chase 


















































































































































C57BL/6N FVB/N C57BL/6N FVB/N 
Tantra et al Figure 4 
MECP2_e1 
MECP2_e2 
SNP rs# Genotype 
N (%) P (OR, [95% CI]) 
GRAS patients GRAS controls allelic, d.f.=1 
Females         
rs2239464 
GG 205 (61.4) 307 (64.0) 
0.45 (1.10, [0.86 - 1.40]) GA 117 (35.0) 158 (32.9) 
AA 12   (3.6) 15   (3.1) 
rs3027933 
CC 236 (70.7) 341 (71.0) 
0.80 (1.04, [0.79 - 1.36]) CG 90 (26.9) 130 (27.1) 
GG 8   (2.4) 9   (1.9) 
rs2075596 
GG 239 (71.3) 344 (71.7) 
0.75 (1.05, [0.79 - 1.37]) GA 87 (26.0) 127 (26.5) 
AA 9   (2.7) 9   (1.9) 
rs2734647 
CC 234 (69.9) 337 (70.2) 
0.77 (1.04, [0.80 - 1.36]) CT 91 (27.2) 132 (27.5) 
TT 10   (3.0) 11   (2.3) 
Males         
rs2239464 
G 582 (81.4) 617 (80.3) 
0.60 (0.93, [0.72 - 1.21]) 
A 133 (18.6) 151 (19.7) 
rs3027933 
C 606 (84.8) 655 (85.3) 
0.77 (1.04, [0.78 - 1.39]) 
G 109 (15.2) 113 (14.7) 
rs2075596 
G 613 (85.2) 660 (85.9) 
0.81 (1.04, [0.78 - 1.39]) 
A 104 (14.5) 108 (14.1) 
rs2734647 
C 608 (84.8) 646 (84.1) 
0.71 (0.95, [0.72 - 1.26]) 












Test for HWE deviation (females) 
P (total) P (controls) P (cases) 
rs2239464 0.19 0.39 0.41 
rs3027933 0.51 0.49 1.00 
rs2075596 0.89 0.59 0.68 
rs2734647 1.00 0.74 0.70 
Tantra et al Figure 5 
1 
rs2075596 rs2734647 rs3027933 rs2239464 
5´ 3´ 
3`UTR can vary in length 
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6. DISCUSSIONS AND SUMMARY 
 
Accumulating evidence consistently suggest neuropsychiatric conditions as results of 
complex interactions between multiple genetic factors and environmental factors. 
Studies of genetic mouse models are an appropriate approach to model such 
complexity, because genetic effects of behavior attributable to mutants are also 
subjects to the similar set of complex interaction between genetics and environmental 
factors (Bazzett 2008). Moreover, not only is the similarity of the mouse and human 
genomes remarkable (Waterston, Lindblad-Toh et al. 2002), behavioral domains 
addressed in this thesis are conserved between these two species. The present 
cumulative thesis addressed the relevance of behavioral characterization of genetic 
mouse models of complex human behavioral disorders such as psychiatric diseases, 
to identify the role of MECP2 and BAIAP3 and their common variants in modulating 
behavioral phenotypes. 
 
In the first project, basic behavioral characterization revealed an increased anxiety, 
especially pronounced in female mice, due to the absence of Baiap3. On the 
pathological level, it was shown that Baiap3 deficiency increased the proneness to 
seizures induced by pentylenetetrazole, a non-competitive GABA antagonist. 
Studying the phenotype/ genotype relationships within the GRAS population, a 
significant association of BAIAP3 risk genotypes with anxiety in women, and 
surprisingly, benzodiazepine abuse in men was established. Upon characterizations 
of Baiap3 deficient mice for their response to benzodiazepines, it was established that 
the tolerance to diazepam developed more quickly in male, but not female Baiap3 
deficient mice. Also, on the cellular level, an increase in basal network activity, 
together with a lack of homeostatic adaptation to diazepam were detected in 
hypothalamus slices of Baiap3 deficient mice.  
 
In summary, it was shown in the first project that (1) the absence of Baiap3 in mice 
was attributable to increased anxiety and proneness to seizures, (2) Baiap3 
deficiency in male, but not female mice led to a faster development of tolerance to 
diazepam, (3) a lack of homeostasis adaptation to diazepam in hypothalamus slices 
of Baiap3 deficient mice was a cellular consequence of Baiap3 deletion, (4) two 
common genetic variants of human BAIAP3 were associated with anxiety in women 
and benzodiazepine abuse in men of the GRAS population. Together, this 
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translational approach yielded the identification of BAIAP3/Baiap3 as a genetic risk 
marker that is associated with anxiety and benzodiazepine abuse, in a gender-
specific manner. For now, the practical implication of these results is limited, as these 
data are based on a phenotype-based genetic association study performed in a 
schizophrenic population. Hence, replications in non-schizophrenic populations are 
the requirement in order to apply these findings to the general population and would 
further substantiate the significance of these findings in elucidating mechanisms 
underlying anxiety and benzodiazepine use disorder. Nevertheless, these findings 
deliver the first evidence for BAIAP3 as a common risk factor in the emergence of 
anxiety and drug dependence.  
 
In the second and third project, a detailed behavioral characterization of mice 
overexpressing a transcriptional regulator protein, Mecp2 at ~1.5fold WT level led to 
the identification of elevated susceptibility to seizures and altered territorial 
aggression as the primary consequences of subtle increased of Mecp2 level. 
Evaluation of the quantitative effect of MECP2 expression level on phenotype is 
relevant, as both increased and reduced expression of MECP2 cause neurological 
disorders, termed MECP2 duplication and Rett syndrome (Amir, Van den Veyver et al. 
1999; Moretti and Zoghbi 2006; Ramocki, Tavyev et al. 2010; Van Esch 2012).  
 
The first project aimed to identify the consequences of mild alterations in the level of 
Mecp2, only at ~1.5fold of the endogenous Mecp2. We argued that a mouse model 
with only mild overexpression of Mecp2 may aid to identify and characterize the 
earliest pathologies emerged due to gain-of-function properties of Mecp2, before the 
major phenotypes of disorders such as MECP2 duplication syndrome appears. The 
transgenic mouse model was established on the FVB/N genetic background. 
Evaluation of the neuronal parameters revealed (1) a reduction in the number of 
tertiary branching sites and increased spine density and (2) altered calcium 
homeostasis as cellular consequences of mild Mecp2 overexpression. Neonatal 
behavioral characterization of male transgenic mice did not reveal any abnormalities. 
Also, activity (locomotion), anxiety and exploratory behavior as well as motor and 
sensory function, including sensorimotor gating were unaffected by the mild increase 
of Mecp2 level. A higher tendency of male transgenic mice to bite was observed 
during daily handling. To quantify this observation, a resident-intruder paradigm for 
testing aggression was performed and revealed an increased aggression phenotype 
Discussions and summary 
112 
of male transgenic mice. Repeatedly, spontaneous seizures were observed in 
transgenic mice. When the mice were tested for their susceptibility to seizure induced 
by PTZ, increased PTZ-induced seizure activity was detected in transgenic male, but 
not in wild-type mice. In agreement with the seizure phenotype in transgenic mice, 
transgenic neurons treated with PTZ also demonstrated a marked increase in 
amplitude and frequency of calcium spikes, which are considered as a correlate of 
epileptic seizures.  
 
Together, Mecp2 expressed at ~1.5fold endogenous level led to (1) a reduction in the 
number of branching sites, (2) increased spine density, (3) alteration of the calcium 
homeostasis, (4) a higher susceptibility to PTZ-induced seizure and (5) a more 
aggressive phenotype in male transgenic mice of the FVB/N background. In 
conclusion, based on ex vivo and in vivo data, it was shown that epileptic seizures are 
manifested as the first symptom when Mecp2 is mildly overexpressed in mice. 
 
In the frame of the third project, transgenic mice with ~1.5fold Mecp2 expression of 
the FVB/N background were backcrossed for 10 generations to the C57BL/6N 
background to create a congenic strain. The third project was designed, among 
others, to explore the role of gender and genetic background (FVB/N versus 
C57BL/6N) for phenotypes associated with mild Mecp2 overexpression in mice, such 
as altered aggression, spontaneous home cage behavior and predisposition to 
seizure. The susceptibility to seizures remained as a pathological consequence of 
mildly overexpressing Mecp2 at ~1.5fold endogenous level, observed across genders 
and genetic backgrounds. It was further shown that mild increased of Mecp2 
expression altered aggression in male mice. While expressing the transgenic 
construct in mice of the FVB/N background resulted in enhanced aggression, 
expressing the same transgenic construct in mice of the C57BL/6N background 
surprisingly led to reduced aggression, accompanied by decreased social interest. 
These results delineate the role of Mecp2 in modulating social behavior, however, the 
phenotypical outcomes appeared to be the subject of modifications by genetic 
backgrounds. 
 
Adding to the picture of the phenotypical spectrums arose from Mecp2 dysfunctions 
(Chao and Zoghbi 2012), our results from the second and third projects suggest that 
~50% elevation of Mecp2 level resulted in relatively milder phenotypes, primarily 
characterized by an elevated predisposition to seizure and altered social behavior, 
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while we did not observe any progressive neurological phenotype or premature 
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Figure 3. Mild Mecp2 overexpression at ~1.5fold endogenous level (Mecp2WT_EGFP) 
led to a subtle neurological phenotype. In the spectrum of Mecp2 dysfunctions, it 
arrays between wild-type and transgenic mice with double Mecp2 level. 
 
The discovery of Mecp2 influence on aggressive behavior in mice could also be 
identified in humans. We report a common genetic variant, SNPs in the 3’UTR of 
MECP2 which influence both the level of MECP2 expression and aggression in male, 
but not female individuals in the GRAS population. Putting results from mice and the 
phenotype-based genetic association studies together, we show that subtle changes 
of MECP2/Mecp2 expression level were sufficient to influence social behavior. 
 
Overall, this thesis shows the practical implications of behavioral studies of transgenic 
mice with an elaborate behavioral repertoire that can be used to model phenotypes of 
complex human behavioral disorders. Behavioral characterizations of these mice 
gave aid to identify behavioral domains targeted by the genetic variations of the 
genes of interest, revealing the probable functional role of the genes within the frame 
of complex human behavioral disorders. The validity of the genetic mouse models 
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described here was further increased by addressing the relevance of the findings in a 
schizophrenic (GRAS) population. Combining results from mouse studies and 
phenotype-based genetic association studies on GRAS database, it was shown that 
the functional consequences of genetic variations of the genes of interest were found 
to affect behavioral domains of both species: Baiap3/ BAIAP3 genetic variations 
modulate anxiety and the response to benzodiazepine, while Mecp2/ MECP2 
variations influence social behavior. Last but not least, the significance of these 
findings could be further substantiated with more studies addressing the relevance of 
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In 2007, a multifaceted syndrome, associated with anti-NMDA receptor autoantibodies (NMDAR-AB) of immunoglobulin-G isotype,
has been described, which variably consists of psychosis, epilepsy, cognitive decline and extrapyramidal symptoms. Prevalence and
significance of NMDAR-AB in complex neuropsychiatric disease versus health, however, have remained unclear. We tested sera of
2817 subjects (1325 healthy, 1081 schizophrenic, 263 Parkinson and 148 affective-disorder subjects) for presence of NMDAR-AB,
conducted a genome-wide genetic association study, comparing AB carriers versus non-carriers, and assessed their influenza AB
status. For mechanistic insight and documentation of AB functionality, in vivo experiments involving mice with deficient blood–
brain barrier (ApoE / ) and in vitro endocytosis assays in primary cortical neurons were performed. In 10.5% of subjects, NMDAR-
AB (NR1 subunit) of any immunoglobulin isotype were detected, with no difference in seroprevalence, titer or in vitro functionality
between patients and healthy controls. Administration of extracted human serum to mice influenced basal and MK-801-induced
activity in the open field only in ApoE / mice injected with NMDAR-AB-positive serum but not in respective controls. Seropositive
schizophrenic patients with a history of neurotrauma or birth complications, indicating an at least temporarily compromised blood–
brain barrier, had more neurological abnormalities than seronegative patients with comparable history. A common genetic variant
(rs524991, P¼ 6.15E 08) as well as past influenza A (P¼ 0.024) or B (P¼ 0.006) infection were identified as predisposing factors for
NMDAR-AB seropositivity. The410% overall seroprevalence of NMDAR-AB of both healthy individuals and patients is unexpectedly
high. Clinical significance, however, apparently depends on association with past or present perturbations of blood–brain barrier
function.




N-methyl-D-aspartate receptors (NMDAR) are glutamate-gated
ion channels, abundantly expressed in mammalian brain.1 They
form heteromers of NR1, NR2 and NR3 subunits, and are pivotal
in regulating synapse function.2 In schizophrenia, NMDAR
hypofunction has been hypothesized due to induction of
psychotic symptoms by antagonists.3 In 2007, Dalmau et al.4,5
described a paraneoplastic syndrome, based on 12 women with
ovarian teratoma, carrying IgG autoantibodies (AB) against the
NMDAR NR1/2 subunits. The syndrome, termed ’anti-NMDAR
encephalitis’, variably consisted of psychosis, memory deficits,
seizures, dyskinesia, decreased consciousness and autonomic
instability. Since its initial description, a flood of publications
appeared. The search for anti-NR1 IgG AB in small samples
(N¼ 46–80) of schizophrenic patients yielded discordant results.6–8
Recently, 4400 previously collected cases of anti-NMDAR
encephalitis have been reviewed, most without associated tumor.9
Similarly, immunomodulatory treatment outcomes of these and
around 100 more cases have been summarized.10 As a syndrome-
pertinent pathophysiological mechanism, an AB-induced decrease of
NMDAR-mediated currents, due to enhanced receptor internalization
and thus reduced surface expression, has been suggested.11
Few studies explored a role of other classes of immunoglobulins
(Ig) in an NMDAR-AB syndrome. In individuals with slow cognitive
impairment, anti-NR1 IgA AB were found, which affected synaptic
protein expression and decreased NMDAR-mediated currents.12
Anti-NR1 IgM AB were described in a patient with bipolar
disorder13 and in patients with herpes simplex encephalitis.14 In
the largest study so far, investigating IgG, IgA and IgM, Steiner
et al.15 reported a higher prevalence of AB of all isotypes in 121
schizophrenic patients, compared with healthy controls or
patients suffering from affective disorders. Apart from tumors,
no sound information is available yet on putative susceptibility
factors for the development of anti-NR1 AB.
The present study was designed to (1) systematically screen in
an unbiased fashion a large number (N¼ 2817) of healthy
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individuals and subjects suffering from schizophrenia or other
brain diseases for presence of NMDAR-AB of IgG, IgA or IgM
isotype; (2) specifically address the question of why healthy AB
carriers might remain healthy, by extending this work to
experiments in vivo and in vitro; (3) search for genetic and
environmental factors predisposing to NMDAR-AB formation.
MATERIALS AND METHODS
Participants
Subject data were collected in accordance with ethical guidelines and the
Declaration of Helsinki. Sample selection was unbiased, that is sera
collection concluded before analysis of NMDAR-AB was planned. Schizo-
phrenic patients (N¼ 1081) were recruited in 2005–2011 at 23 German
sites in the GRAS (Go¨ttingen Research Association for Schizophrenia) study.
Patients fulfilling DSM-IV criteria for schizophrenia (81.5%) or schizoaffec-
tive disorder (18.5%) were included regardless of disease stage.16,17
Healthy GRAS controls were anonymized blood donors (N¼ 1272;
Transfusion Medicine, Go¨ttingen). Health was ensured by pre-donation
screening (questionnaires, interviews, hemoglobin, blood pressure, pulse,
temperature). Patients with affective disorders (N¼ 148) were also
included (ongoing GRAS extension). Parkinson patients (N¼ 263) and
respective controls (N¼ 53) were recruited in 2010–2011 in Italy (Rome
area). Of the GRAS patients, three volunteers carrying high titers of anti-
NR1 IgG, IgA, or IgM, and three seronegative controls agreed to blood
donation for mouse experiments (Supplementary Table S1, Supplementary
Appendix).
Phenotypical analyses
On all schizophrenic (GRAS) patients, extensive phenotypical characteriza-
tion was performed as referenced previously.16,17 Age of onset, age at first
psychotic episode, positive and negative syndrome scale scores,
chlorpromazine equivalents, neurological symptoms (CNI; Cambridge
Neurological Inventory) including fine motor skills (MacQuarrie dotting/
tapping), current cognitive functioning (composite score comprising
reasoning, executive function, verbal learning and memory), premorbid
intelligence and global assessment of functioning were employed as
disease characteristics. As factors affecting blood–brain barrier (BBB)
integrity, past neurotrauma (all severity levels) and birth complications (all
pre- and perinatal complications) were carefully and comprehensively
assessed. The final judgment regarding experience of birth complications
or neurotrauma in the schizophrenic (GRAS) patient cohort was derived
from a number of different sources. First, the information from semi-
structured interviews about birth and neurotrauma history of each patient
was used. To verify the data or increase the amount of detailed
information, all discharge letters of each single patient were screened. In
the case of neurotrauma, other semi-structured interviews on critical life
events, suicidality and aggressive behavior toward others were used to
explore whether patients had experienced serious accidents (including
brain trauma) or committed suicide attempts that included, for example,
falls or jumps from great heights or had been involved in serious fights
leading to head injuries. Finally, information from the physical exam of
each patient was included to check whether any scars on the head or neck
were found indicative of an injury to the head. After collecting all the data,
each patient was dichotomously (yes/no) classified as having or not having
experienced a neurotrauma or birth complication. In case of contradictory
information, the treating physician and even the obstetric hospital were
contacted, and in case of still missing information or a high level of
uncertainty, patients were excluded from the analysis.
Serological analyses
Commercially available recombinant immunofluorescence tests (Euroim-
mun, Lu¨beck, Germany), standard procedures for clinical diagnosis (100%
sensitivity and 100% specificity), were used to detect NMDAR-AB, based on
HEK293 cells transfected with NR1 or NR1/NR2b NMDAR-subunits.5,18
Seropositivity was assessed by two researchers independently. Titers were
double-determined in two laboratories (MPI, Euroimmun) by identifying
the maximum dilution at which specific fluorescence was still visible. Few
samples with discrepant results were re-analyzed, leading to full
concordance. The presence of IgG AB against influenza A and B virus
was determined by ELISA (Novagnost-InfluenzaA-IgG, Novagnost-
InfluenzaB-IgG, Siemens Healthcare Diagnostics GmbH, Eschborn,
Germany), automatically processed on BEPIII (Siemens Healthcare
Diagnostics GmbH), and interpreted (manufacturer’s instructions) as
positive, negative or borderline (the latter negative for statistics).
Immunoglobulin purification
Ammonium sulfate precipitation of a serum fraction containing immu-
noglobulins (Ig) and dialysis was carried out as described.19 IgG, IgA, or IgM
were quantified by immunodiffusion using NOR partigen immunoplates
(Siemens Medical Solutions, Marburg, Germany).
Mouse experiments
Experiments were approved by the local Animal Protection Committee.
Male C57Bl/6N ApoE / 20 and wild-type (WT) mice, aged 12–16 weeks,
were used (housed at 4–5 per cage, 12 h light/dark cycle, food/water ad
libitum). Groups (4–6 each) received either extracted Ig fractions from
NMDAR-AB seropositive (IgG, IgA, or IgM) or seronegative individuals
(information on titer/concentration in Supplementary Table S1 and
Supplementary Appendix). Daily intravenous (tail) injections (150 ml each)
were performed on 3 consecutive days. Examiners were not aware of
group assignment (’blinded’). Spontaneous activity in open field (8min)
was tested in all mice 3–4 days before the first injection (initial group
matching). One day after the last injection, spontaneous activity (8min)
was again measured, followed by intraperitoneal injection (0.3mg per 10 ml
per gram of body weight) of the non-competitive NMDAR antagonist MK-
801 (Dizocilpine; [5R,10S]-(þ )-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cy-
clohepten-5,10-imine; Sigma-Aldrich GmbH, Munich, Germany) and
extended (120min) open-field observation.21 MK-801 acts as use-
dependent ion-channel blocker.
Endocytosis assays and quantification
Primary cortical neurons prepared from mouse embryos (E16) were
cultured on poly-L-lysine-coated glass-coverslips in MEMþ B27 (Invitrogen,
Karlsruhe, Germany) for 14 days. Glass coverslips were washed with cold
Hank’s balanced salt solution (HBSS), and incubated (20min, 4 1C) with Ig
extracts containing either NMDAR-AB of IgG, IgA or IgM isoforms or
seronegative Ig extracts (1:100) in HBSS. The examiner was unaware of the
nature of the extract (‘blinded’). Unbound AB was removed (3 HBSS
washes) before placing cells in pre-warmed (37 1C) growth medium for
15min to allow internalization. After medium wash-off (cold HBSS),
remaining surface NMDAR were labeled with anti-mouse NR1-AB (Abcam,
Cambridge, UK) for 15min on ice. After cold HBSS wash, surface-bound
NR1-AB was labeled (4 1C, 15min) with Alexa-488-coupled 2nd AB (anti-
mouse IgG; Invitrogen, Karlsruhe, Germany). After wash-off (HBSS; 4 1C) of
unbound AB, cells were fixed in 4% paraformaldehyde. For quantification,
confocal images of cell surface staining were taken with identical
acquisition parameter on SP2 LSM (Leica, Wetzlar, Germany). Signal
intensity was quantified with ImageJ, and ratio of intensity per cell surface
area calculated.
Genetic analyses
A semi-custom Axiom myDesign genotyping array (Affymetrix, Santa Clara,
CA, USA) was used. For description of array-specifications, quality controls
and genome-wide genetic association study (GWAS), see Supplementary
Appendix.
Statistical analysis
P-valueso0.05 were considered significant. Data in figures are expressed
as mean±s.e.m., in tables as mean±s.d.
Mouse experiments. Data were compared by analysis of variance, followed
by post-hoc tests where appropriate using Prism5 (GraphPad-Software Inc.,
La Jolla, CA, USA) or SPSS (SPSS-Statistics 17.0, IBM-Deutschland GmbH,
Munich, Germany). Greenhouse–Geisser correction was applied on
violation of sphericity.
Human data. Group differences in categorical and continuous variables
were assessed using Chi-square or Mann–Whitney U tests. A generalized
linear model was employed upon covariate inclusion. At normal
distribution of continuous variables, T-tests were performed. To assess
main effects and interactions between neurotrauma/birth complications
and Ig-positivity regarding CNI scores, two-way independent ANOVA was
conducted. Corrected values reflect linear regression-based residuals when
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age, chlorpromazine and positive and negative syndrome scale negative
scores were independent variables. PLINK (v1.07) was used to test
association between single-nucleotide polymorphisms (SNPs) and anti-
NR1 serological status (allelic test) and deviations from Hardy–Weinberg
equilibrium.22 Principal components were generated using EIGENSTRATQ2
(http://genepath.org. harvard.edu/Breich/EIGENSTRAT.htm). Human leu-
kocyte antigen (HLA) types were imputed for seven HLA genes using
HiBag0.9.1 at four-digit resolution, based on a pre-fit European ancestryQ3
model (http://students.washington.edu/zhengx/HIBAG/). P-values were
multiple-testing corrected (Bonferroni) where indicated, but are
displayed uncorrected.
RESULTS
NMDAR-AB seroprevalence in 2817 individuals
AB of all here analyzed isotypes (IgG, IgA and IgM), directed
against the NMDAR-NR1 subunit, were identified in 10.5% of
subjects (Table 1). Importantly, seroprevalence did not differ
between schizophrenic (GRAS) patients (8.6%) and GRAS controls
(10.8%, P¼ 0.078). An apparently higher incidence in affective-
disorder patients (16.2%) is explained by a higher mean age. In
fact, seroprevalence increases with age (Supplementary Figure S1,
Supplementary Table S2, Supplementary Appendix) and is higher
in male than female subjects (Supplementary Table S3,
Supplementary Appendix, 11.53% versus 8.68%, P¼ 0.017).
Seropositivity between Parkinson patients (13.3%) and respective
controls did not differ (11.3%, P¼ 0.694).
Seroprevalence and titer distribution of NMDAR-AB Ig isotypes
Considering each Ig class separately, again no differences in
seroprevalence among groups arose (Table 1). Occurrence of IgG
anti-NR1 was infrequent (0.6% in total) compared with IgA (5.9%)
or IgM (5.7%). A combination of IgA/IgM AB was present in 1.6%,
combinations including IgG in only 0.1% each. AB exclusively
against the NR1/NR2b heterodimer, that is without reactivity
against NR1 alone, were not identified. Titer distributions in
patient and control groups as possible explanation of NMDAR-AB
pathology did not differ (Supplementary Table S4, Supplementary
Figure S2, Supplementary Appendix).
NMDAR-AB functionality in a neuronal endocytosis assay
We next wondered whether AB from controls and patients differ
in functionality. Extracts from seropositive subjects, independently
of isotype or disease state, resulted in increased endocytosis,
compared with seronegative extracts (Figure 1a, Supplementary
Table S1, Supplementary Appendix).
Relevance of BBB integrity for NMDAR-AB effects in mice
Having comparable serological (% seropositivity, Ig-isotype, titer
distribution) and functional results in controls and patients, we
asked why healthy AB carriers remain healthy. We hypothesized
that a compromised BBB might decide on the pathophysiological
significance of NMDAR-AB. To approach this hypothesis experi-
mentally, we employed ApoE / mice20 (with known BBB
leakage)23–25 versus WT. Intravenous injection of purified Ig
fractions from NMDAR-AB seropositive (IgM, IgG, IgA) subjects
led to alterations in spontaneous open-field activity and the
response to MK-801 exclusively in ApoE / mice. Trends were
comparable in groups receiving IgM, IgG or IgA extracts, resulting
in significant differences on pooling (Figures 1b and c,
Supplementary Figure S3, Supplementary Appendix).
Translating experimental BBB findings to schizophrenic (GRAS)
patients
Overall, schizophrenic anti-NR1 carriers and non-carriers do not
differ with respect to disease phenotypes, covering the symptom
clusters of anti-NMDAR encephalitis (Table 2). Also, occurrence
and duration of prodromal phase and age of disease onset are
similar between the two groups, arguing against a sudden/
atypical syndrome start in AB carriers (Table 2). Following our BBB
hypothesis, we compared individuals with birth complications or
past brain trauma—conditions known to provoke temporary or
persistent (albeit often minor) BBB abnormalities.26,27 Indeed, also
in humans, a clear impact, that is a more severe neurological
phenotype, arises from the combination of compromised BBB
function and circulating NMDAR-AB (Figure 1d).
Identification of first genetic susceptibility factors
GWAS have been successful in identifying associations between
genomic variants and autoimmune disorders, such as rheumatoid
arthritis or systemic lupus erythematosus.28 We performed
GWAS to spot SNPs potentially predisposing to formation of
NMDAR-AB (Supplementary Appendix). We identified a genome-
wide significant SNP, rs524991 (A/G, P¼ 6.15E–08; Bonferroni
threshold P¼ 8.62E–08), with an odds ratio (OR) of 2.22
(95% confidence interval (CI)¼ 1.654–2.991; Supplementary
Figure S6, Supplementary Appendix). This variant with a minor
allele frequency of 12.45% in seropositive versus 6.01% in
seronegative individuals is located in an intergenic region on
chromosome1 (Supplementary Figure S7, Supplementary
Appendix). Its closest neighboring gene is nuclear factor I/A
(NFIA, 218.59 kb downstream), a transcription factor reported
to mediate neuroprotective effects of NMDAR activation.29
Separate analysis of SNP rs524991 association with NMDAR-
AB seropositivity (Table 3) showed a similar tendency for all study
groups (except Parkinson) and no gender difference
(Supplementary Table S8, Supplementary Appendix). Search
for a predisposing role of HLA alleles for NMDAR-AB formation
did not deliver hits, apart from a nominally significant association
Table 1. Prevalence of anti-NR1 AB in patients and controls
Anti-NR1 seropositivity—N (%)
Study group Any IgG IgA IgM IgGþ IgA IgGþ IgM IgAþ IgM IgGþ IgAþ IgM
GRASa patients (N¼ 1081) 93 (8.6) 7 (0.7) 56 (5.2) 46 (4.3) 0 (0) 0 (0) 16 (1.5) 0 (0)
Affective-disorder patients (N¼ 148) 24 (16.2) 5 (3.4) 15 (10.1) 7 (4.7) 1 (0.7) 0 (0) 2 (1.4) 0 (0)
GRASa controls (N¼ 1272) 137 (10.8) 5 (0.4) 75 (5.9) 80 (6.3) 2 (0.2) 3 (0.2) 19 (1.5) 1 (0.1)
Parkinson patients (N¼ 263) 35 (13.3) 1 (0.4) 17 (6.5) 25 (9.5) 1 (0.4) 1 (0.4) 7 (2.7) 1 (0.4)
Parkinson controls (N¼ 53) 6 (11.3) 0 (0) 3 (5.7) 3 (5.7) 0 (0) 0 (0) 0 (0) 0 (0)
Total (N¼ 2817) 295 (10.5) 18 (0.6) 166 (5.9) 161 (5.7) 4 (0.1) 4 (0.1) 44 (1.6) 2 (0.1)
aGRAS patients are schizophrenic individuals of the GRAS data collection (Go¨ttingen Research Association for Schizophrenia). GRAS controls are the respective
healthy control collective (see also Materials and methods).
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of HLA-A03 with seropositivity (P¼ 0.01; Supplementary Table S9,
Supplementary Appendix).
Identification of environmental susceptibility factors
As first risk factor for NMDAR-AB formation, the presence of a
tumor, preferentially an ovarian teratoma was identified.4 Other
predisposing factors have remained speculative. Infections have
been suggested as triggers of AB formation in autoimmune
diseases,30 for example, Epstein-Barr virus in multiple sclerosis.31
We hypothesized that a similar role might be attributed to
influenza for NMDAR-AB. Anti-NMDAR encephalitis was reported
in a patient with influenza H1N1 infection and two subjects after
respective vaccination.9 NMDAR-AB were described in pediatric
cases of encephalitis lethargica, a condition—not unequivocally—
associated with influenza.32,33 Strikingly, we found an increased
anti-NR1 AB prevalence in individuals carrying anti-influenza A
(P¼ 0.024, OR¼ 1.366, CI 95%¼ 1.042–1.790) and B (P¼ 0.006,
OR¼ 1.453, CI 95%¼ 1.109–1.904) IgG (Table 3). This association
was present in males only (Supplementary Table S10,
Supplementary Appendix).
DISCUSSION
The present study provides (1) the first large-scale systematic screen
for presence of NMDAR-AB in serum of healthy and neuropsychia-
trically diseased subjects. In42800 unbiasedly selected individuals,
410% seroprevalence of anti-NR1 AB, independent of group
affiliation, was found. (2) From this unexpected observation, the
fundamental question arose of why healthy AB carriers have
remained healthy, despite comparable distribution of AB isotypes,
titers and in vitro functionality. An experimental mouse model
supports our central hypothesis, that is, the essential role of BBB
integrity. Only in ApoE mutant mice, but not in respective controls,
we find that human NMDAR-AB cause psychosis-related behavioral
perturbation.21 The BBB role is further underlined by a hypothesis-
driven outcome analysis of schizophrenic (GRAS) patients with
history of birth complications or neurotrauma indicating past/
present BBB insufficiency. (3) Ultimately, with a genome-wide
significant marker, SNP rs524991, and an association of
seropositivity with influenza AB status, we provide genetic and
environmental risk factors of NMDAR-AB formation.
The most remarkable finding of the present work is the high
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Mice: Open field activity on MK-801 challenge
p(interaction) < 0.05































































Figure1. NMDAR-AB functionality and relevance of the blood–brain barrier. (a) Reduced AB binding to primary cortical neurons indicates
increased endocytosis of NMDAR after incubation with Ig extracts containing either NMDAR-AB of IgG, IgA or IgM isoforms (all Po0.05), or
seronegative Ig extracts (one-tailed T-tests). Mean values upon AB extracts (each tested in 1–3 independent experiments, dependent on
serum availability) were normalized to the mean of the respective seronegative control extracts. (b) ApoE / (KO) and WT mice do not differ
in spontaneous activity in the open field before AB injection. However, 1 day after the last of three daily injections with seropositive (þAB) or
seronegative (AB) Ig extracts, a decrease in spontaneous activity was evident exclusively in seropositive ApoE / (KOþAB) mice: two-way
ANOVA revealed a significant interaction effect of genotype and serotype (F¼ 8.96, Po0.01), as well as a significant main effect of genotype
(F¼ 27.81, Po0.0001), but not of serotype. (c) Only ApoE / (KO) mice with their known compromised BBB respond to intravenous NMDAR-
AB extracts with a hypersensitive (psychosis-related) response in the open field to the NMDAR antagonist MK-801. Using a generalized linear
model for repeated measures to evaluate results after MK-801 treatment, we obtained significant main effects of time (F¼ 36.25, Po0.001),
genotype (F¼ 9.54, Po0.01) and serotype (F¼ 4.85, Po0.05) as well as a significant genotype  serotype interaction effect (F¼ 5.75, Po0.05).
(d) In the GRAS sample of schizophrenic patients, birth complications and history of neurotrauma as readouts for temporarily/persistently
compromised BBB were examined in NMDAR-AB-positive versus negative subjects with respect to their impact on neurological symptom
severity (CNI total score, z-standardized). Birth complications showed an interaction with serotype (F¼ 5.80, Po0.05) regarding CNI and a
main effect (F¼ 11.24, P¼ 0.001). Likewise, past neurotrauma showed an interaction with serotype (F¼ 4.02, Po0.05). Group sizes are given as
numbers in brackets. *Po0.05; WT, wild type; KO, ApoE / knockout; AB, NMDAR-AB seronegative; þAB, NMDAR-AB seropositive; BC,
birth complications; NT, neurotrauma.
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other study included a considerable number of healthy subjects in
a screen of psychiatric patients but reported seropositivity for only
1 in 240 controls (0.4%) and 2 in 108 (o2%) affective-disorder
patients.15 Seroprevalence in schizophrenic patients (9.9% of 121)
was comparable to our study. Reasons for this discrepancy are
unclear but perhaps related to the smaller number of controls and
Table 2. Baseline characteristics, according to study group
Patients and control groups Total sample Ig-positive individuals Ig-negative individuals
P-value (w2, Z,
T value)a
Schizophrenic (GRAS) patients N¼ 774–1081b N¼ 63–93b N¼ 711–988b
Age, years, mean±s.d., (range) 39.37±12.59 (17–79) 41.15±11.98 (18–75) 39.20±12.63 (17–79) 0.115
(Z¼  1.58)
Gender, N (%) 723 (66.9) 68 (73.1) 655 (66.3) 0.181
(w2¼ 1.79)
Prodrome, N cases (%) 754 (80.6) 64 (79.0) 690 (80.8) 0.698
(w2¼ 0.15)
Duration of prodrome, years,
mean±s.d., (range)
2.81±3.57 (0–28.2) 2.64±3.01 (0–13.0) 2.83±3.62 (0–28.2) 0.853
(Z¼  0.19)
Age at first episode, years,
mean±s.d., (range)
25.88±8.90 (5–68) 25.85±8.98 (12–51) 25.89±8.90 (5–68) 0.890
(Z¼  0.11)
PANSS positive score, mean±s.d.,
(range)
13.74±6.25 (7–38) 13.28±5.71 (7–31) 13.78±6.31 (7–38) 0.597
(Z¼ 0.60)
PANSS negative score, mean±s.d.,
(range)
18.25±7.90 (7–46) 17.00±7.42 (7–37) 18.37±7.93 (7–46) 0.122
(Z¼  1.55)
PANSS general score, mean±s.d.,
(range)
33.74±11.76 (16–82) 32.48±10.80 (16–75) 33.86±11.85 (16–82) 0.373
(Z¼  0.89)
















 0.02±0.84 ( 2.57–2.98)  0.01±0.89 ( 2.12–2.03)  0.02±0.84 ( 2.57–2.98) 0.946
(T¼  0.07)
Premorbid IQ (MWT-Bf ),
mean±s.d., (range)
25.67±6.36 (4–42) 26.64±6.28 (6–36) 5.57±6.36 (4–42) 0.093
(Z¼ –1.68)
Global assessment of functioning,
mean±s.d., (range)
45.70±17.18 (5–90) 46.26±16.54 (10–80) 45.65±17.25 (5–90) 0.642
(Z¼ –0.47)
Neurotrauma, N cases (%) 648 (62.4) 55 (62.6) 593 (59.8) 0.592
(w2¼ 0.29)
Birth complications, N cases (%) 307 (39.7) 27 (42.9) 280 (39.4) 0.589
(w2¼ 0.29)
Healthy (GRAS) controls N¼ 1272 N¼ 137 N¼ 1135
Age, years, mean±s.d., (range) 37.43±13.24 (18–69) 40.90±12.17 (19–68) 37.01±13.31 (18–69) o0.001
(Z¼ –3.56)
Gender, N, male (%) 780 (61.3) 95 (69.3) 685 (60.4) 0.041
(w2¼ 4.17)
Affective-disorder patients N¼ 148 N¼ 24 N¼ 124
Age, years, mean±s.d., (range) 49.70±15.49 (20–92) 47.38±11.87 (25–76) 50.15±16.09 (20–92) 0.314
(Z¼ –1.01)
Gender, N male (%) 70 (47.3) 11 (45.8) 59 (47.6) 0.875
(w2¼ 0.03)
Parkinson patients N¼ 253–263 b N¼ 33–35b N¼ 220–228b
Age, years, mean±s.d., (range) 66.04±10.08 (36–86) 69.06±8.33 (45–81) 65.59±10.26 (36–86) 0.055
(Z¼  1.92)
Gender, N male (%) 175 (66.5) 28 (80.0) 147 (64.5) 0.070
(w2¼ 3.29)
Parkinson controls N¼ 51–53b N¼ 6b N¼ 45–47b
Age, years, mean±s.d., (range) 63.31±11.68 (22–80) 67.50±12.58 (44–78) 62.76±11.59 (22–80) 0.188
(Z¼  1.33)
Gender, N male (%) 21 (39.6) 2 (33.3) 19 (40.4) 0.738
(w2¼ 0.11)
Abbreviations: CPZ, chlorpromazine equivalents; GRAS, Go¨ttingen Research Association for Schizophrenia; PANSS, positive and negative syndrome scale.
Bolded values, Po0.05. aFor statistical methods, Mann–Whitney U or w2 tests and for normally distributed variables, T-tests were used. bDue to missing data,
sample sizes vary. cMean value if more than 95 items were available. dCorrected for age and CPZ. eCorrected for age, PANSS negative and CPZ. fMehrfach-
Wortschatz-Intelligenz test (multiple choice vocabulary test).
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their younger age.15 Importantly, analytical materials/methods of
both studies were identical, schizophrenia patients show
comparable seroprevalence, and the here randomly selected
positive specimens for in vitro analyses all confirmed AB
functionality.
For exerting pathological effects, NMDAR-AB have to reach
NMDAR in the brain. This brain presence may occur via (1) AB
transfer over a compromised BBB, which normally restricts large
molecules from directly entering the brain in appreciable amounts
(expected transfer over an intact BBB, for example, IgG is only 1/
500, of IgA 1/600, and of IgM 1/3000 of the serum concentration);
(2) slow accumulation of these large molecules due to reduced
cerebrospinal fluid (CSF) flow,34 in which case, however, a
retrograde CSF circulation would have to deliver the AB back to
brain tissue, or (3) intrathecal synthesis by B lymphocytes.34,35 Our
seroprevalence data do not allow any conclusion on AB
production in brain. Therefore, healthy AB carriers may differ at
least in part from seropositive disease groups by lack of intrathecal
AB synthesis. Nevertheless, with in vivo experiments in mice and a
hypothesis-driven human database screening, we underscore the
likely critical role of an intact BBB as protective mechanism against
circulating AB-mediated pathology in mouse and man.
Wild-type mice were not behaviorally affected after injection of
human serum extract containing IgG, IgA or IgM NMDAR-AB.
In contrast, ApoE / mice showed differences in behavior on
AB injection, that is reduced spontaneous activity in the open
field and hyperlocomotion following MK-801. These behavioral
phenomena may be explained by the reported receptor
internalization and hypofunction after hippocampal infusion of
NMDAR-AB,11 as exactly opposite effects were described after
NMDA application in rats.36 Stimulation of locomotion by the
NMDAR antagonist MK-801 may be caused by hyperexcitability of
limbic circuits through NMDAR blockade on inhibitory GABAergic
neurons.37,38 This consequence of NMDA receptor inhibition
would be amplified by NMDAR-AB. Similarly, increased motor
cortex excitability in mice was provoked by NMDAR-AB injection
into the prefrontal area.39
In the GRAS sample of schizophrenic individuals, well-docu-
mented history of birth complications and brain trauma were
evaluated as proxy variables of past or present BBB impair-
ment.26,27 Indeed, affected individuals show more severe
neurological abnormalities when carrying NMDAR-AB. These
findings strengthen the hypothesis of BBB involvement in
NMDAR-AB pathology, and—replication provided—may even
justify recommendations of anti-NR1 serum screening in case of
neurotrauma or other conditions with anticipated BBB
dysfunction.
Importantly, we did not find any clinically relevant differences
when comparing all schizophrenic NMDAR-AB carriers with all
non-carriers. Perhaps with information on CSF (which we do not
have in our large cohort), an expected 30% of individuals with
permanent barrier dysfunction40 could have been extracted and
would have allowed us to uncover a clinically relevant difference
between AB carriers and non-carriers among them. Instead, we
found a clinical difference between AB carriers and non-carriers
with past birth complication or neurotrauma as a proxy for at least
temporary BBB disturbance.26 It is interesting to speculate that the
reported 30% of schizophrenic patients with compromised barrier
function40 and the post-trauma individuals recognized here might
represent an (partly) overlapping subpopulation of schizophrenic
subjects. Along these lines of thought, future studies may be
initiated, analyzing CSF samples of a large number of
schizophrenic patients for NMDAR-AB titers and determining the
CSF-serum albumin quotient34 as marker of blood–CSF barrier
(dys)function.
Our study is the first to investigate putative genetic suscept-
ibility factors for the formation of anti-NR1 AB. A GWAS approach
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rs524991. Further experiments providing mechanistic insight as
well as replication analyses are warranted. By a hypothesis-driven
approach,9,32,33 we uncovered an association of influenza A or B
AB with anti-NR1 seropositivity, suggesting molecular mimicry.
This phenomenon induces generation of AB reacting both against
pathogenic elements and autoantigens,30 and has a role in
autoimmune diseases.41,42 As the influenza A M2 channel and
NMDAR share a common ligand, the antiviral compound
amantadine,43 a putative structural homology might act as
inducer of NMDAR-AB. The observed association was found in
males only. Interestingly, males have a higher incidence of
influenza,44 and male mice exert a more vigorous immune
response on influenza infection.45 This gender disposition might
also explain the higher anti-NR1 AB prevalence in males.
In conclusion, our study draws an increasingly complex picture
of NMDAR-AB pathology, with anti-NMDAR encephalitis possibly
constituting the extreme end of a broad spectrum of mild to
severe phenotypes associated with NMDAR autoimmunity.
Beyond the NMDAR-AB studied here, loss of blood–brain barrier
integrity may generally constitute a major risk factor for
detrimental effects of peripheral AB against central nervous
system epitopes.
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Table S1. Characteristics of sera used for in vivo and in vitro experiments 
 
List of sera of patients and healthy controls used for determination of AB functionality in vitro (receptor endocytosis assay) and in vivo 
(mouse intravenous injection experiments). Total concentrations of the respective Ig subclass in the ammonium sulfate precipitated 
serum fractions are consistent with published serum levels of immunoglobulins in the general adult population (Gonzalez-Quintela A, 
et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, 
smoking and common metabolic abnormalities. Clin Exp Immunol 2008;151:42-50). 




in Ig extract 
Total concentration in fraction (g/l) Usage of purified serum 
IgG IgA IgM Endocytosis Injection 
IgG 706594 49 m healthy control 32 10 16.84 4.35 1.44 ¥  
 BPD00045 45 f bipolar affective disorder 100 32 4.25 NA NA ¥  
 SCZ00979 27 m schizoaffective disorder 320 100 11.50 NA NA ¥  
 SCZ01025 40 f schizoaffective disorder 100 100 14.37 NA NA ¥  
 UPD00066 32 f major depressive disorder 320 100 10.41 NA NA ¥  
 UPD00071 43 m major depressive disorder 1000 1000 20.13 1.92 1.26 ¥ ¥ 
IgA 706026 39 m healthy control 3200 3200 13.78 1.57 2.09 ¥  
 706472 37 m healthy control 1000 1000 18.13 3.42 2.44 ¥  
 SCZ00547 31 m schizophrenia 1000 1000 14.98 2.98 2.02 ¥  
 SCZ00857 43 f schizophrenia 1000 1000 20.81 4.86 1.15 ¥ ¥ 
 UPD00035 46 m major depressive disorder 320 320 13.78 4.86 1.50 ¥  
IgM 707334 47 m healthy control 3200 1000 14.98 3.09 1.44 ¥  
 708436 49 m healthy control 3200 320 21.51 2.88 1.32 ¥  
 SCZ00996 46 m schizoaffective disorder 1000 1000 32.20 4.86 1.56 ¥  
 SCZ00926 35 m schizoaffective disorder 1000 100 25.12 2.38 0.66 ¥ ¥ 
Negative 707340 37 f healthy control NA NA 9.89 0.81 1.26 ¥  
 708438 48 f healthy control NA NA 11.50 1.41 0.89 ¥  
  BPD00028 41 m bipolar affective disorder NA NA 16.21 5.52 1.21 ¥ ¥FRQWUROIRU,J$ 
 SCZ00071 41 m schizophrenia NA NA 25.12 1.74 1.62 ¥ ¥FRQWUROIRU,J* 
 SCZ00097 46 f schizophrenia NA NA 13.20 1.17 1.69 ¥  
 SCZ00397 37 m schizophrenia NA NA 16.84 3.20 1.56 ¥  
 SCZ00437 43 m schizophrenia NA NA 17.48 1.10 1.38 ¥ ¥FRQWUROIRU,J0 
 
m, male; f, female; NA, not available.
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Mean age in years (SD) 
Seropositive Seronegative 
all IgG IgA IgM 
GRAS patients 41.1 (12.0) 34.0 (11.7) 42.0   (9.9) 43.4 (13.7) 39.2 (12.6)* 
Affective disorder patients 47.4 (11.9)* 45.6   (9.8) 50.6   (9.8)* 41.9 (11.0) 50.2 (16.1)* 
GRAS controls 40.9 (12.2) 43.8 (12.6) 39.6 (13.0) 42.2 (13.9) 37.0 (13.3) 
Parkinson patients 69.1   (8.3) 52.00  (NA) 68.8   (8.4) 68.1   (8.4) 65.6 (10.3) 
Parkinson controls 67.5 (12.6) NA 70.3   (6.5) 64.7 (18.1) 62.8 (11.6) 
 
* denotes significant difference (p 0.05) of patient group versus respective controls. p values were calculated using 2-tailed 









Figure S1. Age dependence of seropositivity  
 
Dotted lines connect single data points (seroprevalence per year of age), solid lines represent linear trends. Only GRAS patients 
and GRAS controls were included due to the significantly smaller size of the other cohorts. Patients younger than 23 and older 














p (Pearson Chi²) 
Male (N=1769) Female (N=1048) 
all 11.53% 8.68% 0.017 
IgG 0.51% 0.86% 0.260 
IgA 6.56% 4.77% 0.052 
IgM 6.33% 4.68% 0.067 
 




Table S4. Distribution of anti-NR1 AB titers 
 
    Anti-NR1 AB titer (% of seropositive subjects) 
Study cohort Isotype 1:10 1:32 1:100 1:320 1:1000 1:3200 1:10000 all 
GRAS patients IgG 2 (28.6) 2 (28.6) 1 (14.3) 2 (28.6) 0   (0.0) 0   (0.0) 0   (0.0) 7 (100.0) 
 IgA 13 (23.3) 21 (37.5) 10 (17.9) 5   (8.9) 6 (10.7) 1   (1.8) 0   (0.0) 56 (100.0) 
 IgM 9 (19.6) 10 (21.7) 16 (34.8) 5 (10.9) 5 (10.9) 0   (0.0) 1   (2.2) 46 (100.0) 
Affective disorder patients IgG 0   (0.0) 2 (40.0) 1 (20.0) 1 (20.0) 1 (20.0) 0   (0.0) 0   (0.0) 5 (100.0) 
 IgA 3 (20.0) 6 (40.0) 4 (26.7) 2 (13.3) 0   (0.0) 0   (0.0) 0   (0.0) 15 (100.0) 
 IgM 0   (0.0) 1 (14.3) 4 (57.1) 1 (14.3) 1 (14.3) 0   (0.0) 0   (0.0) 7 (100.0) 
GRAS controls IgG 0   (0.0) 1 (20.0) 2 (40.0) 2 (40.0) 0   (0.0) 0   (0.0) 0   (0.0) 5 (100.0) 
 IgA 16 (21.3) 21 (28.0) 29 (38.7) 6   (8.0) 1   (1.3) 2   (2.7) 0   (0.0) 75 (100.0) 
 IgM 9 (11.3) 16 (20.0) 40 (50.0) 7   (8.8) 6   (7.5) 2   (2.5) 0   (0.0) 80 (100.0) 
Parkinson  patients IgG 0   (0.0) 0   (0.0) 0   (0.0) 1 (100.0) 0   (0.0) 0   (0.0) 0   (0.0) 1 (100.0) 
 IgA 4 (23.5) 3 (17.6) 6 (35.3) 2 (11.8) 2 (11.8) 0   (0.0) 0   (0.0) 17 (100.0) 
 IgM 4 (16.0) 9 (36.0) 10 (40.0) 1   (4.0) 1   (4.0) 0   (0.0) 0   (0.0) 25 (100.0) 
Parkinson  controls IgG 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 
 IgA 0   (0.0) 2 (66.7) 1 (33.3) 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 3 (100.0) 
 IgM 0   (0.0) 2 (66.7) 1 (33.3) 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 3 (100.0) 




Figure S2. Anti-NR1 AB titers: 100% stacked chart 
 
 
100% stacked column chart, depicting cumulative distribution of titers, separated by Ig isotype 
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Figure S3. Mouse AB injection experiments presented separately for isotypes 
(Note: The IgM set of experiments includes a non-injection group to exclude effects of injection on spontaneous open field activity) 
  
Left panels: Spontaneous activity in the open field - Total distance traveled before and after Ig injection. Right panels: Open field activity upon MK-801 challenge.  
m, meter; WT, wildtype; KO, ApoE-/- knockout; -AB, NMDAR-AB seronegative; +AB, NMDAR-AB seropositive; no, non-injection control; N=4-6 per group.
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SNP array specifications and genotyping quality control 
 
Genotyping was performed using a semi-custom Axiom® myDesignTM genotyping array 
(Affymetrix, Santa Clara, CA, USA), based on a CEU (Caucasian residents of European 
ancestry from Utah, USA) marker backbone including 518.722 SNPs, and a custom marker 
set including 102.537 SNPs. The array was designed using the Axiom® Design center 
(www.affymetrix.com), applying diverse selection criteria (Table S5). Genotyping was 
performed by Affymetrix on a GeneTitan® platform. 
 
Table S5. Marker selection criteria 
 
Marker group Threshold # of markers 
Axiom CEU backbone MAF > 0.025, direct selection 518,722 
Functional Variants (CDS, UTR, exonic) MAF > 0.2, direct selection 27,369 
Markers contained in RefSeq / UCSC genes (+/- 2kbp) MAF > 0.2, r² > 0.8 31,190 
Markers in the MHC genomic region best tag 15,395 
Markers in CpG islands MAF > 0.2, direct selection 5,511 
Markers in  known splice sites MAF > 0.1, direct selection 95 
Markers in microRNA regions MAF > 0.2, direct selection 56 
Manual selection of candidate SNPs MAF > 0.2, best tag 22,921 
Affymetrix SNPs for quality control  3,334 
TOTAL   624,593 
 
MAF, minor allele frequency; CDS, coding sequence; UTR, untranslated region; RefSeq, NCBI reference sequence; UCSC, 
University of California Santa Cruz Genome Browser; kbp, kilo base pairs; MHC, major histocompatibility complex. 
 
In total, 3128 individuals were subjected to genotyping (Table S6). 
 
Table S6. Patient and healthy control groups selected for genotyping 
 
Study group N (%) 
GRAS patients 1177 (37.6) 
Affective disorder patients 173   (5.5) 
GRAS controls 1274 (40.7) 
Parkinson patients 276   (8.8) 
Parkinson controls 182   (5.8) 
Autism patients 29   (0.9) 
Other conditions 17   (0.5) 
TOTAL 3128  (100) 
 
Quality control (QC) was performed on sample and SNP level, according to the 
PDQXIDFWXUHU¶VUHFRPPHQGDWLRQV7able S7). A total of 3.086 individuals and 612.121 SNPs 




Table S7. Axiom® array quality control 
 
  
Filter criteria Threshold for inclusion N 
Sample 
level     




 3,128  (100) 
 
Dish QC  3,124 (99.8) 
 
Cluster call rate  3,086 (98.7) 
SNP level     SNPs passing QC step (%) 
 
Pre QC 
 624,593  (100) 
 
SNP call rate  
612,121 (98.0) 
 
Fisher's Linear Discriminant (FLD)  
 
Heterozygous Cluster Strength Offset 
(HetSO) -0.1 
  
Homozygote Ratio Offset (HomRO)  
 
 
Genome-wide association study (GWAS) 
 
GRAS and affective disorder patients, as well as the healthy GRAS controls, were collected 
in Germany, whereas the Parkinson samples and controls were collected in Italy. An analysis 
of principal components (PCA) was performed, showing a clear clustering of samples by 
descent (Figure S4). Therefore, to reduce population stratification bias, GWAS was 
performed including only GRAS and affective disorder patients, as well as GRAS controls. 
 










Graphical presentation including all individuals 
showing the first 3 principal components. 
Samples collected in Germany are depicted in 





For the GWAS, PLINK v1.07 was used to calculate association statistics, applying a basic 
allelic model, and using the following filter criteria for SNP and sample exclusion: 
x Markers located on sex chromosomes 
x Hardy-Weinberg p < 5x10-7 in controls 
x Minor allele frequency < 0.01 
x missingness per marker > 0.05 
x missingness per individual > 0.02 
Overall, a total of 580.297 SNPs remained for analysis. The final dataset consisted of 245 
cases (anti-NR1 positive) and 2152 controls (anti-NR1 negative). 
A Q-Q plot was generated to visualize possible confounders (Figure S5). The genomic 
inflation factor was Ȝ=1.01 (Devlin B, Roeder K. Genomic control for association studies. 
Biometrics 1999;55:997-1004). This low genomic inflation value justifies not including 












Figure S6. Manhattan plot 
 
Manhattan plot of single SNP test statistics. The genomic position is shown on the X axis, and the -log10(p) 
on the Y axis. The horizontal line denotes the threshold for significance after Bonferroni correction for 
580.297 tests (p=8.62E-08). A marker on chromosome 1 (rs524991) showing genome-wide significance, 
as well as surrounding SNPs (+/- 50kbp) are depicted in green. 
 
Figure S7. SNP rs524991 regional association plot 
 
 
Regional association SORW VKRZLQJ NES ¶ DQG µ of rs524991 (p=8.62E-08). The positions of 
neighboring genes are shown on the X axis, and the -log10(p) on the Y axis. Color coding denotes LD 










N      Genotypes (frequencies) p  (trend test) p (OR, [95% CI]) 
d.f.=1 allelic, d.f.=1 
Both genders 
   GG (%) GA (%) AA (%)     
GRAS patients + 92 65 (70.7) 27 (29.3) 0 (0.0) 2.92E-06 3.23E-06  (2.80, [1.78 - 4.39]) 
- 976 867 (88.8) 105 (10.8) 4 (0.4) 
Affective disorder 
patients 
+ 24 18 (75.0) 6 (25.0) 0 (0.0) 0.118 0.133   (2.12, [0.78 - 5.79]) 
- 119 104 (87.4) 15 (12.6) 0 (0.0) 
GRAS controls + 135 111 (82.2) 19 (14.1) 5 (3.7) 0.007 0.006   (1.78, [1.17 - 2.72] 
- 1115 977 (87.6) 135 (12.1) 3 (0.3) 
Parkinson patients + 35 31 (88.6) 4 (11.4) 0 (0.0) 0.547 0.551   (0.72, [0.25 - 2.11]) 
- 220 187 (85.0) 32 (14.5) 1 (4.6) 
Parkinson controls + 6 4 (66.7) 2 (33.3) 0 (0.0) 0.081 0.091 (4.30, [0.70 - 26.52]) 
- 45 41 (91.1) 4    (8.9) 0 (0.0) 
TOTAL + 292 229 (78.4) 58 (19.9) 5 (1.7) 7.64E-07 7.48E-07   (1.99, [1.51 - 2.63]) 
- 2475 2176 (87.9) 291 (11.8) 8 (0.3) 
Males only 
    GG (%) GA (%) AA (%)     
GRAS patients + 67 51 (76.1) 16 (23.9) 0 (0.0) 0.004 0.004   (2.28, [1.28 - 4.04]) 
- 649 579 (89.2) 67 (10.3) 3 (0.5) 
Affective disorder 
patients 
+ 11 9 (81.8) 2 (18.2) 0 (0.0) 0.251 0.262 (2.65, [0.45 - 15.45]) 
- 55 51 (92.7) 4    (7.2) 0 (0.0) 
GRAS controls + 92 76 (82.6) 13 (14.1) 3 (3.3) 0.064 0.063    (1.64, [0.97 - 2.76]) 
- 646 562 (87.0) 83 (12.8) 1 (0.2) 
Parkinson patients + 28 25 (89.3) 3 (10.7) 0 (0.0) 0.465 0.465    (0.63, [0.18 - 2.18]) 
- 140 118 (84.3) 21 (15.0) 1 (0.7) 
Parkinson controls + 2 1 (50.0) 1 (50.0) 0 (0.0) 0.04 0.046 (12.3, [0.61 - 250.5]) 
- 19 18 (94.7) 1    (5.3) 0 (0.0) 
TOTAL + 200 162 (81.0) 35 (17.5) 3 (1.5) 0.002 2.04E-03  (1.74, [1.22 - 2.48]) 
- 1509 1328 (88.0) 176 (11.7) 5 (3.3) 
Females only 
    GG (%) GA (%) AA (%)     
GRAS patients + 25 14 (56.0) 11 (44.0) 0 (0.0) 2.11E-05 2.97E-05 (4.33, [2.06 - 9.09]) 
- 327 288 (88.1) 38 (11.6) 1 (0.3) 
Affective disorder 
patients 
+ 13 9 (69.2) 4 (30.8) 0 (0.0) 0.272 0.300 (1.90, [0.55 - 6.52]) 
- 63 52 (82.5) 11 (17.5) 0 (0.0) 
GRAS controls + 39 31 (79.5) 6 (15.4) 2 (5.1) 0.024 0.022 (2.28, [1.11 - 4.69]) 
- 421 371 (88.1) 49 (11.6) 1 (0.2) 
Parkinson patients + 7 6 (85.7) 1 (14.3) 0 (0.0) 0.969 0.970 (1.04, [0.12 - 8.82]) 
- 80 69 (86.3) 11 (13.7) 0 (0.0) 
Parkinson controls + 4 3 (75.0) 1 (25.0) 0 (0.0) 0.461 0.477 (2.33, [0.21 - 25.66]) 
- 26 23 (88.5) 3 (11.5) 0 (0.0) 
TOTAL + 88 63 (71.6) 23 (26.1) 2 (2.3) 7.42E-06 8.81E-06 (2.68, [1.71 - 4.21]) 
- 917 803 (87.6) 112 (12.2) 2 (0.2) 
 




Table S9. HLA type association with seropositivity 
 
HLA allele 
Anti-NR1 seropositivity (%) p 
OR 
CI 95% Imputation 
- (N=2483) + (N=294) 
3HDUVRQ¶V
chi²) low high quality (mean) 
HLA-A               
1 14.0% 12.6% 0.343 0.88 0.68 1.14 0.954 
2 29.7% 28.7% 0.615 0.95 0.79 1.15 0.937 
3 15.6% 19.7% 0.010 1.33 1.07 1.65 0.944 
11 5.7% 4.8% 0.370 0.83 0.56 1.24 0.943 
24 9.6% 10.0% 0.727 1.05 0.79 1.40 0.907 
HLA-B               
7 13.3% 13.1% 0.874 0.98 0.76 1.26 0.833 
8 9.8% 8.5% 0.305 0.85 0.63 1.16 0.940 
15 8.4% 8.5% 0.917 1.02 0.75 1.38 0.616 
18 5.5% 4.9% 0.554 0.89 0.60 1.32 0.570 
35 10.6% 12.4% 0.168 1.20 0.93 1.56 0.476 
40 6.4% 7.1% 0.467 1.13 0.81 1.58 0.554 
44 11.9% 9.9% 0.150 0.81 0.61 1.08 0.869 
51 6.2% 5.4% 0.490 0.88 0.60 1.27 0.752 
HLA-C               
2 5.2% 5.3% 0.937 1.02 0.69 1.49 0.973 
3 13.2% 13.1% 0.927 0.99 0.77 1.27 0.945 
4 12.8% 15.3% 0.095 1.23 0.96 1.56 0.967 
5 7.1% 7.0% 0.932 0.99 0.70 1.38 0.967 
6 10.2% 11.2% 0.463 1.11 0.84 1.45 0.963 
7 31.0% 30.4% 0.793 0.98 0.81 1.17 0.957 
12 7.1% 6.8% 0.798 0.96 0.68 1.34 0.947 
HLA-DPB1               
1 5.2% 4.8% 0.624 0.91 0.61 1.35 0.885 
2 13.9% 14.3% 0.785 1.03 0.81 1.32 0.826 
3 9.7% 9.2% 0.696 0.94 0.70 1.27 0.713 
4 56.5% 58.0% 0.497 1.06 0.89 1.26 0.859 
HLA-DQA1         
1 41.8% 43.9% 0.331 1.09 0.92 1.29 0.892 
2 12.5% 11.6% 0.531 0.92 0.70 1.20 0.941 
3 14.3% 14.6% 0.819 1.03 0.81 1.31 0.823 
5 28.3% 27.7% 0.771 0.97 0.80 1.18 0.926 
HLA-DQB1               
2 19.8% 17.9% 0.273 0.88 0.71 1.10 0.947 
3 35.5% 36.4% 0.669 1.04 0.87 1.24 0.927 
5 17.4% 17.3% 0.985 1.00 0.80 1.25 0.937 
6 24.4% 26.5% 0.254 1.12 0.92 1.36 0.882 
HLA-DRB1               
1 10.5% 11.4% 0.511 1.09 0.84 1.43 0.838 
3 11.0% 9.5% 0.266 0.85 0.64 1.13 0.886 
4 13.7% 13.6% 0.932 0.99 0.77 1.27 0.727 
7 12.4% 11.6% 0.540 0.92 0.70 1.20 0.889 
11 14.1% 14.1% 0.968 1.00 0.79 1.28 0.603 
13 12.0% 14.5% 0.092 1.23 0.97 1.58 0.822 
15 14.0% 13.9% 0.995 1.00 0.78 1.28 0.892 
 
HLA types were imputed at 4-digit resolution for all genotyped subjects. However, for statistical power issues, statistics were 
performed at 2-digit resolution. A minimal allele frequency of 5% in seronegative or seropositive subjects was set as inclusion 
criterion for statistical analysis. Bolded values, p<0.05; -, seronegative; +, seropositive; OR, odds ratio; CI, confidence intervals. 
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Table S10. Influenza association with anti-NR1 seropositivity, gender-specific 
 
Study cohort GRAS patients Affective disorder patients GRAS controls Parkinson patients Parkinson controls TOTAL 
anti-NR1 seropositivity + - + - + - + - + - + - 
Influenza A (males) 
N seropositive (%) 55 (80.9) 427 (65.7) 8 (72.7) 45 (76.3) 68 (71.6) 454 (66.4) 19 (67.9) 85 (57.8) 2 (100.0) 11 (57.9) 152 (74.5) 1022 (65.6) 
p (Pearson's chi²) 0.011 0.461 0.312 0.322 0.243 0.011 
OR [CI 95%] 2.210 [1.182 - 4.131] 0.830 [0.193 - 3.559] 1.276 [0.795 - 2.048] 1.540 [0.653 - 3.632] NA 1.536 [1.102 - 2.140] 
Influenza B (males) 
N seropositive (%) 26 (38.2) 135 (20.8) 3 (27.3) 19 (32.2) 28 (29.5) 146 (21.3) 11 (39.3) 54 (36.7) 0 (0) 4 (21.1) 68 (33.3) 358 (23.0) 
p (Pearson's chi²) 0.001 0.746 0.075 0.798 0.471 0.001 
OR [CI 95%] 2.362 [1.398 - 3.990] 0.789 [0.188 - 3.315] 1.540 [0.955 - 2.482] 1.114 [0.486 - 2.554] NA 1.677 [1.225 - 2.296] 
Influenza A (females) 
N seropositive (%) 16 (66.7) 221 (67.2) 8 (61.5) 45 (71.4) 29 (69.0) 310 (68.9) 6 (85.7) 56 (69.1) 4 (100.0) 17 (60.7) 63 (70.0) 649 (68.2) 
p (Pearson's chi²) 0.959 0.48 0.983 0.356 0.122 0.732 
OR [CI 95%] 0.977 [0.406 - 2.355] 0.640 [0.184 - 2.220] 1.007 [0.508 - 1.996] 2.679 [0.306 - 23.433] NA 1.086 [0.678 - 1.739] 
Influenza B (females) 
N seropositive (%) 4 (16.7) 67 (20.4) 2 (15.4) 13 (20.6) 9 (21.4) 75 (16.7) 1 (14.3) 25 (30.9) 0 (0) 4 (14.3) 16 (17.8) 184 (19.3) 
p (Pearson's chi²) 0.663 0.665 0.433 0.356 0.419 0.718 
OR [CI 95%] 0.782 [0.259 - 2.365] 0.699 [0.138 - 3.553] 1.364 [0.627 - 2.968] 0.373 [0.043 - 3.266] NA 0.901 [0.513 - 1.584] 
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